PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
18283240-3	2008	Toward this end, the present study examines the serum concentrations of IgM and IgA against LPS of the gram-negative enterobacteria, Hafnia Alvei, Pseudomonas Aeruginosa, Morganella Morganii, Pseudomonas Putida, Citrobacter Koseri, and Klebsielle Pneumoniae in MDD patients and normal controls.	lps	92-95	CD79a molecule	Homo sapiens	80-83
18283240-4	2008	We found that the prevalences and median values for serum IgM and IgA against LPS of enterobacteria are significantly greater in patients with MDD than in normal volunteers.	lps	78-81	CD79a molecule	Homo sapiens	66-69
17632098-7	2007	In lipopolysaccharide from Escherichia coli (LPS)-treated RAW 264.7 macrophages, NCX 6560 reduced iNOS expression and dimer assembly more efficiently than atorvastatin and inhibited nitrite accumulation (IC(50)=6.7+/-1.6 microM) and TNFalpha release.	lps	45-48	solute carrier family 8 member A1	Rattus norvegicus	81-84
18299711-2	2007	A single injection of LPS caused an elevation of IL-10 in serum from GF, LPS-GF (germfree mice given drinking water containing LPS) and CV mice.	lps	22-25	interleukin 10	Mus musculus	49-54
18299711-2	2007	A single injection of LPS caused an elevation of IL-10 in serum from GF, LPS-GF (germfree mice given drinking water containing LPS) and CV mice.	lps	73-76	interleukin 10	Mus musculus	49-54
18299711-2	2007	A single injection of LPS caused an elevation of IL-10 in serum from GF, LPS-GF (germfree mice given drinking water containing LPS) and CV mice.	lps	73-76	interleukin 10	Mus musculus	49-54
18299711-6	2007	The levels of IL-10 in culture medium from Kupffer cells treated with LPS showed similar results to serum in GF and CV mice.	lps	70-73	interleukin 10	Mus musculus	14-19
18299711-7	2007	These results suggest that high levels of IL-10 in serum from germfree mice may be partly responsible for the lower in vivo responsiveness of these proinflammatory cytokines to LPS in these mice, although PGE(2) was not responsible for the lower responsiveness of these inflammatory cytokines to LPS.	lps	177-180	interleukin 10	Mus musculus	42-47
18299711-7	2007	These results suggest that high levels of IL-10 in serum from germfree mice may be partly responsible for the lower in vivo responsiveness of these proinflammatory cytokines to LPS in these mice, although PGE(2) was not responsible for the lower responsiveness of these inflammatory cytokines to LPS.	lps	296-299	interleukin 10	Mus musculus	42-47
18039275-4	2007	In particular, LPS-induced TNF is required for bronchoconstriction, but dispensable for inflammatory cell recruitment.	lps	15-18	tumor necrosis factor	Mus musculus	27-30
18039275-6	2007	Inhibition of pulmonary MAPK activity abrogates LPS-induced TNF production, bronchoconstriction, neutrophil recruitment into the lungs and broncho-alveolar space.	lps	48-51	tumor necrosis factor	Mus musculus	60-63
17699741-7	2007	In thioglycollate-induced peritonitis and lipopolysaccaride (LPS)-induced lung inflammation, chimeric mice lacking Galpha(i2) in hematopoietic cells showed about 50% reduced neutrophil recruitment similar to that seen in Gnai2(-/-) mice.	lps	61-64	guanine nucleotide binding protein (G protein), alpha inhibiting 2	Mus musculus	115-124
17453155-5	2007	The results showed that UDN glycoprotein (200 mug/ml) has an inhibitory effect on the activation of iNOS, COX-2, and MMP-9 proteins in the LPS-treated HT-29 cells.	lps	139-142	nitric oxide synthase 2	Homo sapiens	100-104
17453155-5	2007	The results showed that UDN glycoprotein (200 mug/ml) has an inhibitory effect on the activation of iNOS, COX-2, and MMP-9 proteins in the LPS-treated HT-29 cells.	lps	139-142	prostaglandin-endoperoxide synthase 2	Homo sapiens	106-111
17453155-5	2007	The results showed that UDN glycoprotein (200 mug/ml) has an inhibitory effect on the activation of iNOS, COX-2, and MMP-9 proteins in the LPS-treated HT-29 cells.	lps	139-142	matrix metallopeptidase 9	Homo sapiens	117-122
17675415-5	2007	Moreover, we documented that peripherally injected LPS triggers a specific spatiotemporal pattern of expression of IL-1beta mRNA within the brain, suggesting that IL-1beta could be a major regulator of the central inflammatory cascade.	lps	51-54	interleukin 1 beta	Mus musculus	115-123
17965763-6	2007	MCE also reduced the concentration of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the Raw264.7 cells that were activated by LPS.	lps	178-181	tumor necrosis factor	Mus musculus	38-65
17965763-6	2007	MCE also reduced the concentration of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the Raw264.7 cells that were activated by LPS.	lps	178-181	interleukin 1 beta	Mus musculus	79-96
17965763-6	2007	MCE also reduced the concentration of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the Raw264.7 cells that were activated by LPS.	lps	178-181	interleukin 1 beta	Mus musculus	98-106
17965763-6	2007	MCE also reduced the concentration of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the Raw264.7 cells that were activated by LPS.	lps	178-181	interleukin 6	Mus musculus	112-125
17675415-5	2007	Moreover, we documented that peripherally injected LPS triggers a specific spatiotemporal pattern of expression of IL-1beta mRNA within the brain, suggesting that IL-1beta could be a major regulator of the central inflammatory cascade.	lps	51-54	interleukin 1 beta	Mus musculus	163-171
17481364-2	2007	Food intake was reduced 2 h after LPS injection (500 microg/kg, intraperitoneally) and remained decreased for 24 h. Plasma TNF-alpha and IL-6 levels increased by LPS administration at 0.5 and 2 h, and at 2 and 4 h, respectively.	lps	34-37	tumor necrosis factor	Rattus norvegicus	123-132
17481364-2	2007	Food intake was reduced 2 h after LPS injection (500 microg/kg, intraperitoneally) and remained decreased for 24 h. Plasma TNF-alpha and IL-6 levels increased by LPS administration at 0.5 and 2 h, and at 2 and 4 h, respectively.	lps	34-37	interleukin 6	Rattus norvegicus	137-141
17481364-2	2007	Food intake was reduced 2 h after LPS injection (500 microg/kg, intraperitoneally) and remained decreased for 24 h. Plasma TNF-alpha and IL-6 levels increased by LPS administration at 0.5 and 2 h, and at 2 and 4 h, respectively.	lps	162-165	tumor necrosis factor	Rattus norvegicus	123-132
17481364-2	2007	Food intake was reduced 2 h after LPS injection (500 microg/kg, intraperitoneally) and remained decreased for 24 h. Plasma TNF-alpha and IL-6 levels increased by LPS administration at 0.5 and 2 h, and at 2 and 4 h, respectively.	lps	162-165	interleukin 6	Rattus norvegicus	137-141
17481364-4	2007	IL-6 levels in the CSF were elevated at 2 and 4 h. Hypothalamic cytokines tended to increase as early as 0.5 h after LPS injection and remained increased until 16 h. LPS-induced anorexia was attenuated in insulin-deficient STZ rats and was abolished by insulin treatment.	lps	166-169	interleukin 6	Rattus norvegicus	0-4
17481364-5	2007	The hypothalamic expression of NPY, a target of insulin"s anorexic effect, was decreased 2 h after LPS administration, and central NPY injection (3 nM) prevented LPS-induced anorexia.	lps	99-102	neuropeptide Y	Rattus norvegicus	31-34
17481364-5	2007	The hypothalamic expression of NPY, a target of insulin"s anorexic effect, was decreased 2 h after LPS administration, and central NPY injection (3 nM) prevented LPS-induced anorexia.	lps	162-165	neuropeptide Y	Rattus norvegicus	31-34
17481364-5	2007	The hypothalamic expression of NPY, a target of insulin"s anorexic effect, was decreased 2 h after LPS administration, and central NPY injection (3 nM) prevented LPS-induced anorexia.	lps	162-165	neuropeptide Y	Rattus norvegicus	131-134
16631199-2	2006	Toll-Like receptor 4 (TLR-4) has been implicated as the proximal transmembrane receptor for the LPS/CD 14 complex during the activation of lipopolysacharide (LPS)-induced sepsis.	lps	96-99	toll-like receptor 4	Rattus norvegicus	0-20
17379010-2	2007	The aim of this study in rats with acute endotoxicity induced by an injection of LPS was to investigate whether bezafibrate, a ligand for peroxisome proliferator-activated receptor alpha and a lipoprotein lipase (LPL) activator, improved cachectic conditions, including impaired lipid metabolism.	lps	81-84	lipoprotein lipase	Rattus norvegicus	193-211
17379010-6	2007	Administration of LPS was also associated with a decrease in the level of messenger RNA (mRNA) expression for LPL in white adipose tissue and skeletal muscle and an increase in the mRNA levels for uncoupling protein 3 in skeletal muscle.	lps	18-21	lipoprotein lipase	Rattus norvegicus	110-113
17379010-6	2007	Administration of LPS was also associated with a decrease in the level of messenger RNA (mRNA) expression for LPL in white adipose tissue and skeletal muscle and an increase in the mRNA levels for uncoupling protein 3 in skeletal muscle.	lps	18-21	uncoupling protein 3	Rattus norvegicus	197-217
17621557-6	2007	When added to human macrophage culture, rFC blocks the LPS-induced phosphorylation of p38, which, in turn, inhibits the consequential overexpression of TNF-alpha and IL-8.	lps	55-58	mitogen-activated protein kinase 14	Homo sapiens	86-89
17621557-6	2007	When added to human macrophage culture, rFC blocks the LPS-induced phosphorylation of p38, which, in turn, inhibits the consequential overexpression of TNF-alpha and IL-8.	lps	55-58	tumor necrosis factor	Homo sapiens	152-161
17621557-6	2007	When added to human macrophage culture, rFC blocks the LPS-induced phosphorylation of p38, which, in turn, inhibits the consequential overexpression of TNF-alpha and IL-8.	lps	55-58	C-X-C motif chemokine ligand 8	Homo sapiens	166-170
17621557-8	2007	Thus, rFC binds and neutralizes LPS to arrest signal transduction via the p38 pathway.	lps	32-35	mitogen-activated protein kinase 14	Homo sapiens	74-77
17075848-9	2006	Immuno-electron microscopy localized TNF-alpha, IL-10, and TGF-beta2 in recruited PIMMs in rats challenged with both E. coli and LPS.	lps	129-132	tumor necrosis factor	Rattus norvegicus	37-46
17075848-9	2006	Immuno-electron microscopy localized TNF-alpha, IL-10, and TGF-beta2 in recruited PIMMs in rats challenged with both E. coli and LPS.	lps	129-132	interleukin 10	Rattus norvegicus	48-53
17075848-9	2006	Immuno-electron microscopy localized TNF-alpha, IL-10, and TGF-beta2 in recruited PIMMs in rats challenged with both E. coli and LPS.	lps	129-132	transforming growth factor, beta 2	Rattus norvegicus	59-68
17075848-10	2006	ELISA on lung homogenates showed higher concentrations of TNF-alpha, IL-10, and TGF-beta2 in rats treated with both E. coli and LPS compared with those treated with only LPS or E. coli (P<0.05).	lps	128-131	tumor necrosis factor	Rattus norvegicus	58-67
17075848-10	2006	ELISA on lung homogenates showed higher concentrations of TNF-alpha, IL-10, and TGF-beta2 in rats treated with both E. coli and LPS compared with those treated with only LPS or E. coli (P<0.05).	lps	128-131	interleukin 10	Rattus norvegicus	69-74
17075848-10	2006	ELISA on lung homogenates showed higher concentrations of TNF-alpha, IL-10, and TGF-beta2 in rats treated with both E. coli and LPS compared with those treated with only LPS or E. coli (P<0.05).	lps	128-131	transforming growth factor, beta 2	Rattus norvegicus	80-89
17216716-2	2006	Alteration of c-Fos-positive cells quantity in different hypothalamic structures after electric pain stimulation (EPS), intravenous (iv) injection of antigens (lioppolysaccharide (LPS) and bovine serum albumir (BSA)) was detected with immunohistochemical method.	lps	180-183	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-19
17216716-3	2006	EPS and iv injection of antigens (LPS and BSA) result in c-Fos-positive cells quantity increase in all observed hypothalamic structures.	lps	34-37	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	57-62
17216716-6	2006	LPS injection results in more pronounced cell activation in AHN, PVH, LHA-28 and DMH (according to quantity of c-Fos-positive cells), than BSA injection.	lps	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	111-116
16717027-9	2006	Serum amyloid A1, which is an acute-phase systemic inflammation marker and can be induced by LPS exposure, was significantly upregulated in the LPS and smoke-LPS groups.	lps	93-96	serum amyloid A 1	Mus musculus	0-16
16717027-9	2006	Serum amyloid A1, which is an acute-phase systemic inflammation marker and can be induced by LPS exposure, was significantly upregulated in the LPS and smoke-LPS groups.	lps	144-147	serum amyloid A 1	Mus musculus	0-16
16717027-9	2006	Serum amyloid A1, which is an acute-phase systemic inflammation marker and can be induced by LPS exposure, was significantly upregulated in the LPS and smoke-LPS groups.	lps	144-147	serum amyloid A 1	Mus musculus	0-16
16717027-10	2006	MARCO, a scavenger receptor expressed in macrophages that may play a significant role in LPS-induced inflammatory response, was upregulated in the LPS group and the smoke-LPS group, but not in the smoke group.	lps	89-92	macrophage receptor with collagenous structure	Mus musculus	0-5
16717027-10	2006	MARCO, a scavenger receptor expressed in macrophages that may play a significant role in LPS-induced inflammatory response, was upregulated in the LPS group and the smoke-LPS group, but not in the smoke group.	lps	147-150	macrophage receptor with collagenous structure	Mus musculus	0-5
16717027-10	2006	MARCO, a scavenger receptor expressed in macrophages that may play a significant role in LPS-induced inflammatory response, was upregulated in the LPS group and the smoke-LPS group, but not in the smoke group.	lps	147-150	macrophage receptor with collagenous structure	Mus musculus	0-5
16839411-3	2006	Ovalbumin (Ova)-sensitized BALB/c mice were primed with 10 microg intranasal Lps 24 h before the start of Ova challenges (20 min on 3 consecutive days).	lps	77-80	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	0-9
16631199-2	2006	Toll-Like receptor 4 (TLR-4) has been implicated as the proximal transmembrane receptor for the LPS/CD 14 complex during the activation of lipopolysacharide (LPS)-induced sepsis.	lps	96-99	toll-like receptor 4	Rattus norvegicus	22-27
16631199-2	2006	Toll-Like receptor 4 (TLR-4) has been implicated as the proximal transmembrane receptor for the LPS/CD 14 complex during the activation of lipopolysacharide (LPS)-induced sepsis.	lps	96-99	CD14 molecule	Rattus norvegicus	100-105
16631199-2	2006	Toll-Like receptor 4 (TLR-4) has been implicated as the proximal transmembrane receptor for the LPS/CD 14 complex during the activation of lipopolysacharide (LPS)-induced sepsis.	lps	158-161	toll-like receptor 4	Rattus norvegicus	0-20
16631199-2	2006	Toll-Like receptor 4 (TLR-4) has been implicated as the proximal transmembrane receptor for the LPS/CD 14 complex during the activation of lipopolysacharide (LPS)-induced sepsis.	lps	158-161	toll-like receptor 4	Rattus norvegicus	22-27
16631199-2	2006	Toll-Like receptor 4 (TLR-4) has been implicated as the proximal transmembrane receptor for the LPS/CD 14 complex during the activation of lipopolysacharide (LPS)-induced sepsis.	lps	158-161	CD14 molecule	Rattus norvegicus	100-105
16631199-3	2006	It is our hypothesis that TLR-4 is present on lung pericytes and is up-regulated in response to LPS.	lps	96-99	toll-like receptor 4	Rattus norvegicus	26-31
16631199-8	2006	An increase in the mRNA was observed in CD-14, TLR-2, and TLR-4 in the presence of increasing LPS 4 h after treatment.	lps	94-97	CD14 molecule	Rattus norvegicus	40-45
16631199-8	2006	An increase in the mRNA was observed in CD-14, TLR-2, and TLR-4 in the presence of increasing LPS 4 h after treatment.	lps	94-97	toll-like receptor 2	Rattus norvegicus	47-52
16631199-8	2006	An increase in the mRNA was observed in CD-14, TLR-2, and TLR-4 in the presence of increasing LPS 4 h after treatment.	lps	94-97	toll-like receptor 4	Rattus norvegicus	58-63
16631199-10	2006	CONCLUSIONS: The up-regulation of TLR-4 in the presence of increasing LPS suggests its importance in pericyte LPS-induced activation.	lps	70-73	toll-like receptor 4	Rattus norvegicus	34-39
16631199-10	2006	CONCLUSIONS: The up-regulation of TLR-4 in the presence of increasing LPS suggests its importance in pericyte LPS-induced activation.	lps	110-113	toll-like receptor 4	Rattus norvegicus	34-39
16631199-11	2006	Pericyte TLR-4 recognition of LPS could play a role in capillary leak seen in sepsis.	lps	30-33	toll-like receptor 4	Rattus norvegicus	9-14
16672668-8	2006	Interestingly, inhibition of nuclear factor kappaB (NF-kappaB) suppressed LPS- but not GSNO-induced expression of GFAP, suggesting that NO does not require NF-kappaB to induce GFAP and that NF-kappaB functions upstream of NO production.	lps	74-77	nuclear factor kappa B subunit 1	Homo sapiens	52-61
16364709-5	2006	The in vivo osteolysis experiment showed that LPS (lipopolisaccharide)-induced osteolysis occurred more rapidly and extensively in bgn deficient mice compared to wild type (WT) mice.	lps	46-49	biglycan	Mus musculus	131-134
16321552-4	2005	LPS increased bursa and liver total and high affinity CAT mRNA expression (P<0.05) and transiently increased pectoralis total CAT mRNA expression (P<0.05).	lps	0-3	catalase	Gallus gallus	54-57
16574909-6	2006	Using lipopolysacharide (LPS)-challenged mice as an in vivo model of NO-induced cytotoxicity, we found that a single dose of LPS (120,000 U/g IP) induced 90% fatality of SR-BI-null mice within 3 days, whereas all of the wild-type littermates survived (n=20), demonstrating that SR-BI is highly protective against NO cytotoxicity in vivo.	lps	25-28	scavenger receptor class B, member 1	Mus musculus	170-175
16574909-6	2006	Using lipopolysacharide (LPS)-challenged mice as an in vivo model of NO-induced cytotoxicity, we found that a single dose of LPS (120,000 U/g IP) induced 90% fatality of SR-BI-null mice within 3 days, whereas all of the wild-type littermates survived (n=20), demonstrating that SR-BI is highly protective against NO cytotoxicity in vivo.	lps	125-128	scavenger receptor class B, member 1	Mus musculus	170-175
16574909-6	2006	Using lipopolysacharide (LPS)-challenged mice as an in vivo model of NO-induced cytotoxicity, we found that a single dose of LPS (120,000 U/g IP) induced 90% fatality of SR-BI-null mice within 3 days, whereas all of the wild-type littermates survived (n=20), demonstrating that SR-BI is highly protective against NO cytotoxicity in vivo.	lps	125-128	scavenger receptor class B, member 1	Mus musculus	278-283
16574909-7	2006	Importantly, SR-BI prevents LPS-induced death without eliminating NO production, suggesting that SR-BI prevents NO-induced cytotoxicity post-NO synthesis.	lps	28-31	scavenger receptor class B, member 1	Mus musculus	13-18
16387840-3	2006	We herein demonstrate that human peripheral blood mononuclear cells (PBMC) from healthy adults/elderly, cultured with IL-12 for 24 h and with LPS for an additional 24 h, produced a much larger amount of TNF (which increased age-dependently) than did PBMC without IL-12 priming.	lps	142-145	tumor necrosis factor	Homo sapiens	203-206
16387840-7	2006	CD56+natural killer cells, CD56+T cells, and CD57+T cells (NK-T cells), which age-dependently increased in PBMC, produced much larger amounts of IFN-gamma after IL-12 priming than that of conventional CD56-CD57-T cells and also induced cocultured macrophages to produce TNF by subsequent LPS stimulation.	lps	288-291	neural cell adhesion molecule 1	Homo sapiens	0-4
16387840-7	2006	CD56+natural killer cells, CD56+T cells, and CD57+T cells (NK-T cells), which age-dependently increased in PBMC, produced much larger amounts of IFN-gamma after IL-12 priming than that of conventional CD56-CD57-T cells and also induced cocultured macrophages to produce TNF by subsequent LPS stimulation.	lps	288-291	interferon gamma	Homo sapiens	145-154
16484046-6	2006	The secretion of the inflammatory cytokines interleukine-6 and TNF-a from LPS-stimulated murine macrophages was also significantly reduced (p < 0.05 and 0.01) by 50 and 100 microM of MA.	lps	74-77	tumor necrosis factor	Mus musculus	63-68
16321552-4	2005	LPS increased bursa and liver total and high affinity CAT mRNA expression (P<0.05) and transiently increased pectoralis total CAT mRNA expression (P<0.05).	lps	0-3	catalase	Gallus gallus	129-132
16321552-5	2005	Total CAT mRNA expression in the thymus decreased 7.7-fold from 0 to 8 h after LPS injection (P<0.05).	lps	79-82	catalase	Gallus gallus	6-9
16321552-7	2005	LPS increased total and high affinity CAT mRNA 2-fold in both the bursa and liver (P<0.05) and did not change thymus total and high affinity CAT mRNA expression (P>0.05).	lps	0-3	catalase	Gallus gallus	38-41
16394599-2	2005	The aim of this study was to test a clinical hypothesis that IFN therapy for hepatitis C virus may induce ventricular late potentials (LPs) and related arrhythmias in patients with chronic active hepatitis.	lps	135-138	interferon alpha 1	Homo sapiens	61-64
16253122-12	2005	Mice that had received whole IgM effluent (1.5 mg/l of anti-LPS O6 IgM antibodies) before the challenge with LPS O6 presented 20.5 microg/l of IL-6 and 1.5 microg/l of TNF-alpha.	lps	60-63	interleukin 6	Mus musculus	143-153
16259779-6	2005	TNF-alpha and interleukin (IL)-10 reached maximum levels 1.5 h after the LPS injection.	lps	73-76	tumor necrosis factor	Mus musculus	0-9
16259779-6	2005	TNF-alpha and interleukin (IL)-10 reached maximum levels 1.5 h after the LPS injection.	lps	73-76	interleukin 10	Mus musculus	14-33
15894110-2	2005	The effects of LY294002 and wortmannin, inhibitors of PI3K, on nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression in lipoploysaccharide (LPS)-induced Raw 264.7 cells were investigated.	lps	169-172	nitric oxide synthase 2, inducible	Mus musculus	96-127
15916771-16	2005	Moreover, while iNOS may play a role in LPS induced gastric luminal fluid accumulation, it does not appear to be a major mediator of the gastrointestinal ileus caused by LPS.	lps	40-43	nitric oxide synthase 2	Rattus norvegicus	16-20
15894110-2	2005	The effects of LY294002 and wortmannin, inhibitors of PI3K, on nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression in lipoploysaccharide (LPS)-induced Raw 264.7 cells were investigated.	lps	169-172	nitric oxide synthase 2, inducible	Mus musculus	129-133
14633514-4	2004	The alveolar macrophages collected after large V(t) ventilation revealed a 20-fold increase in LPS-induced TNF-alpha release compared with those collected after small V(t) ventilation, whereas TNF-alpha was undetectable without LPS stimulation.	lps	95-98	tumor necrosis factor	Oryctolagus cuniculus	107-116
15965713-5	2005	The Celecoxib COX-2 inhibitor reduced RTHR and the number of cells in BAL and lung neutrophils influx of rats treated with LPS.	lps	123-126	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19
15337172-7	2004	Hepatic cytosolic iNOS showed an increase of 34% in PH-C animals with respect to Sh, and LPS-treatment increased iNOS protein levels 30% compared with PH-C. Bax and p53 protein levels showed significant increases in LPS- and SNP-treated hepatectomised rats with respect to PH-C.	lps	89-92	nitric oxide synthase 2	Rattus norvegicus	113-117
15337172-7	2004	Hepatic cytosolic iNOS showed an increase of 34% in PH-C animals with respect to Sh, and LPS-treatment increased iNOS protein levels 30% compared with PH-C. Bax and p53 protein levels showed significant increases in LPS- and SNP-treated hepatectomised rats with respect to PH-C.	lps	89-92	BCL2 associated X, apoptosis regulator	Rattus norvegicus	157-160
15337172-7	2004	Hepatic cytosolic iNOS showed an increase of 34% in PH-C animals with respect to Sh, and LPS-treatment increased iNOS protein levels 30% compared with PH-C. Bax and p53 protein levels showed significant increases in LPS- and SNP-treated hepatectomised rats with respect to PH-C.	lps	89-92	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	165-168
15337172-7	2004	Hepatic cytosolic iNOS showed an increase of 34% in PH-C animals with respect to Sh, and LPS-treatment increased iNOS protein levels 30% compared with PH-C. Bax and p53 protein levels showed significant increases in LPS- and SNP-treated hepatectomised rats with respect to PH-C.	lps	216-219	BCL2 associated X, apoptosis regulator	Rattus norvegicus	157-160
15337172-7	2004	Hepatic cytosolic iNOS showed an increase of 34% in PH-C animals with respect to Sh, and LPS-treatment increased iNOS protein levels 30% compared with PH-C. Bax and p53 protein levels showed significant increases in LPS- and SNP-treated hepatectomised rats with respect to PH-C.	lps	216-219	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	165-168
15246588-4	2004	Blood levels of TNF-alpha, IL-1beta, IL-6, IL-10, INF-gamma and IL-1 receptor antagonist were significantly increased in LPS and PLV + LPS groups.	lps	121-124	tumor necrosis factor	Rattus norvegicus	16-25
15246588-4	2004	Blood levels of TNF-alpha, IL-1beta, IL-6, IL-10, INF-gamma and IL-1 receptor antagonist were significantly increased in LPS and PLV + LPS groups.	lps	121-124	interleukin 1 beta	Rattus norvegicus	27-35
15246588-4	2004	Blood levels of TNF-alpha, IL-1beta, IL-6, IL-10, INF-gamma and IL-1 receptor antagonist were significantly increased in LPS and PLV + LPS groups.	lps	121-124	interleukin 6	Rattus norvegicus	37-41
15246588-4	2004	Blood levels of TNF-alpha, IL-1beta, IL-6, IL-10, INF-gamma and IL-1 receptor antagonist were significantly increased in LPS and PLV + LPS groups.	lps	121-124	interleukin 10	Rattus norvegicus	43-48
15246588-6	2004	mRNA expression of IL-6 in PLV + LPS group was significantly increased in comparison with LPS group.	lps	33-36	interleukin 6	Rattus norvegicus	19-23
15246588-6	2004	mRNA expression of IL-6 in PLV + LPS group was significantly increased in comparison with LPS group.	lps	90-93	interleukin 6	Rattus norvegicus	19-23
15246588-7	2004	Other cytokine mRNA expression including IL-10 and IL-1beta was also potentiated in PLV + LPS group, however this was not significant.	lps	90-93	interleukin 10	Rattus norvegicus	41-46
15246588-7	2004	Other cytokine mRNA expression including IL-10 and IL-1beta was also potentiated in PLV + LPS group, however this was not significant.	lps	90-93	interleukin 1 beta	Rattus norvegicus	51-59
14633514-6	2004	A large V(t) applied to LPS-instilled lungs increased the pulmonary albumin permeability and TNF-alpha release into the plasma.	lps	24-27	tumor necrosis factor	Oryctolagus cuniculus	93-102
15312471-6	2004	RESULTS: Apoptosis and TGFbeta(1) secretion could be induced by LPS in dose of 0.1 to 100 micro g/ml when compared with that without LPS challenge (P < 0.05 - 0.01).	lps	64-67	transforming growth factor beta 1	Homo sapiens	23-33
15010209-10	2004	These data indicate that Mn augments LPS-induced expression of NOS2 in C6 cells by increasing mitochondrial ROS and activation of NF-kappaB.	lps	37-40	nitric oxide synthase 2	Homo sapiens	63-67
15010209-10	2004	These data indicate that Mn augments LPS-induced expression of NOS2 in C6 cells by increasing mitochondrial ROS and activation of NF-kappaB.	lps	37-40	nuclear factor kappa B subunit 1	Homo sapiens	130-139
15159284-5	2004	Administration of LPS (0.4 and 4 mg x kg(-1)) under continuous infusion of vasopressin inhibited the neurogenic vasopressor response by 25 and 50%, respectively.	lps	18-21	arginine vasopressin	Rattus norvegicus	75-86
15010209-4	2004	Exposure of C6 glioma cells to lipopopolysaccharide (LPS) resulted in increased expression of NOS2 and production of NO that was dramatically potentiated by Mn and was blocked through overexpression of mutant IkappaBalpha (S32/36A).	lps	53-56	nitric oxide synthase 2	Homo sapiens	94-98
15010209-4	2004	Exposure of C6 glioma cells to lipopopolysaccharide (LPS) resulted in increased expression of NOS2 and production of NO that was dramatically potentiated by Mn and was blocked through overexpression of mutant IkappaBalpha (S32/36A).	lps	53-56	NFKB inhibitor alpha	Homo sapiens	209-221
15010209-5	2004	LPS-induced DNA binding of p65/p50 was similarly enhanced by Mn and was decreased by mutant IkappaBalpha.	lps	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	27-30
15010209-5	2004	LPS-induced DNA binding of p65/p50 was similarly enhanced by Mn and was decreased by mutant IkappaBalpha.	lps	0-3	nuclear factor kappa B subunit 1	Homo sapiens	31-34
15010209-5	2004	LPS-induced DNA binding of p65/p50 was similarly enhanced by Mn and was decreased by mutant IkappaBalpha.	lps	0-3	NFKB inhibitor alpha	Homo sapiens	92-104
15010209-6	2004	Phosphorylation of IkappaBalpha was potentiated by Mn and LPS and was not blocked by U0126, a selective inhibitor of ERK1/2.	lps	58-61	NFKB inhibitor alpha	Homo sapiens	19-31
15312471-8	2004	In contrary, LPS in high dose (50 and 100 micro g/ml) could promote VEGF secretion (P < 0.01) but exerted no effects on the proliferation of U937 cells.	lps	13-16	vascular endothelial growth factor A	Homo sapiens	68-72
15312471-9	2004	CONCLUSION: U937 cells could be activated to increase the secretion of TGFbeta(1) by LPS in optimal dose of 0.1 - 10.0 micro g/ml, but the secretion of VEGF could only be promoted by LPS in higher concentration.	lps	85-88	transforming growth factor beta 1	Homo sapiens	71-81
15312471-9	2004	CONCLUSION: U937 cells could be activated to increase the secretion of TGFbeta(1) by LPS in optimal dose of 0.1 - 10.0 micro g/ml, but the secretion of VEGF could only be promoted by LPS in higher concentration.	lps	183-186	vascular endothelial growth factor A	Homo sapiens	152-156
12957692-1	2003	Lipoprotein particles (Lps) in normal human cerebrospinal fluid (CSF) are distinct from those found in plasma and include unique apolipoprotein E (apoE indicates protein; APOE, gene) containing lipoproteins rarely seen in human plasma.	lps	23-26	apolipoprotein E	Homo sapiens	129-145
15646376-2	2004	The aim of this study was to analyze the effect of ozone oxidative preconditioning on the level of tumor necrosis factor-alpha (TNF-alpha) in the serum of mice treated with lipopolysaccaride (LPS).	lps	192-195	tumor necrosis factor	Mus musculus	99-126
15646376-2	2004	The aim of this study was to analyze the effect of ozone oxidative preconditioning on the level of tumor necrosis factor-alpha (TNF-alpha) in the serum of mice treated with lipopolysaccaride (LPS).	lps	192-195	tumor necrosis factor	Mus musculus	128-137
15646376-5	2004	One hour after LPS injection, a significant mean increase of TNF-alpha in mouse serum was observed.	lps	15-18	tumor necrosis factor	Mus musculus	61-70
15646376-7	2004	Statistically significant decreases in TNF-alpha levels after LPS injection were observed either with ozone intraperitoneal applications at 0.2 (78 %), 0.4 (98.5 %) and 1.2 (98.6 %) mg/ kg or by rectal application at 0.2 (46.2 %) and 0.4 (97.4 %) mg/kg.	lps	62-65	tumor necrosis factor	Mus musculus	39-48
12957692-1	2003	Lipoprotein particles (Lps) in normal human cerebrospinal fluid (CSF) are distinct from those found in plasma and include unique apolipoprotein E (apoE indicates protein; APOE, gene) containing lipoproteins rarely seen in human plasma.	lps	23-26	apolipoprotein E	Homo sapiens	147-151
12957692-1	2003	Lipoprotein particles (Lps) in normal human cerebrospinal fluid (CSF) are distinct from those found in plasma and include unique apolipoprotein E (apoE indicates protein; APOE, gene) containing lipoproteins rarely seen in human plasma.	lps	23-26	apolipoprotein E	Homo sapiens	171-175
12957692-9	2003	These data provide novel indirect evidence suggesting that after SAH CSF Lps undergo remodelling and apoE containing Lps are selectively reduced in brain injury CSF.	lps	117-120	apolipoprotein E	Homo sapiens	101-105
12943799-1	2003	A novel bactericidal permeability-increasing protein/lipopolysaccharide (LPS)-binding protein (BPI/LBP) was isolated from common carp Cyprinus carpio L. by EST analysis.	lps	73-76	LBP (LPS binding protein)/BPI (bactericidal/permeability-increasing protein)-1	Oncorhynchus mykiss	99-102
12909129-10	2003	The CCL17 promoter offered the highest level of expression in DCs and was further activated by culture with LPS or interleukin-4 (IL-4).	lps	108-111	chemokine (C-C motif) ligand 17	Mus musculus	4-9
12909129-12	2003	Endogenous CCL17 and B7-DC mRNAs were increased similarly in IL-4 cultured DCs but only CCL17 was induced by LPS.	lps	109-112	chemokine (C-C motif) ligand 17	Mus musculus	88-93
12943799-5	2003	This LPS-binding domain had high identity (76.9%) to that of rainbow trout LBP/BPI-2.	lps	5-8	LBP (LPS binding protein)/BPI (bactericidal/permeability-increasing protein) like-2	Oncorhynchus mykiss	75-84
12943799-8	2003	Liver and head kidney stimulated with LPS (10 microg/ml) for 3, 6, 12, 24 and 48 h expressed carp BPI/LBP gene at all stimulation time periods.	lps	38-41	LBP (LPS binding protein)/BPI (bactericidal/permeability-increasing protein)-1	Oncorhynchus mykiss	102-105
12965051-2	2003	ApoE is known to regulate cholesterol metabolism in the periphery through its action as a ligand for receptor mediated uptake of lipoprotein particles (Lps).	lps	152-155	apolipoprotein E	Homo sapiens	0-4
12875990-1	2003	Adenosine A(2A) receptor (A(2A)R) agonists synergize with Escherichia coli (E. coli) LPS [toll-like receptor (TLR)4 agonist] to up-regulate vascular endothelial growth factor (VEGF) expression in murine macrophages.	lps	85-88	vascular endothelial growth factor A	Mus musculus	176-180
12965051-6	2003	There was a marked decrease in apoE containing Lps in the TBI CSF compared to controls (p=0.002).	lps	47-50	apolipoprotein E	Homo sapiens	31-35
12965051-9	2003	The dramatic loss of apoE containing Lps from the CSF, and the substantial increase in CSF cholesterol, support the concept that apoE and cholesterol metabolism are intimately linked in the context of acute brain injury.	lps	37-40	apolipoprotein E	Homo sapiens	21-25
12509806-3	2003	Exposure of primary cultures of rat cortical microglial cells to LPS significantly stimulated TNFalpha mRNA expression and release.	lps	65-68	tumor necrosis factor	Rattus norvegicus	94-102
12918124-2	2003	HO-1 is induced by many stimuli including heme, Hb, heat stress,lipopolysaccharide (LPS) and cytokines.	lps	84-87	heme oxygenase 1	Mus musculus	0-4
12918124-3	2003	Previous studies demonstrated that LPS induced HO-1 gene activation and HO-1 expression in liver.	lps	35-38	heme oxygenase 1	Mus musculus	47-51
12918124-3	2003	Previous studies demonstrated that LPS induced HO-1 gene activation and HO-1 expression in liver.	lps	35-38	heme oxygenase 1	Mus musculus	72-76
12918124-4	2003	However, the mechanisms of LPS-induced HO-1 expression in liver remain unknown.	lps	27-30	heme oxygenase 1	Mus musculus	39-43
12918124-5	2003	The effect of toll-like receptor-4 (TLR4) on LPS-induced liver HO-1 expression and the role of TNF-alpha and IL-1beta in this condition were determined.	lps	45-48	toll-like receptor 4	Mus musculus	36-40
12918124-5	2003	The effect of toll-like receptor-4 (TLR4) on LPS-induced liver HO-1 expression and the role of TNF-alpha and IL-1beta in this condition were determined.	lps	45-48	heme oxygenase 1	Mus musculus	63-67
12918124-8	2003	RESULTS: A low dose of LPS significantly increased HO-1 expression in the liver which was localized in Kupffer cells only.	lps	23-26	heme oxygenase 1	Mus musculus	51-55
12918124-9	2003	Furthermore, HO-1 expression was enhanced by three doses of LPS.	lps	60-63	heme oxygenase 1	Mus musculus	13-17
12918124-11	2003	While the liver HO-1 expression in TNF KO mice was much lower than that in C57 mice following the same LPS treatment, IL-1beta KO had a slight influence on liver HO-1 expression following LPS treatment.	lps	188-191	interleukin 1 beta	Mus musculus	118-126
12918124-11	2003	While the liver HO-1 expression in TNF KO mice was much lower than that in C57 mice following the same LPS treatment, IL-1beta KO had a slight influence on liver HO-1 expression following LPS treatment.	lps	188-191	heme oxygenase 1	Mus musculus	162-166
12918124-12	2003	CONCLUSION: The present results confirm that macrophages are the major source of HO-1 in the liver induced by LPS.	lps	110-113	heme oxygenase 1	Mus musculus	81-85
12918124-13	2003	This study demonstrates that TLR4 plays a dominant role in mediating HO-1 expression following LPS.	lps	95-98	toll-like receptor 4	Mus musculus	29-33
12918124-13	2003	This study demonstrates that TLR4 plays a dominant role in mediating HO-1 expression following LPS.	lps	95-98	heme oxygenase 1	Mus musculus	69-73
12918124-14	2003	LPS-induced HO-1 expression is mainly mediated by endogenous TNF-alpha, but only partially by endogenous IL-1beta.	lps	0-3	heme oxygenase 1	Mus musculus	12-16
12918124-14	2003	LPS-induced HO-1 expression is mainly mediated by endogenous TNF-alpha, but only partially by endogenous IL-1beta.	lps	0-3	tumor necrosis factor	Mus musculus	61-70
12918124-14	2003	LPS-induced HO-1 expression is mainly mediated by endogenous TNF-alpha, but only partially by endogenous IL-1beta.	lps	0-3	interleukin 1 beta	Mus musculus	105-113
12918124-0	2003	TLR4 mediates LPS-induced HO-1 expression in mouse liver: role of TNF-alpha and IL-1beta.	lps	14-17	toll-like receptor 4	Mus musculus	0-4
12918124-0	2003	TLR4 mediates LPS-induced HO-1 expression in mouse liver: role of TNF-alpha and IL-1beta.	lps	14-17	heme oxygenase 1	Mus musculus	26-30
12918124-0	2003	TLR4 mediates LPS-induced HO-1 expression in mouse liver: role of TNF-alpha and IL-1beta.	lps	14-17	tumor necrosis factor	Mus musculus	66-75
12918124-0	2003	TLR4 mediates LPS-induced HO-1 expression in mouse liver: role of TNF-alpha and IL-1beta.	lps	14-17	interleukin 1 beta	Mus musculus	80-88
12509806-6	2003	Given this stereoselectivity, the ability of (+)WIN 55,212-2 to inhibit LPS-induced TNFalpha release from microglia is most likely receptor-mediated.	lps	72-75	tumor necrosis factor	Rattus norvegicus	84-92
12509806-9	2003	Consistent with this finding is the observation that the ablative effect of (+)WIN 55,212-2 on LPS-evoked release of TNFalpha was not sensitive to the G(i/o) protein inactivator pertussis toxin.	lps	95-98	tumor necrosis factor	Rattus norvegicus	117-125
12509806-10	2003	In addition, the cAMP elevating agents dibutyryl cAMP and forskolin both abolished LPS-induced TNFalpha release, thus rendering unlikely the possibility that (+)WIN 55,212-2 could ablate TNFalpha release through the inhibition of adenylate cyclase via the G(i)-coupled cannabinoid receptors type 1 and 2.	lps	83-86	tumor necrosis factor	Rattus norvegicus	95-103
12509806-11	2003	In summary, our data indicate that both synthetic and endogenous cannabinoids inhibit LPS-induced release of TNFalpha from microglial cells.	lps	86-89	tumor necrosis factor	Rattus norvegicus	109-117
12021174-9	2002	In contrast, transcripts of fos-related antigen-2, growth arrest and DNA damage-inducible protein-45, and signal transducer and activator of transcription-3 were significantly increased in the LPs of T + E2-treated animals, but the increases were reversed by cotreatment with ICI.	lps	193-196	FOS like 2, AP-1 transcription factor subunit	Rattus norvegicus	28-49
12505718-6	2003	Cell surface protein expression (CD14 and CD11b) did not change following ozone exposure, but the effect of lipopolysaccharride (LPS) on TNF-alpha production following ozone exposure changed compared to filtered air/LPS-exposed cells.	lps	129-132	tumor necrosis factor	Homo sapiens	137-146
12430673-5	2002	Patients mobilized with SCF plus G-CSF plus CCP showed the highest numbers of neutrophils and monocytes, whereas the highest numbers of lymphocytes and NK cells were observed in LPs from G-CSF-mobilized patients.	lps	178-181	colony stimulating factor 3	Homo sapiens	187-192
12430673-8	2002	CONCLUSIONS: The use of different mobilization regimens modifies the overall number of CD34+ HPCs obtained during leukapheresis procedures, and also affects both the absolute and the relative composition of the LPs in different CD34+ and CD34- cell subsets.	lps	211-214	CD34 molecule	Homo sapiens	228-232
12430673-8	2002	CONCLUSIONS: The use of different mobilization regimens modifies the overall number of CD34+ HPCs obtained during leukapheresis procedures, and also affects both the absolute and the relative composition of the LPs in different CD34+ and CD34- cell subsets.	lps	211-214	CD34 molecule	Homo sapiens	228-232
12219035-2	2002	We have previously shown that resuscitated hemorrhagic shock primes for increased lung injury in response to lippolysaccharide (LPS), in part by preventing upregulation of the counterinflammatory cytokine IL-10.	lps	128-131	interleukin 10	Homo sapiens	205-210
12219035-3	2002	Because the mitogen-activated protein kinase (MAPK) family is known to participate in LPS signaling, we hypothesized that altered upstream signaling through these kinases might contribute to impaired LPS-simulated IL-10 release after shock and resuscitation.	lps	86-89	interleukin 10	Homo sapiens	214-219
12219035-3	2002	Because the mitogen-activated protein kinase (MAPK) family is known to participate in LPS signaling, we hypothesized that altered upstream signaling through these kinases might contribute to impaired LPS-simulated IL-10 release after shock and resuscitation.	lps	200-203	interleukin 10	Homo sapiens	214-219
12219035-10	2002	To discern whether this reduction in LPS-stimulated MAPK activation after shock might contribute to reduced IL-10, specific inhibitors were used.	lps	37-40	interleukin 10	Homo sapiens	108-113
12219035-11	2002	Inhibition of p38 MAPK completely inhibited LPS-induced IL-10 production, whereas blockade of extracellular-regulated protein kinase pathway had no effect.	lps	44-47	mitogen-activated protein kinase 14	Homo sapiens	14-17
12219035-11	2002	Inhibition of p38 MAPK completely inhibited LPS-induced IL-10 production, whereas blockade of extracellular-regulated protein kinase pathway had no effect.	lps	44-47	interleukin 10	Homo sapiens	56-61
12219035-13	2002	For the critical counterinflammatory cytokine IL-10, inhibition of p38 activation appears to contribute to the reduced levels of this cytokine in response to LPS.	lps	158-161	interleukin 10	Homo sapiens	46-51
12219035-13	2002	For the critical counterinflammatory cytokine IL-10, inhibition of p38 activation appears to contribute to the reduced levels of this cytokine in response to LPS.	lps	158-161	mitogen-activated protein kinase 14	Homo sapiens	67-70
12021174-9	2002	In contrast, transcripts of fos-related antigen-2, growth arrest and DNA damage-inducible protein-45, and signal transducer and activator of transcription-3 were significantly increased in the LPs of T + E2-treated animals, but the increases were reversed by cotreatment with ICI.	lps	193-196	signal transducer and activator of transcription 3	Rattus norvegicus	106-156
12021174-11	2002	Lastly, levels of A-RAF, VIP-1 receptor, and calpastatin mRNA were distinctly lessen in rat LPs under T + E2 influence, but rebound with ICI cotreatment.	lps	92-95	A-Raf proto-oncogene, serine/threonine kinase	Rattus norvegicus	18-23
11516215-4	2001	METHODS: We studied the interaction between nuclear factor kappaB (NF-kappaB) binding activity and tumor necrosis factor alpha (TNF-alpha) secretion in an experimental system using LPS-stimulated human peripheral blood mononuclear cells (PBMCs), after neutralization of LPS with polymyxin B. PBMCs were incubated with LPS in vitro, and TNF-alpha secretion and NF-kappaB activation were assessed.	lps	181-184	nuclear factor kappa B subunit 1	Homo sapiens	67-76
11805217-5	2002	Selective PDE1 inhibition (8-methoxymethyl-3-isobutyl-1-methylxanthine) blockaded lipopolysaccharide-endotoxin (LPS)-mediated biosynthesis of interleukin (IL)-6, but this pathway had no inhibitory effect on tumor necrosis factor-alpha (TNF-alpha).	lps	112-115	interleukin 6	Homo sapiens	142-160
11805217-5	2002	Selective PDE1 inhibition (8-methoxymethyl-3-isobutyl-1-methylxanthine) blockaded lipopolysaccharide-endotoxin (LPS)-mediated biosynthesis of interleukin (IL)-6, but this pathway had no inhibitory effect on tumor necrosis factor-alpha (TNF-alpha).	lps	112-115	tumor necrosis factor	Homo sapiens	207-234
11805217-5	2002	Selective PDE1 inhibition (8-methoxymethyl-3-isobutyl-1-methylxanthine) blockaded lipopolysaccharide-endotoxin (LPS)-mediated biosynthesis of interleukin (IL)-6, but this pathway had no inhibitory effect on tumor necrosis factor-alpha (TNF-alpha).	lps	112-115	tumor necrosis factor	Homo sapiens	236-245
11805217-6	2002	Furthermore, inhibition of PDE3 (amrinone) abolished the effect of LPS on IL-6, but attenuated TNF-alpha production.	lps	67-70	interleukin 6	Homo sapiens	74-78
11805217-10	2002	Finally, nonselective inhibition of PDE by pentoxifylline suppressed LPS-mediated secretion of IL-6 and TNF-alpha.	lps	69-72	interleukin 6	Homo sapiens	95-99
11805217-10	2002	Finally, nonselective inhibition of PDE by pentoxifylline suppressed LPS-mediated secretion of IL-6 and TNF-alpha.	lps	69-72	tumor necrosis factor	Homo sapiens	104-113
12537696-6	2002	The proportion of monocytes producing TNF-alpha after LPS stimulus was higher in HV than SP (mean +/- SD = 25.2 +/- 14.2% and 2.2 +/- 2.6%, respectively, P < 0.001).	lps	54-57	tumor necrosis factor	Homo sapiens	38-47
12537696-7	2002	LPS-induced CD69 on T CD8+ and CD8- lymphocytes was similar for patients and controls.	lps	0-3	CD69 molecule	Homo sapiens	12-16
12537696-7	2002	LPS-induced CD69 on T CD8+ and CD8- lymphocytes was similar for patients and controls.	lps	0-3	CD8a molecule	Homo sapiens	22-25
12537696-7	2002	LPS-induced CD69 on T CD8+ and CD8- lymphocytes was similar for patients and controls.	lps	0-3	CD8a molecule	Homo sapiens	31-34
11781619-10	2001	The CD34(+) compartment of CB grafts contained a significantly higher percentage (12.1%) of CD34(+)CD7(+)CD3(-) T cell progenitors than those of BM grafts (5.1%) and LPs (3.6%).	lps	166-169	CD34 antigen	Mus musculus	4-8
11781619-12	2001	In summary, LPs, CB allografts and BM allografts differ widely with respect to the cellular composition of their lymphocyte compartments, which is partially affected by a varying mobilization efficiency of G-CSF for distinct lymphocyte subsets.	lps	12-15	peripheral blood stem cell response to granulocyte colony stimulating factor 1	Mus musculus	206-211
11698145-4	2001	When rats were pre-treated with Escherichia coli lipopolisaccharide (LPS), an enhancement of cardiovascular response elicited by IL-1 beta and TNF alpha was found.	lps	69-72	interleukin 1 beta	Rattus norvegicus	129-138
11698145-4	2001	When rats were pre-treated with Escherichia coli lipopolisaccharide (LPS), an enhancement of cardiovascular response elicited by IL-1 beta and TNF alpha was found.	lps	69-72	tumor necrosis factor	Rattus norvegicus	143-152
12701623-6	2002	Pretreatment of THP-1 cells with PTx attenuated LPS-induced activation of c-Jun-N-terminal kinase (JNK) and p38 kinase, and production of tumor necrosis factor-alpha (TN-alpha) and thromboxane B2 (TXB2).	lps	48-51	mitogen-activated protein kinase 8	Homo sapiens	74-97
12701623-6	2002	Pretreatment of THP-1 cells with PTx attenuated LPS-induced activation of c-Jun-N-terminal kinase (JNK) and p38 kinase, and production of tumor necrosis factor-alpha (TN-alpha) and thromboxane B2 (TXB2).	lps	48-51	mitogen-activated protein kinase 8	Homo sapiens	99-102
12701623-6	2002	Pretreatment of THP-1 cells with PTx attenuated LPS-induced activation of c-Jun-N-terminal kinase (JNK) and p38 kinase, and production of tumor necrosis factor-alpha (TN-alpha) and thromboxane B2 (TXB2).	lps	48-51	mitogen-activated protein kinase 14	Homo sapiens	108-111
12701623-8	2002	Therefore, the Ga i-coupled signaling pathways and Src tyrosine kinase-coupled signaling pathways are necessary for LPS-induced TNF-alpha and TxB2 production, but differ in their effects on MAPK activation.	lps	116-119	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
12701623-8	2002	Therefore, the Ga i-coupled signaling pathways and Src tyrosine kinase-coupled signaling pathways are necessary for LPS-induced TNF-alpha and TxB2 production, but differ in their effects on MAPK activation.	lps	116-119	tumor necrosis factor	Homo sapiens	128-137
12701623-10	2002	However, PP2 inhibited LPS-induced NF-kappaB transactivation of a luciferase reporter gene construct in a concentration-dependent manner.	lps	23-26	nuclear factor kappa B subunit 1	Homo sapiens	35-44
12701623-11	2002	Thus, LPS induction of Src tyrosine kinases may be essential in downstream NF-kappaB tansactivation of genes following DNA binding.	lps	6-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	23-26
12701623-11	2002	Thus, LPS induction of Src tyrosine kinases may be essential in downstream NF-kappaB tansactivation of genes following DNA binding.	lps	6-9	nuclear factor kappa B subunit 1	Homo sapiens	75-84
12372980-10	2002	Ninety minutes after LPS injection, a peak of serum TNF activity was detected in both groups compared with naive levels.	lps	21-24	tumor necrosis factor-like	Rattus norvegicus	52-55
11516215-4	2001	METHODS: We studied the interaction between nuclear factor kappaB (NF-kappaB) binding activity and tumor necrosis factor alpha (TNF-alpha) secretion in an experimental system using LPS-stimulated human peripheral blood mononuclear cells (PBMCs), after neutralization of LPS with polymyxin B. PBMCs were incubated with LPS in vitro, and TNF-alpha secretion and NF-kappaB activation were assessed.	lps	181-184	tumor necrosis factor	Homo sapiens	99-126
11516215-4	2001	METHODS: We studied the interaction between nuclear factor kappaB (NF-kappaB) binding activity and tumor necrosis factor alpha (TNF-alpha) secretion in an experimental system using LPS-stimulated human peripheral blood mononuclear cells (PBMCs), after neutralization of LPS with polymyxin B. PBMCs were incubated with LPS in vitro, and TNF-alpha secretion and NF-kappaB activation were assessed.	lps	181-184	tumor necrosis factor	Homo sapiens	128-137
11516215-6	2001	RESULTS: Immediate inhibition of NF-kappaB binding activity and suppression of TNF-alpha secretion were observed after LPS neutralization with polymyxin B regardless of whether PBMCs were already producing TNF-alpha.	lps	119-122	nuclear factor kappa B subunit 1	Homo sapiens	33-42
11516215-6	2001	RESULTS: Immediate inhibition of NF-kappaB binding activity and suppression of TNF-alpha secretion were observed after LPS neutralization with polymyxin B regardless of whether PBMCs were already producing TNF-alpha.	lps	119-122	tumor necrosis factor	Homo sapiens	79-88
10937574-0	2000	IFN-gamma and LPS-mediated IL-10-dependent suppression of retinal microglial activation.	lps	14-17	interleukin 10	Homo sapiens	27-32
11728162-9	2001	Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3).	lps	127-130	vascular endothelial growth factor A	Mus musculus	84-88
11728162-10	2001	A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid.	lps	31-34	vascular endothelial growth factor A	Mus musculus	43-47
11556519-8	2001	RESULTS: We have demonstrated that aceclofenac, 4"-hydroxyaceclofenac and diclofenac significantly decreased interleukin-6 production at concentrations ranged among 1 to 30 microM and fully blocked prostaglandin E2 synthesis by IL-1beta- or LPS-stimulated human chondrocytes.	lps	241-244	interleukin 6	Homo sapiens	109-122
11401996-7	2001	Equivalent levels of induction of spleen gamma interferon mRNA and anti-lipopolysaccharide (LPS) of immunoglobulin G2a (IgG2a) subtype antibodies were observed in mice injected with B. abortus S19 or the cgs mutant.	lps	92-95	immunoglobulin heavy variable V1-9	Mus musculus	120-125
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	RELA proto-oncogene, NF-kB subunit	Homo sapiens	367-370
11256945-3	2001	LPS accelerated the degradation of inhibitory kappaB-alpha (IkappaB-alpha), accompanied by enhancing its phosphorylation in the cytosolic compartment but not in the nucleus.	lps	0-3	NFKB inhibitor alpha	Homo sapiens	60-73
11256945-5	2001	Interleukin-1 receptor antagonist (IL-1ra) decreased the nuclear abundance of p50, p65 and p75, and subsequently depressed the DNA-binding activity induced by LPS.	lps	159-162	interleukin 1 receptor antagonist	Homo sapiens	0-33
11256945-5	2001	Interleukin-1 receptor antagonist (IL-1ra) decreased the nuclear abundance of p50, p65 and p75, and subsequently depressed the DNA-binding activity induced by LPS.	lps	159-162	interleukin 1 receptor antagonist	Homo sapiens	35-41
11256945-5	2001	Interleukin-1 receptor antagonist (IL-1ra) decreased the nuclear abundance of p50, p65 and p75, and subsequently depressed the DNA-binding activity induced by LPS.	lps	159-162	nuclear factor kappa B subunit 1	Homo sapiens	78-81
11256945-5	2001	Interleukin-1 receptor antagonist (IL-1ra) decreased the nuclear abundance of p50, p65 and p75, and subsequently depressed the DNA-binding activity induced by LPS.	lps	159-162	RELA proto-oncogene, NF-kB subunit	Homo sapiens	83-86
11256945-7	2001	LPS induced endogenous IL-1beta biosynthesis in a time-dependent manner; the administration of exogenous recombinant human interleukin 1 (rhIL-1) resulted in a dose-dependent activation of NF-kappaB.	lps	0-3	interleukin 1 beta	Homo sapiens	23-31
11256945-7	2001	LPS induced endogenous IL-1beta biosynthesis in a time-dependent manner; the administration of exogenous recombinant human interleukin 1 (rhIL-1) resulted in a dose-dependent activation of NF-kappaB.	lps	0-3	interleukin 1 alpha	Homo sapiens	123-144
11256945-7	2001	LPS induced endogenous IL-1beta biosynthesis in a time-dependent manner; the administration of exogenous recombinant human interleukin 1 (rhIL-1) resulted in a dose-dependent activation of NF-kappaB.	lps	0-3	nuclear factor kappa B subunit 1	Homo sapiens	189-198
10854425-1	2000	Lipopolysacharide (LPS) induced acute phase response (APR) in mouse liver leads to elevation of the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP).	lps	19-22	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	121-151
10854425-1	2000	Lipopolysacharide (LPS) induced acute phase response (APR) in mouse liver leads to elevation of the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP).	lps	19-22	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	153-164
10854425-1	2000	Lipopolysacharide (LPS) induced acute phase response (APR) in mouse liver leads to elevation of the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP).	lps	19-22	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	174-223
10854425-1	2000	Lipopolysacharide (LPS) induced acute phase response (APR) in mouse liver leads to elevation of the low molecular weight CCAAT/Enhancer binding protein (C/EBP) beta isoform, liver-enriched transcriptional inhibitory protein (LIP).	lps	19-22	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	225-228
10854425-4	2000	Our data demonstrate that binding of cytoplasmic proteins to the 5" region of C/EBPbeta mRNA is altered in response to LPS administration.	lps	119-122	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	78-87
10854425-7	2000	CUGBP1 immunoprecipitated from livers of LPS-treated mice, but not from normal animals, is capable of inducing LIP translation in a cell-free translation system.	lps	41-44	CUGBP, Elav-like family member 1	Mus musculus	0-6
10854425-7	2000	CUGBP1 immunoprecipitated from livers of LPS-treated mice, but not from normal animals, is capable of inducing LIP translation in a cell-free translation system.	lps	41-44	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	111-114
10823826-6	2000	TLR-2 synthesis is strongly induced in the adipocyte by LPS, TNFalpha, and the yeast cell wall extract zymosan.	lps	56-59	toll-like receptor 2	Mus musculus	0-5
10823826-7	2000	TLR-2 undergoes a lengthy intracellular maturation process with a half-life of exit from the ER of approximately 3 h. Furthermore, LPS treatment of adipocytes results in dramatic changes at the level of gene expression, including the synthesis of a distinct set of secretory proteins such as interleukin-6.	lps	131-134	toll-like receptor 2	Mus musculus	0-5
10823826-7	2000	TLR-2 undergoes a lengthy intracellular maturation process with a half-life of exit from the ER of approximately 3 h. Furthermore, LPS treatment of adipocytes results in dramatic changes at the level of gene expression, including the synthesis of a distinct set of secretory proteins such as interleukin-6.	lps	131-134	interleukin 6	Mus musculus	292-305
11521172-2	2001	Given the supersensitivity of endothelial PAR-2 under endotoxaemia, we investigated if endotoxin/lipopolysaccharide (LPS) could alter the sensitivity of PAR-2 in the salivary glands.	lps	117-120	coagulation factor II (thrombin) receptor-like 1	Mus musculus	153-158
11521172-4	2001	administration of the PAR-2-activating peptide SLIGRL-NH2, but not of carbachol, gradually decreased 6-20 h after LPS administration in the mice.	lps	114-117	coagulation factor II (thrombin) receptor-like 1	Mus musculus	22-27
11521172-5	2001	The LPS-induced hyporeactivity to the PAR-2 agonist was partially reversed by repeated administration of aprotinin, a non-specific protease inhibitor.	lps	4-7	coagulation factor II (thrombin) receptor-like 1	Mus musculus	38-43
11521172-6	2001	PAR-2 mRNA levels in the salivary glands, as assessed by the semi-quantitative RT-PCR analysis, remained unchanged following LPS challenge.	lps	125-128	coagulation factor II (thrombin) receptor-like 1	Mus musculus	0-5
11521172-7	2001	Our findings indicate that in contrast to the supersensitivity of endothelial PAR-2 as described previously, subsensitivity of PAR-2 in the salivary glands develops during the LPS-induced systemic inflammation, which might involve desensitisation of PAR-2 by endogenous proteases.	lps	176-179	coagulation factor II (thrombin) receptor-like 1	Mus musculus	127-132
11521172-7	2001	Our findings indicate that in contrast to the supersensitivity of endothelial PAR-2 as described previously, subsensitivity of PAR-2 in the salivary glands develops during the LPS-induced systemic inflammation, which might involve desensitisation of PAR-2 by endogenous proteases.	lps	176-179	coagulation factor II (thrombin) receptor-like 1	Mus musculus	127-132
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	nuclear factor kappa B subunit 1	Homo sapiens	217-226
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	nuclear factor kappa B subunit 1	Homo sapiens	232-235
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	RELA proto-oncogene, NF-kB subunit	Homo sapiens	238-242
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	RELA proto-oncogene, NF-kB subunit	Homo sapiens	244-247
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	REL proto-oncogene, NF-kB subunit	Homo sapiens	253-258
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	interleukin 2 receptor subunit beta	Homo sapiens	260-263
11256945-2	2001	In a model of foetal alveolar type II epithelial cells in vitro, we showed that lipopolysaccharide endotoxin (LPS) differentially, but selectively, induced the nuclear subunit composition of nuclear factor kappaB(1) (NF-kappaB(1)) (p50), RelA (p65) and c-Rel (p75), in parallel to up-regulating the DNA-binding activity (supershift indicating the presence of the p50-p65 complex).	lps	110-113	nuclear factor kappa B subunit 1	Homo sapiens	363-366
11150025-7	2001	Yet lepirudin blunted the LPS-induced increase in circulating P-selectin by one half (P <.005 vs placebo), whereas both heparins did not diminish the increase in this platelet or endothelial activation marker as compared with placebo.	lps	26-29	selectin P	Homo sapiens	62-72
11150025-9	2001	Of potential clinical interest is the observation that the direct thrombin inhibitor lepirudin, in contrast to heparins, mitigated LPS-induced platelet activation.	lps	131-134	coagulation factor II, thrombin	Homo sapiens	66-74
11603297-7	2000	However, at higher stimulation with LPS 100 mg/L and PMA 200 nmol/L, they downregulated TNF alpha production.	lps	36-39	tumor necrosis factor	Homo sapiens	88-97
10937574-13	2000	However, proinflammatory stimulation with IFNgamma-LPS induces an IL-10-mediated downregulation of cell surface antigen expression and loss of migratory and phagocytic activity.	lps	51-54	interleukin 10	Homo sapiens	66-71
10930989-1	2000	Activated protein C (APC) protects against sepsis in animal models and inhibits the lipopolysacharide (LPS)-induced elaboration of proinflammatory cytokines from monocytes.	lps	103-106	APC regulator of WNT signaling pathway	Homo sapiens	0-19
10930989-3	2000	We assessed the effect of APC on LPS-induced tumour necrosis factor alpha (TNF-alpha) production and on the activation of the central proinflammatory transcription factor nuclear factor-kappaB (NF-kappaB) in a THP-1 cell line.	lps	33-36	tumor necrosis factor	Homo sapiens	75-84
10930989-5	2000	APC inhibited LPS-induced production of TNF-alpha both in the presence and absence of fetal calf serum (FCS), although the effect was less marked with 10% FCS.	lps	14-17	tumor necrosis factor	Homo sapiens	40-49
10930989-6	2000	APC also inhibited LPS-induced activation of NF-kappaB, with APC (200 microg/ml) abolishing the effect of LPS (100 ng/ml).	lps	19-22	nuclear factor kappa B subunit 1	Homo sapiens	45-54
10930989-7	2000	The ability of APC to inhibit LPS-induced translocation of NF-kappaB is likely to be a significant event given the critical role of the latter in the host inflammatory response.	lps	30-33	nuclear factor kappa B subunit 1	Homo sapiens	59-68
10670845-2	2000	Endotoxin (bacterial lipopolysacchride [LPS]) causes an increased production of nitric oxide (NO) by inducing nitric oxide synthase (iNOS) expression in various tissues.	lps	40-43	nitric oxide synthase 2	Rattus norvegicus	133-137
10678970-2	2000	In mice, these two conjugates elicited high levels of immunoglobulin G (IgG) anti-lipopolysaccharide (LPS) in serum with bactericidal activity (E. Konadu, J. Shiloach, D. A. Bryla, J.	lps	102-105	immunoglobulin heavy variable V1-62	Mus musculus	54-70
10678970-2	2000	In mice, these two conjugates elicited high levels of immunoglobulin G (IgG) anti-lipopolysaccharide (LPS) in serum with bactericidal activity (E. Konadu, J. Shiloach, D. A. Bryla, J.	lps	102-105	immunoglobulin heavy variable V1-62	Mus musculus	72-75
10678970-8	2000	At 4 weeks after injection, there were significant increases of the geometric mean IgG and IgM anti-LPS levels in the adults and teenagers: both conjugates elicited a greater than fourfold rise in the IgG anti-LPS level in serum in >/=80% of the volunteers.	lps	100-103	immunoglobulin heavy variable V1-62	Mus musculus	201-204
10678970-8	2000	At 4 weeks after injection, there were significant increases of the geometric mean IgG and IgM anti-LPS levels in the adults and teenagers: both conjugates elicited a greater than fourfold rise in the IgG anti-LPS level in serum in >/=80% of the volunteers.	lps	210-213	immunoglobulin heavy variable V1-62	Mus musculus	201-204
10678970-9	2000	SPA-TT(2) elicited slightly higher, though not statistically significantly, levels of IgG anti-LPS than did SPA-TT(1) in these age groups.	lps	95-98	immunoglobulin heavy variable V1-62	Mus musculus	86-89
10678970-13	2000	A significant rise in the IgG anti-LPS titer was elicited by the first injection (P = 0.0001); a second injection did not elicit a booster response.	lps	35-38	immunoglobulin heavy variable V1-62	Mus musculus	26-29
10999440-2	2000	TJ-48-lipopolysaccharide (LPS) combination induced iNOS mRNA expression earlier, stronger and remained longer that paralleled but with a higher NO production compared to LPS stimulation.	lps	26-29	nitric oxide synthase 2, inducible	Mus musculus	51-55
10605950-13	1999	The next morning after exercise, the LPS-induced IL-8 production increased 137, 89, and 96%, respectively, in control, low-, and high-dose wine groups, probably due to a rise in epinephrine and activation of platelets.	lps	37-40	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
10207613-4	1999	), which was carried out to examine how much more effective is i.c.v.-LPS than i.p.-LPS, showed that the pattern of alteration of expression of CYP isozymes induced by i.c.v.-LPS was different from that caused by i.p.-LPS at an effective dose (10 micrograms/rat).	lps	70-73	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-147
10354505-2	1999	Expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 mRNA in response to LPS stimulation was suppressed in LPS-tolerant macrophages.	lps	91-94	tumor necrosis factor	Mus musculus	14-47
10354505-2	1999	Expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 mRNA in response to LPS stimulation was suppressed in LPS-tolerant macrophages.	lps	91-94	interleukin 6	Mus musculus	52-70
10354505-2	1999	Expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 mRNA in response to LPS stimulation was suppressed in LPS-tolerant macrophages.	lps	125-128	tumor necrosis factor	Mus musculus	14-47
10354505-2	1999	Expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 mRNA in response to LPS stimulation was suppressed in LPS-tolerant macrophages.	lps	125-128	interleukin 6	Mus musculus	52-70
10354505-5	1999	In addition to these proteins, another MAPK family protein, JNK, was also suppressed in LPS-tolerant macrophages.	lps	88-91	mitogen-activated protein kinase 1	Mus musculus	39-43
10354505-5	1999	In addition to these proteins, another MAPK family protein, JNK, was also suppressed in LPS-tolerant macrophages.	lps	88-91	mitogen-activated protein kinase 8	Mus musculus	60-63
10354505-6	1999	Activation of Raf-1, located in the upstream portion of ERK cascades, was also suppressed by LPS-tolerance induction.	lps	93-96	v-raf-leukemia viral oncogene 1	Mus musculus	14-19
10354505-6	1999	Activation of Raf-1, located in the upstream portion of ERK cascades, was also suppressed by LPS-tolerance induction.	lps	93-96	mitogen-activated protein kinase 1	Mus musculus	56-59
10354505-8	1999	Activation of the transcription factor NF-kappaB, which is supposed to be one of the components of another important pathway for transduction of LPS-stimulated cytokine producing signals, was strongly suppressed and degradation of IkappaB, an inhibitor of NF-kappaB, was also severely diminished in LPS-tolerant macrophages.	lps	145-148	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	39-48
10354505-8	1999	Activation of the transcription factor NF-kappaB, which is supposed to be one of the components of another important pathway for transduction of LPS-stimulated cytokine producing signals, was strongly suppressed and degradation of IkappaB, an inhibitor of NF-kappaB, was also severely diminished in LPS-tolerant macrophages.	lps	145-148	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	256-265
10354505-8	1999	Activation of the transcription factor NF-kappaB, which is supposed to be one of the components of another important pathway for transduction of LPS-stimulated cytokine producing signals, was strongly suppressed and degradation of IkappaB, an inhibitor of NF-kappaB, was also severely diminished in LPS-tolerant macrophages.	lps	299-302	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	39-48
10354505-8	1999	Activation of the transcription factor NF-kappaB, which is supposed to be one of the components of another important pathway for transduction of LPS-stimulated cytokine producing signals, was strongly suppressed and degradation of IkappaB, an inhibitor of NF-kappaB, was also severely diminished in LPS-tolerant macrophages.	lps	299-302	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	256-265
10354505-12	1999	This may then induce a refractory state in key LPS-signal transducer molecules located downstream of the cell membrane LPS receptor and upstream of the branching point in intracellular cascades for activation of MAPK and NF-kappaB, probably in some initial steps of intracellular signaling.	lps	47-50	mitogen-activated protein kinase 1	Mus musculus	212-216
10354505-12	1999	This may then induce a refractory state in key LPS-signal transducer molecules located downstream of the cell membrane LPS receptor and upstream of the branching point in intracellular cascades for activation of MAPK and NF-kappaB, probably in some initial steps of intracellular signaling.	lps	47-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	221-230
10353736-16	1999	Processing LPs leads to a similar CD34+ cell yield, a higher TC depletion compared to standard CD34+ cell selection, and no delay in hematopoietic recovery.	lps	11-14	CD34 molecule	Homo sapiens	34-38
10353736-16	1999	Processing LPs leads to a similar CD34+ cell yield, a higher TC depletion compared to standard CD34+ cell selection, and no delay in hematopoietic recovery.	lps	11-14	CD34 molecule	Homo sapiens	95-99
10207613-4	1999	), which was carried out to examine how much more effective is i.c.v.-LPS than i.p.-LPS, showed that the pattern of alteration of expression of CYP isozymes induced by i.c.v.-LPS was different from that caused by i.p.-LPS at an effective dose (10 micrograms/rat).	lps	84-87	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-147
10084255-6	1999	The frequencies of CFCs, week 5 CAFCs and week 8 CAFCs were 1.6-, 8.4- and 10.3-fold higher in the CD34+ compartment of mobilized blood than that of marrow, resulting in significantly higher yields of clonogenic HPCs in LPs when compared to BM grafts.	lps	220-223	CD34 molecule	Homo sapiens	99-103
10207613-4	1999	), which was carried out to examine how much more effective is i.c.v.-LPS than i.p.-LPS, showed that the pattern of alteration of expression of CYP isozymes induced by i.c.v.-LPS was different from that caused by i.p.-LPS at an effective dose (10 micrograms/rat).	lps	84-87	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-147
10207613-4	1999	), which was carried out to examine how much more effective is i.c.v.-LPS than i.p.-LPS, showed that the pattern of alteration of expression of CYP isozymes induced by i.c.v.-LPS was different from that caused by i.p.-LPS at an effective dose (10 micrograms/rat).	lps	84-87	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-147
10207613-5	1999	These results indicate that the decrease in hepatic CYP isozymes caused by i.c.v.-LPS could not be explained by the LPS leaked from the brain, suggesting that the decrease in hepatic CYP isozymes by i.c.v.-LPS may be caused by a central action of LPS.	lps	82-85	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	52-55
10207613-5	1999	These results indicate that the decrease in hepatic CYP isozymes caused by i.c.v.-LPS could not be explained by the LPS leaked from the brain, suggesting that the decrease in hepatic CYP isozymes by i.c.v.-LPS may be caused by a central action of LPS.	lps	82-85	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	183-186
10207613-6	1999	In this study, the possible involvement of sympathetic nervous and adrenocortical systems in the down-regulation of CYP isozymes by i.c.v.-LPS was investigated using surgical or chemical sympathetecomized or adrenalectomized rats.	lps	139-142	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	116-119
10207613-12	1999	Intracerebroventricular LPS decreased the total P450 content and the activities of CYP dependent drug metabolizing enzymes, ethoxyresorufin O-deethylase (EROD), pentoxyresorufin O-depentylase (PROD), imipramine N-demethylase (IMND) and erythromycin N-demethylase (ERND) after 24 h in both sympathetectomized rats and non-denervated rats.	lps	24-27	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	83-86
10207613-16	1999	Also, the adrenal glands, especially the adrenocortical system, play a suppressive role in the decrease in CYP isozymes caused by i.c.v.-LPS.	lps	137-140	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	107-110
9728932-4	1998	We analyzed the percentage of malignant cells and the number of CD34+ PBSCs in LPs mobilized by granulocyte colony-stimulating factor (G-CSF) alone (LP-S) compared with high-dose cyclophosphamide plus G-CSF (LP-CY) in patients with multiple myeloma (MM).	lps	79-82	CD34 molecule	Homo sapiens	64-68
9793002-9	1998	In cell cultures, the LPS-induced release of the inflammatory cytokines doubled for IL-1beta (P < 0.0001) and for IL-1ra (P < 0.0001).	lps	22-25	interleukin 1 beta	Homo sapiens	84-92
9793002-9	1998	In cell cultures, the LPS-induced release of the inflammatory cytokines doubled for IL-1beta (P < 0.0001) and for IL-1ra (P < 0.0001).	lps	22-25	interleukin 1 receptor antagonist	Homo sapiens	117-123
9728932-5	1998	A quantitative polymerase chain reaction assay involving CDR3-specific primers based on the method of limiting dilutions was used to determine the tumor loads of LPs.	lps	162-165	CDR3	Homo sapiens	57-61
9728932-9	1998	We conclude that mobilization by cyclophosphamide plus G-CSF leads to a lower number of malignant cells per CD34+ cell in LPs compared with G-CSF alone.	lps	122-125	colony stimulating factor 3	Homo sapiens	55-60
10503937-4	1999	The effect of LPS (6 x 10(3) u/ml) on TNF alpha release by J774, following overnight incubation with MG or L-NAME (1 mM), was examined 3 hours after LPS challenge.	lps	14-17	tumor necrosis factor	Rattus norvegicus	38-47
10503937-5	1999	LPS-stimulated J774 released 287.83+/-88 u/ml TNF alpha into the culture medium.	lps	0-3	tumor necrosis factor	Rattus norvegicus	46-55
10503937-9	1999	Serum TNF alpha levels in LPS treated rats 2 h after LPS challenge were 88.33+/-31.7 u/ml as compared to the serum TNF alpha levels of control rats (undetectable).	lps	26-29	tumor necrosis factor	Rattus norvegicus	6-15
10503937-9	1999	Serum TNF alpha levels in LPS treated rats 2 h after LPS challenge were 88.33+/-31.7 u/ml as compared to the serum TNF alpha levels of control rats (undetectable).	lps	26-29	tumor necrosis factor	Rattus norvegicus	115-124
10503937-9	1999	Serum TNF alpha levels in LPS treated rats 2 h after LPS challenge were 88.33+/-31.7 u/ml as compared to the serum TNF alpha levels of control rats (undetectable).	lps	53-56	tumor necrosis factor	Rattus norvegicus	6-15
9728932-9	1998	We conclude that mobilization by cyclophosphamide plus G-CSF leads to a lower number of malignant cells per CD34+ cell in LPs compared with G-CSF alone.	lps	122-125	CD34 molecule	Homo sapiens	108-112
9728932-4	1998	We analyzed the percentage of malignant cells and the number of CD34+ PBSCs in LPs mobilized by granulocyte colony-stimulating factor (G-CSF) alone (LP-S) compared with high-dose cyclophosphamide plus G-CSF (LP-CY) in patients with multiple myeloma (MM).	lps	79-82	colony stimulating factor 3	Homo sapiens	96-133
9728932-4	1998	We analyzed the percentage of malignant cells and the number of CD34+ PBSCs in LPs mobilized by granulocyte colony-stimulating factor (G-CSF) alone (LP-S) compared with high-dose cyclophosphamide plus G-CSF (LP-CY) in patients with multiple myeloma (MM).	lps	79-82	colony stimulating factor 3	Homo sapiens	135-140
9590656-1	1998	The aim of this study was to develop an inexpensive method for reducing the number of differentiated cells from granulocyte colony-stimulating factor-mobilized leukocytapheresis products (LPs) containing peripheral blood stem cells.	lps	188-191	colony stimulating factor 3	Homo sapiens	112-149
9660485-5	1998	The anti-inflammatory activity of aqueous humor and CGRP was assayed by treating IFN-gamma-lipopolysaccharide (LPS)-activated RAW 264.7 cells (macrophages) with aqueous humor, aqueous humor plus anti-CGRP antibody, or CGRP alone.	lps	111-114	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	52-56
9660485-5	1998	The anti-inflammatory activity of aqueous humor and CGRP was assayed by treating IFN-gamma-lipopolysaccharide (LPS)-activated RAW 264.7 cells (macrophages) with aqueous humor, aqueous humor plus anti-CGRP antibody, or CGRP alone.	lps	111-114	interferon gamma	Oryctolagus cuniculus	81-90
10189073-7	1998	In LPS-treated rats, the production of PGE2 was significantly higher than in the lungs of control rats, probably due to the induction of COX-2.	lps	3-6	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	137-142
9603137-10	1998	Despite equivalent serum endotoxin between groups, circulating TNF-alpha was 8-fold higher in BDL + LPS than in Sham + LPS rats at 1.5 and 3.5 h (p < 0.001), whereas serum TNF-alpha did not differ between BDL + NS and Sham + NS rats.	lps	100-103	tumor necrosis factor	Rattus norvegicus	63-72
9603137-10	1998	Despite equivalent serum endotoxin between groups, circulating TNF-alpha was 8-fold higher in BDL + LPS than in Sham + LPS rats at 1.5 and 3.5 h (p < 0.001), whereas serum TNF-alpha did not differ between BDL + NS and Sham + NS rats.	lps	119-122	tumor necrosis factor	Rattus norvegicus	63-72
9603137-11	1998	IL-6 likewise was increased differentially by 1.5 h in BDL + LPS animals (11.98 +/- 2.42 ng/ml) versus Sham + LPS rats (3.05 +/- 0.58 ng/ml, p < 0.05).	lps	61-64	interleukin 6	Rattus norvegicus	0-4
9603137-11	1998	IL-6 likewise was increased differentially by 1.5 h in BDL + LPS animals (11.98 +/- 2.42 ng/ml) versus Sham + LPS rats (3.05 +/- 0.58 ng/ml, p < 0.05).	lps	110-113	interleukin 6	Rattus norvegicus	0-4
9590656-6	1998	The adherence of CD34+ cells to the polyamide fiber was partially mediated by activated platelets that were present in the LPs.	lps	123-126	CD34 molecule	Homo sapiens	17-21
9704149-7	1998	The spontaneous and LPS-induced activity of TNF-alpha and IL-6 were measured with bioassays using indicator cell lines WEHI-164.13 and 7TD1, respectively.	lps	20-23	tumor necrosis factor	Homo sapiens	44-53
9616379-7	1998	The stimulation of LPS, rhIFN-gamma and rhIL-1 beta showed more NO induction than that of LPS with either IFN-gamma or IL-1 beta, suggesting the synergistic effects of cytokines.	lps	90-93	interleukin 1 beta	Homo sapiens	42-51
9704149-7	1998	The spontaneous and LPS-induced activity of TNF-alpha and IL-6 were measured with bioassays using indicator cell lines WEHI-164.13 and 7TD1, respectively.	lps	20-23	interleukin 6	Homo sapiens	58-62
9704149-10	1998	Addition of LF to the cultures of LPS-activated mononuclear cells stimulated IL-6 production, most markedly in the group of septic survivor patients (mean 1479, 1452, 1728, 1980 pg/ml on day 1, 2, 3 and 6 respectively).	lps	34-37	interleukin 6	Homo sapiens	77-81
9536123-10	1998	The ability of GBS to impair PKC-dependent cell signalling was also demonstrated by the reduced c-fos gene expression in GBS-infected macrophages with respect to control macrophages, after LPS stimulation.	lps	189-192	guanine nucleotide binding protein (G protein), beta 5	Mus musculus	15-18
9536123-10	1998	The ability of GBS to impair PKC-dependent cell signalling was also demonstrated by the reduced c-fos gene expression in GBS-infected macrophages with respect to control macrophages, after LPS stimulation.	lps	189-192	FBJ osteosarcoma oncogene	Mus musculus	96-101
9071433-3	1997	LTNPs or RIs, as well as LPs or TPs, exhibited similar titers of coculture p24 antigen; the differences between the former and the latter were statistically significant at all the time points tested (p = 0.0001; 0.0003 and 0.0001).	lps	25-28	transmembrane p24 trafficking protein 2	Homo sapiens	75-78
9129992-4	1997	Unhydrolyzed thalidomide at 4.0 micrograms/ml consistently enhanced the synthesis of IL-2 in SEA-stimulated cells, and suppressed the synthesis of TNF-alpha in LPS-stimulated cells; whereas, hydrolyzed thalidomide had no enhancing effect on SEA stimulated-cell synthesis of IL-2 or suppressive effect on LPS stimulated-cell synthesis of TNF-alpha.	lps	160-163	tumor necrosis factor	Homo sapiens	147-156
8735625-23	1996	Endotoxaemia for 6 h was also associated with a significant increase in iNOS activity in lung and liver, which was significantly reduced in lung or liver homogenates obtained from LPS-rats treated with 1-amino-2-hydroxy-guanidine.	lps	180-183	nitric oxide synthase 2	Rattus norvegicus	72-76
9070178-9	1997	Splenocyte IL-4 production was significantly upregulated in the FFx-LPS group that received anti-IL-10; maximal IL-4 production was on Day 5, with a greater than sevenfold increase compared to all other groups.	lps	68-71	interleukin 4	Mus musculus	11-15
9070178-9	1997	Splenocyte IL-4 production was significantly upregulated in the FFx-LPS group that received anti-IL-10; maximal IL-4 production was on Day 5, with a greater than sevenfold increase compared to all other groups.	lps	68-71	interleukin 10	Mus musculus	97-102
9070178-9	1997	Splenocyte IL-4 production was significantly upregulated in the FFx-LPS group that received anti-IL-10; maximal IL-4 production was on Day 5, with a greater than sevenfold increase compared to all other groups.	lps	68-71	interleukin 4	Mus musculus	112-116
9070178-11	1997	Treatment with anti-IL-10 antibody after FFx injury and septic challenge with LPS is associated with an upregulation of splenocyte IL-4 synthesis, as well as an increase in mortality in this murine model.	lps	78-81	interleukin 10	Mus musculus	20-25
9070178-11	1997	Treatment with anti-IL-10 antibody after FFx injury and septic challenge with LPS is associated with an upregulation of splenocyte IL-4 synthesis, as well as an increase in mortality in this murine model.	lps	78-81	interleukin 4	Mus musculus	131-135
8888507-2	1996	LPS is known to release cytokines from macrophages such as TNF, IL-1, IL-6 and induce metallothionein (MT) in the liver, kidney, heart, etc.	lps	0-3	interleukin 6	Rattus norvegicus	70-74
9020023-3	1997	Pharmacological studies showed that formation of PGE2 was mediated predominantly by COX-2, PGD2 by COX-1, and TXB2 by both COX-1 and COX-2 depending upon the timing of LPS stimulation.	lps	168-171	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	123-128
9020023-3	1997	Pharmacological studies showed that formation of PGE2 was mediated predominantly by COX-2, PGD2 by COX-1, and TXB2 by both COX-1 and COX-2 depending upon the timing of LPS stimulation.	lps	168-171	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	133-138
9020023-5	1997	Thus, concordant induction of terminal PGE2 synthase with COX-2 leads to the preferred production of PGE2 to TXB2 and PGD2 by LPS-stimulated macrophages.	lps	126-129	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	58-63
8847278-3	1995	In endothelium-denuded rings, the LPS-induced increase in contraction in response to ANG II was completely abolished.	lps	34-37	angiotensinogen	Rattus norvegicus	85-91
8920166-5	1996	Progesterone (10(-7) M) modestly (40%) reduced the levels of IL-6 mRNA and protein during culture, whereas LPS dramatically (8-fold) and rapidly induced IL-6 and IL-1 beta mRNAs and proteins.	lps	107-110	interleukin 6	Mus musculus	153-157
8920166-5	1996	Progesterone (10(-7) M) modestly (40%) reduced the levels of IL-6 mRNA and protein during culture, whereas LPS dramatically (8-fold) and rapidly induced IL-6 and IL-1 beta mRNAs and proteins.	lps	107-110	interleukin 1 beta	Mus musculus	162-171
8920166-9	1996	After LPS injection, IL-1 beta immunopositive cells were dispersed in the myometrium and mesometrial deciduum.	lps	6-9	interleukin 1 beta	Mus musculus	21-30
8920166-10	1996	In contrast, after LPS injection (2 h), IL-6 mRNA was abundant in "cords" of cells that traverse the mesometrial deciduum longitudinally, as well as in cells dispersed throughout the myometrium.	lps	19-22	interleukin 6	Mus musculus	40-44
8704096-1	1996	We evaluate the influence of IL-4, IL-10 and TGF-beta upon the release of IL-1 alpha, tumor necrosis factor-alpha (TNF-alpha), and IL-6 by lipopolisaccharide (LPS, 1 microgram/ml) stimulated alveolar macrophages (AM).	lps	159-162	interleukin 1 alpha	Homo sapiens	74-84
8704096-1	1996	We evaluate the influence of IL-4, IL-10 and TGF-beta upon the release of IL-1 alpha, tumor necrosis factor-alpha (TNF-alpha), and IL-6 by lipopolisaccharide (LPS, 1 microgram/ml) stimulated alveolar macrophages (AM).	lps	159-162	interleukin 6	Homo sapiens	131-135
8704096-2	1996	IL-4 reduced TNF-alpha release, in a dose dependent manner, to 62% and IL-1 alpha release to 42% of LPS-stimulated AM without IL-4.	lps	100-103	interleukin 4	Homo sapiens	0-4
8704096-2	1996	IL-4 reduced TNF-alpha release, in a dose dependent manner, to 62% and IL-1 alpha release to 42% of LPS-stimulated AM without IL-4.	lps	100-103	interleukin 1 alpha	Homo sapiens	71-81
8704096-4	1996	IL-10 suppressed LPS induced release of IL-alpha and TNF-alpha to approximately 50% of control without affecting IL-6 release.	lps	17-20	interleukin 10	Homo sapiens	0-5
8704096-4	1996	IL-10 suppressed LPS induced release of IL-alpha and TNF-alpha to approximately 50% of control without affecting IL-6 release.	lps	17-20	tumor necrosis factor	Homo sapiens	53-62
8704096-6	1996	Low concentrations of LPS (0.1 microgram/ml), allowed a dose-dependent TGF-beta-induced suppression of TNF-alpha-release to approximately 80% of control.	lps	22-25	transforming growth factor beta 1	Homo sapiens	71-79
8704096-6	1996	Low concentrations of LPS (0.1 microgram/ml), allowed a dose-dependent TGF-beta-induced suppression of TNF-alpha-release to approximately 80% of control.	lps	22-25	tumor necrosis factor	Homo sapiens	103-112
8847278-4	1995	Because the contraction induced by ANG II is modulated by the simultaneous release of prostaglandins, we tested the hypothesis that LPS interferes with this modulation.	lps	132-135	angiotensinogen	Rattus norvegicus	35-41
8847278-5	1995	We found that the LPS-induced increase in contraction to ANG II was inhibited in the presence of the cyclooxygenase inhibitor indomethacin (10(-5) M) or the prostaglandin H2/thromboxane A2-receptor antagonist SQ-29548 (2 x 10(-7) M).	lps	18-21	angiotensinogen	Rattus norvegicus	57-63
8847278-5	1995	We found that the LPS-induced increase in contraction to ANG II was inhibited in the presence of the cyclooxygenase inhibitor indomethacin (10(-5) M) or the prostaglandin H2/thromboxane A2-receptor antagonist SQ-29548 (2 x 10(-7) M).	lps	18-21	thromboxane A2 receptor	Rattus norvegicus	174-197
8847278-6	1995	Conversely, the LPS-induced increase in contraction in response to ANG II was not inhibited by the presence of dexamethasone (10(-6) M), which inhibits new protein synthesis.	lps	16-19	angiotensinogen	Rattus norvegicus	67-73
8847278-8	1995	We conclude that short exposure to LPS produces a specific increase in the constrictor response to ANG II via mechanisms mediated by prostaglandin H2/thromboxane A2.	lps	35-38	angiotensinogen	Rattus norvegicus	99-105
8847278-9	1995	This effect could be a LPS-induced shift in favor of constrictor prostanoids in the balance of dilator/constrictor prostanoids, the release of which is associated with stimulation by ANG II.	lps	23-26	angiotensinogen	Rattus norvegicus	183-189
8747796-8	1995	LPS infusion resulted in marked suppression of the pressor response to NE, AII, and VP in both conscious and anesthetized rats.	lps	0-3	angiotensinogen	Rattus norvegicus	75-78
8747796-8	1995	LPS infusion resulted in marked suppression of the pressor response to NE, AII, and VP in both conscious and anesthetized rats.	lps	0-3	arginine vasopressin	Rattus norvegicus	84-86
8747796-9	1995	LPS infusion suppressed the response to NPY in conscious, but not in anesthetized rats.	lps	0-3	neuropeptide Y	Rattus norvegicus	40-43
7537123-9	1995	With a probability of 95%, eg, 0.4 steady-state PB CD34+ cells x 10(6)/L allowed to collect in six LPs 2.5 x 10(6) CD34+ cells/kg, the reported threshold-dose of progenitor cells required for rapid and sustained engraftment after high-dose therapy.	lps	99-102	CD34 molecule	Homo sapiens	51-55
8588341-1	1995	Supernatants from feline peritoneal exudate cells (PECs) exposed to lipopolysaccharde (LPS) produced significantly (P < 0.05) more tumor necrosis factor (TNF) activity than supernatants from cells exposed to media.	lps	87-90	tumor necrosis factor	Felis catus	134-155
8588341-1	1995	Supernatants from feline peritoneal exudate cells (PECs) exposed to lipopolysaccharde (LPS) produced significantly (P < 0.05) more tumor necrosis factor (TNF) activity than supernatants from cells exposed to media.	lps	87-90	tumor necrosis factor	Felis catus	157-160
8588341-2	1995	An in vitro LPS response was obtained following incubation of whole blood with 10 micrograms ml-1 LPS for 2 h. Intravenous infusion of LPS (750 micrograms kg-1 rapidly increased plasma TNF activity to a maximum at 60 min after initiation of LPS infusion.	lps	12-15	tumor necrosis factor	Felis catus	185-188
8588341-2	1995	An in vitro LPS response was obtained following incubation of whole blood with 10 micrograms ml-1 LPS for 2 h. Intravenous infusion of LPS (750 micrograms kg-1 rapidly increased plasma TNF activity to a maximum at 60 min after initiation of LPS infusion.	lps	98-101	tumor necrosis factor	Felis catus	185-188
8588341-2	1995	An in vitro LPS response was obtained following incubation of whole blood with 10 micrograms ml-1 LPS for 2 h. Intravenous infusion of LPS (750 micrograms kg-1 rapidly increased plasma TNF activity to a maximum at 60 min after initiation of LPS infusion.	lps	98-101	tumor necrosis factor	Felis catus	185-188
8588341-2	1995	An in vitro LPS response was obtained following incubation of whole blood with 10 micrograms ml-1 LPS for 2 h. Intravenous infusion of LPS (750 micrograms kg-1 rapidly increased plasma TNF activity to a maximum at 60 min after initiation of LPS infusion.	lps	98-101	tumor necrosis factor	Felis catus	185-188
8588341-4	1995	Cats produce TNF in response to LPS in a manner similar to other species.	lps	32-35	tumor necrosis factor	Felis catus	13-16
7791330-0	1995	Nitric oxide inhibits LPS-induced IL-6 production in enterocytes.	lps	22-25	interleukin 6	Rattus norvegicus	34-38
7791330-1	1995	In recent studies, production of interleukin-6 (IL-6) in cultured enterocytes was stimulated by lipolysaccharide (LPS).	lps	114-117	interleukin 6	Rattus norvegicus	33-46
7791330-1	1995	In recent studies, production of interleukin-6 (IL-6) in cultured enterocytes was stimulated by lipolysaccharide (LPS).	lps	114-117	interleukin 6	Rattus norvegicus	48-52
7791330-3	1995	We tested the hypothesis that LPS-induced IL-6 production in the enterocyte is regulated, at least in part, by NO.	lps	30-33	interleukin 6	Rattus norvegicus	42-46
7791330-8	1995	Treatment of IEC-6 cells with LPS stimulated IL-6 production.	lps	30-33	interleukin 6	Rattus norvegicus	45-49
7791330-9	1995	LPS-induced IL-6 production was further increased by NNA in a dose-dependent fashion.	lps	0-3	interleukin 6	Rattus norvegicus	12-16
7791330-13	1995	PCR revealed an increase in iNOS mRNA expression in IEC-6 cells after administration of 1 microgram/ml LPS.	lps	103-106	nitric oxide synthase 2	Rattus norvegicus	28-32
7791330-14	1995	The results suggest that NO inhibits LPS-induced IL-6 production in the enterocyte.	lps	37-40	interleukin 6	Rattus norvegicus	49-53
7537123-9	1995	With a probability of 95%, eg, 0.4 steady-state PB CD34+ cells x 10(6)/L allowed to collect in six LPs 2.5 x 10(6) CD34+ cells/kg, the reported threshold-dose of progenitor cells required for rapid and sustained engraftment after high-dose therapy.	lps	99-102	CD34 molecule	Homo sapiens	115-119
8024362-4	1994	Bactericidal/permeability-increasing protein is a product of polymorphomononuclear cells (PMNs) that is stored in azurophilic granules and exhibits LPS-neutralizing activity in vitro and in some in vivo models.	lps	148-151	bactericidal permeability increasing protein	Homo sapiens	0-44
7535595-3	1995	The proportion of CD34+ cells in the leukapheresis products (LPs) was 1.4-fold greater than in BM samples that were obtained at the same day (LP: median, 1.4% v BM: median, 1.0%, P < .01).	lps	61-64	CD34 molecule	Homo sapiens	18-22
7535595-8	1995	The proportion of CD34+/CD45RA(bright) cells representing late colony-forming unit granulocyte-macrophage (CFU-GM) was smaller in LPs compared with BM (P < .05).	lps	130-133	CD34 molecule	Homo sapiens	18-22
8024362-7	1994	RESULTS: The BPI-treated animals demonstrated significantly (p < 0.03) lower circulating LPS-limulus amoebocyte lysate (LAL) activity compared with the control animals, but this reduction in LPS-LAL activity was not associated with improved survival.	lps	92-95	bactericidal permeability increasing protein	Homo sapiens	13-16
8024362-7	1994	RESULTS: The BPI-treated animals demonstrated significantly (p < 0.03) lower circulating LPS-limulus amoebocyte lysate (LAL) activity compared with the control animals, but this reduction in LPS-LAL activity was not associated with improved survival.	lps	194-197	bactericidal permeability increasing protein	Homo sapiens	13-16
7932624-6	1993	LPS stimulated IL-6 production showed similar patterns for TB patients, healthy and social controls (median values of 6806, 1291 and 2667 pg/10(6) cells respectively, p < 0.001).	lps	0-3	interleukin 6	Homo sapiens	15-19
8044172-5	1994	This complex formation was also achieved in an in vitro mixture of cell-free hemolymph and LPS at 25 degrees C but not at 1 degree C. The lipophorin-LPS complex had a significantly lower capacity to elicit the mRNA of cecropin B, an antibacterial protein.	lps	149-152	cecropin CBM2-2	Bombyx mori	218-228
8025980-6	1994	LPS caused significant deterioration in indices of hemodynamic function and a significant increase in plasma CGRP concentration at all sampling sites by 120 min (P < 0.01).	lps	0-3	Calcitonin gene-related peptide	Sus scrofa	109-113
8025980-9	1994	These data confirm our previous findings of CGRP elevations in endotoxemic rats, and indicate that 1) LPS is a potent stimulus for the systemic release of CGRP, 2) increasing plasma CGRP concentrations temporally correlates with cardiovascular deterioration during LPS shock, and 3) there is little evidence that the portal circulation is a major source of circulating CGRP levels during LPS shock.	lps	102-105	Calcitonin gene-related peptide	Sus scrofa	155-159
8025980-9	1994	These data confirm our previous findings of CGRP elevations in endotoxemic rats, and indicate that 1) LPS is a potent stimulus for the systemic release of CGRP, 2) increasing plasma CGRP concentrations temporally correlates with cardiovascular deterioration during LPS shock, and 3) there is little evidence that the portal circulation is a major source of circulating CGRP levels during LPS shock.	lps	102-105	calcitonin-related polypeptide alpha	Rattus norvegicus	155-159
8025980-9	1994	These data confirm our previous findings of CGRP elevations in endotoxemic rats, and indicate that 1) LPS is a potent stimulus for the systemic release of CGRP, 2) increasing plasma CGRP concentrations temporally correlates with cardiovascular deterioration during LPS shock, and 3) there is little evidence that the portal circulation is a major source of circulating CGRP levels during LPS shock.	lps	102-105	calcitonin-related polypeptide alpha	Rattus norvegicus	155-159
8301216-3	1994	TGF-beta inhibits the cytotoxic activity of endotoxin/lipopolysaccharide (LPS)-activated macrophage cell lines and primary macrophage cultures, reducing their expression of cytokines and nitric oxide.	lps	74-77	transforming growth factor, beta 1	Mus musculus	0-8
8301216-4	1994	In this report we demonstrate that TGF-beta also attenuates the LPS-induced synthesis and secretion of prostaglandin E2 in murine RAW 264.7 macrophage cells.	lps	64-67	transforming growth factor, beta 1	Mus musculus	35-43
8301216-6	1994	While TGF-beta alone has no effect on expression from the TIS10/PGS-2 gene, this cytokine inhibits LPS-induced TIS10/PGS-2 protein accumulation and synthesis, as well as LPS-induced TIS10/PGS-2 message accumulation in RAW 264.7 cells.	lps	99-102	prostaglandin-endoperoxide synthase 2	Mus musculus	111-116
8301216-6	1994	While TGF-beta alone has no effect on expression from the TIS10/PGS-2 gene, this cytokine inhibits LPS-induced TIS10/PGS-2 protein accumulation and synthesis, as well as LPS-induced TIS10/PGS-2 message accumulation in RAW 264.7 cells.	lps	99-102	decorin	Mus musculus	117-122
8301216-6	1994	While TGF-beta alone has no effect on expression from the TIS10/PGS-2 gene, this cytokine inhibits LPS-induced TIS10/PGS-2 protein accumulation and synthesis, as well as LPS-induced TIS10/PGS-2 message accumulation in RAW 264.7 cells.	lps	99-102	prostaglandin-endoperoxide synthase 2	Mus musculus	111-116
8301216-6	1994	While TGF-beta alone has no effect on expression from the TIS10/PGS-2 gene, this cytokine inhibits LPS-induced TIS10/PGS-2 protein accumulation and synthesis, as well as LPS-induced TIS10/PGS-2 message accumulation in RAW 264.7 cells.	lps	99-102	decorin	Mus musculus	117-122
8301216-6	1994	While TGF-beta alone has no effect on expression from the TIS10/PGS-2 gene, this cytokine inhibits LPS-induced TIS10/PGS-2 protein accumulation and synthesis, as well as LPS-induced TIS10/PGS-2 message accumulation in RAW 264.7 cells.	lps	170-173	transforming growth factor, beta 1	Mus musculus	6-14
8301216-7	1994	TGF-beta concentrations in the range of 0.1-1.0 ng/ml (4-40 pM) maximally inhibit LPS-induced TIS10/PGS-2 message accumulation.	lps	82-85	transforming growth factor, beta 1	Mus musculus	0-8
8301216-7	1994	TGF-beta concentrations in the range of 0.1-1.0 ng/ml (4-40 pM) maximally inhibit LPS-induced TIS10/PGS-2 message accumulation.	lps	82-85	prostaglandin-endoperoxide synthase 2	Mus musculus	94-99
8301216-7	1994	TGF-beta concentrations in the range of 0.1-1.0 ng/ml (4-40 pM) maximally inhibit LPS-induced TIS10/PGS-2 message accumulation.	lps	82-85	decorin	Mus musculus	100-105
8301216-9	1994	TGF-beta also attenuates LPS-induced accumulation of unspliced TIS10/PGS-2 transcripts in RAW 264.7 cells, suggesting that this cytokine exerts its effects on TIS10/PGS-2 expression at the transcriptional level.	lps	25-28	transforming growth factor, beta 1	Mus musculus	0-8
8301216-9	1994	TGF-beta also attenuates LPS-induced accumulation of unspliced TIS10/PGS-2 transcripts in RAW 264.7 cells, suggesting that this cytokine exerts its effects on TIS10/PGS-2 expression at the transcriptional level.	lps	25-28	prostaglandin-endoperoxide synthase 2	Mus musculus	63-68
8301216-9	1994	TGF-beta also attenuates LPS-induced accumulation of unspliced TIS10/PGS-2 transcripts in RAW 264.7 cells, suggesting that this cytokine exerts its effects on TIS10/PGS-2 expression at the transcriptional level.	lps	25-28	decorin	Mus musculus	69-74
8301216-9	1994	TGF-beta also attenuates LPS-induced accumulation of unspliced TIS10/PGS-2 transcripts in RAW 264.7 cells, suggesting that this cytokine exerts its effects on TIS10/PGS-2 expression at the transcriptional level.	lps	25-28	prostaglandin-endoperoxide synthase 2	Mus musculus	159-164
8301216-9	1994	TGF-beta also attenuates LPS-induced accumulation of unspliced TIS10/PGS-2 transcripts in RAW 264.7 cells, suggesting that this cytokine exerts its effects on TIS10/PGS-2 expression at the transcriptional level.	lps	25-28	decorin	Mus musculus	165-170
8301216-10	1994	TGF-beta inhibits the LPS-induced accumulation of TIS10/PGS-2 protein and message in cultured murine peritoneal macrophages, as well as in macrophage cell lines.	lps	22-25	transforming growth factor, beta 1	Mus musculus	0-8
8301216-10	1994	TGF-beta inhibits the LPS-induced accumulation of TIS10/PGS-2 protein and message in cultured murine peritoneal macrophages, as well as in macrophage cell lines.	lps	22-25	prostaglandin-endoperoxide synthase 2	Mus musculus	50-55
8301216-10	1994	TGF-beta inhibits the LPS-induced accumulation of TIS10/PGS-2 protein and message in cultured murine peritoneal macrophages, as well as in macrophage cell lines.	lps	22-25	decorin	Mus musculus	56-61
7932624-7	1993	In all three groups, LPS-stimulated cells produced significantly more IL-6 than non-stimulated cultures (p < 0.001).	lps	21-24	interleukin 6	Homo sapiens	70-74
1928366-4	1991	Although colchicine resulted in a statistically significant increase in LPS-stimulated human alveolar macrophage IL-1 beta release, the increase was not as great as that observed with monocytes.	lps	72-75	interleukin 1 beta	Homo sapiens	113-122
1727430-2	1992	After in vitro activation by lipopolysaccharide acid (LPS), these macrophages hyperexpress IL-1 beta mRNA and hyperproduce IL-1 protein in comparison with +/+ controls.	lps	54-57	interleukin 1 beta	Mus musculus	91-100
1727430-2	1992	After in vitro activation by lipopolysaccharide acid (LPS), these macrophages hyperexpress IL-1 beta mRNA and hyperproduce IL-1 protein in comparison with +/+ controls.	lps	54-57	interleukin 1 complex	Mus musculus	91-95
1727430-4	1992	The hyperexpression of IL-1 beta mRNA in sg/sg macrophages is present whatever the duration of LPS stimulation, even for periods as short as 15 min, although it reaches a maximum after 4 h of stimulation.	lps	95-98	interleukin 1 beta	Mus musculus	23-32
1727430-7	1992	In addition, hyperexpression of two other cytokines, i.e., tumor necrosis factor-alpha and IL-1 alpha mRNAs, is also detected in LPS-stimulated macrophages of mutant mice.	lps	129-132	tumor necrosis factor	Mus musculus	59-86
1727430-7	1992	In addition, hyperexpression of two other cytokines, i.e., tumor necrosis factor-alpha and IL-1 alpha mRNAs, is also detected in LPS-stimulated macrophages of mutant mice.	lps	129-132	interleukin 1 alpha	Mus musculus	91-101
1439287-8	1992	RESULTS: 17.6% of all patients (except for IVCD) showed LPs with MAC12, 20.0% with ART, 30.3% with FUKUDA, and 14.1% with MAC1.	lps	56-59	integrin subunit alpha M	Homo sapiens	65-69
1439287-10	1992	4.3% of the PVC group showed LPs with MAC12, 13.0% with ART and FUKUDA, but no cases showed LPs with MAC1.	lps	29-32	integrin subunit alpha M	Homo sapiens	38-42
1439287-11	1992	25.5% of the myocardial infarction group showed LPs with MAC12 and MAC1, 30.9% with ART and 36.3% with FUKUDA.	lps	48-51	integrin subunit alpha M	Homo sapiens	57-61
1439287-17	1992	R value in high frequency low amplitude signals duration under 40 microV of LPs positive patients in MAC1 was 0.51 between ART and MAC 12, 0.18 between MAC12 and MAC1, and 0.32 between ART and MAC1.	lps	76-79	integrin subunit alpha M	Homo sapiens	101-105
1439287-17	1992	R value in high frequency low amplitude signals duration under 40 microV of LPs positive patients in MAC1 was 0.51 between ART and MAC 12, 0.18 between MAC12 and MAC1, and 0.32 between ART and MAC1.	lps	76-79	integrin subunit alpha M	Homo sapiens	152-156
1439287-17	1992	R value in high frequency low amplitude signals duration under 40 microV of LPs positive patients in MAC1 was 0.51 between ART and MAC 12, 0.18 between MAC12 and MAC1, and 0.32 between ART and MAC1.	lps	76-79	integrin subunit alpha M	Homo sapiens	152-156
1928366-1	1991	To study the role of microtubules in cytokine production, the effect of the microtubule depolymerizing agent colchicine on lipopolysaccharide endotoxin (LPS)-induced interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) release by blood monocytes and alveolar macrophages were examined.	lps	153-156	interleukin 1 beta	Homo sapiens	166-184
1928366-3	1991	Colchicine resulted in approximately 50% increase in LPS-induced IL-1 beta release and a 50% decrease in LPS-induced TNF-alpha release by human monocytes at all doses of LPS tested.	lps	53-56	interleukin 1 beta	Homo sapiens	65-74
1928366-3	1991	Colchicine resulted in approximately 50% increase in LPS-induced IL-1 beta release and a 50% decrease in LPS-induced TNF-alpha release by human monocytes at all doses of LPS tested.	lps	105-108	tumor necrosis factor	Homo sapiens	117-126
1928366-5	1991	Northern blot analysis suggested that the colchicine effect occurs pretranslationally because colchicine caused an increase in LPS-stimulated IL-1 beta mRNA levels and a decrease in TNF-alpha mRNA levels.	lps	127-130	interleukin 1 beta	Homo sapiens	142-151
1928366-3	1991	Colchicine resulted in approximately 50% increase in LPS-induced IL-1 beta release and a 50% decrease in LPS-induced TNF-alpha release by human monocytes at all doses of LPS tested.	lps	105-108	tumor necrosis factor	Homo sapiens	117-126
2269476-3	1990	Lipopylosaccharide (LPS) or Borrelia burgdorferi spirochetes (Bb) were used to induce TNF-alpha and IL-6 production in cultures.	lps	20-23	tumor necrosis factor	Homo sapiens	86-95
1874086-4	1991	During following observation, pts with LPs and SVT induced 5 of the 6 appeared clinical SVT or ventricular fibrillation (VF) repetitiously, and 1 died from sudden cardiac death.	lps	39-42	sodium voltage-gated channel alpha subunit 5	Homo sapiens	95-145
2269476-3	1990	Lipopylosaccharide (LPS) or Borrelia burgdorferi spirochetes (Bb) were used to induce TNF-alpha and IL-6 production in cultures.	lps	20-23	interleukin 6	Homo sapiens	100-104
2269476-6	1990	IL-6 was produced by 64 +/- 8% or 71 +/- 9% (means +/- SD) of the non-IVIg-exposed monocytes after LPS or Bb stimulation, respectively (n = 12).	lps	99-102	interleukin 6	Homo sapiens	0-4
2269476-8	1990	In these cultures 24 +/- 12% or 29 +/- 12% of the monocytes made IL-6 in response to LPS or Bb.	lps	85-88	interleukin 6	Homo sapiens	65-69
2269476-11	1990	LPS or Bb stimulation resulted in 47 +/- 18% or 69 +/- 7% TNF-alpha producing cells versus 48 +/- 9% or 59 +/- 8% in IVIg-supplemented cultures.	lps	0-3	tumor necrosis factor	Homo sapiens	58-67
34675802-11	2021	Our results also showed dramatic increases in the expression of iNOS and TNF-alpha in hippocampus of LPS-injected mice, which was significantly attenuated by SVHRP treatment.	lps	101-104	nitric oxide synthase 2, inducible	Mus musculus	64-68
34948033-9	2021	The injection of CAF reduced the LPS-induced expression of TNF mRNA in the ChP.	lps	33-36	tumor necrosis factor	Ovis aries	59-62
2307935-0	1990	Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6.	lps	68-71	interleukin 6	Mus musculus	147-160
2307935-0	1990	Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6.	lps	103-106	interleukin 6	Mus musculus	147-160
2307935-4	1990	The protection afforded by O side chain-specific antisera against endotoxin lethality was associated with decreased LPS-induced serum TNF and IL-6 levels, whereas core LPS antibodies had no effect on TNF or IL-6 levels.	lps	116-119	tumor necrosis factor	Mus musculus	134-137
2307935-4	1990	The protection afforded by O side chain-specific antisera against endotoxin lethality was associated with decreased LPS-induced serum TNF and IL-6 levels, whereas core LPS antibodies had no effect on TNF or IL-6 levels.	lps	116-119	interleukin 6	Mus musculus	142-146
34771674-6	2021	In contrast, DCs pulsed with LPs induced CD4+ and CD8+ T cell responses and one of them, designated L82, delayed LLC1 growth in vivo.	lps	29-32	CD4 antigen	Mus musculus	41-44
34675802-11	2021	Our results also showed dramatic increases in the expression of iNOS and TNF-alpha in hippocampus of LPS-injected mice, which was significantly attenuated by SVHRP treatment.	lps	101-104	tumor necrosis factor	Mus musculus	73-82
34675802-12	2021	In vitro results showed that SVHRP attenuated LPS-elicited expression of iNOS and TNF-alpha in different cultures without cell toxicity, which might be attributed to suppression of NF-kappaB and MAPK pathways by SVHRP.	lps	46-49	nitric oxide synthase 2, inducible	Mus musculus	73-77
34675802-12	2021	In vitro results showed that SVHRP attenuated LPS-elicited expression of iNOS and TNF-alpha in different cultures without cell toxicity, which might be attributed to suppression of NF-kappaB and MAPK pathways by SVHRP.	lps	46-49	tumor necrosis factor	Mus musculus	82-91
34153665-5	2021	The results showed that Z-312 significantly decreased the production of nitric oxide (NO), interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 in LPS-stimulated microglial cells.	lps	161-164	interleukin 1 alpha	Mus musculus	91-113
34153665-5	2021	The results showed that Z-312 significantly decreased the production of nitric oxide (NO), interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 in LPS-stimulated microglial cells.	lps	161-164	tumor necrosis factor	Mus musculus	115-148
34153665-5	2021	The results showed that Z-312 significantly decreased the production of nitric oxide (NO), interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 in LPS-stimulated microglial cells.	lps	161-164	interleukin 6	Mus musculus	153-157
35453419-16	2022	LPS significantly increased TNF-alpha, IL-6, TBARS, and H2O2 levels and decreased SOD, -SH groups, tGSH, the GSH/GSSG ratio, and GSH levels in rat ventricles and atria while alpha-LA administered after the injection of LPS significantly decreased TNF-alpha, IL-6, TBARS, and H2O2 levels.	lps	0-3	tumor necrosis factor	Rattus norvegicus	28-37
34139835-1	2021	Objective: To investigate the role of Bruton"s tyrosine kinase (BTK) in pyroptosis of intestinal cells caused by endotoxin/lipopolysaccharide (LPS) in scalded mice.	lps	143-146	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	38-62
34139835-1	2021	Objective: To investigate the role of Bruton"s tyrosine kinase (BTK) in pyroptosis of intestinal cells caused by endotoxin/lipopolysaccharide (LPS) in scalded mice.	lps	143-146	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	64-67
34139835-12	2021	Phosphorylation of BTK in intestinal tissue of mice in scald+LPS group at PIH 12 and 24 were obviously increased compared with those in scald alone group.	lps	61-64	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22
34139835-13	2021	Phosphorylation of BTK in intestinal tissue of mice in scald+LPS+3 mg/kg LFM-A13 group, scald+LPS+10 mg/kg LFM-A13 group, and scald+LPS+30 mg/kg LFM-A13 group were obviously decreased compared with those in scald+LPS group, and the degrees of decline gradually increased with increase of dose in LFM-A13.	lps	61-64	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22
34139835-13	2021	Phosphorylation of BTK in intestinal tissue of mice in scald+LPS+3 mg/kg LFM-A13 group, scald+LPS+10 mg/kg LFM-A13 group, and scald+LPS+30 mg/kg LFM-A13 group were obviously decreased compared with those in scald+LPS group, and the degrees of decline gradually increased with increase of dose in LFM-A13.	lps	94-97	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22
34139835-13	2021	Phosphorylation of BTK in intestinal tissue of mice in scald+LPS+3 mg/kg LFM-A13 group, scald+LPS+10 mg/kg LFM-A13 group, and scald+LPS+30 mg/kg LFM-A13 group were obviously decreased compared with those in scald+LPS group, and the degrees of decline gradually increased with increase of dose in LFM-A13.	lps	132-135	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22
34139835-13	2021	Phosphorylation of BTK in intestinal tissue of mice in scald+LPS+3 mg/kg LFM-A13 group, scald+LPS+10 mg/kg LFM-A13 group, and scald+LPS+30 mg/kg LFM-A13 group were obviously decreased compared with those in scald+LPS group, and the degrees of decline gradually increased with increase of dose in LFM-A13.	lps	213-216	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22
34139835-17	2021	(3) Compared with those in sham injury group and scald alone group, protein expressions of cleaved caspase-1 and caspase-11 in intestinal tissue of mice in scald+LPS group were obviously increased at PIH 12 and 24 (P<0.01).	lps	162-165	caspase 1	Mus musculus	99-108
34139835-19	2021	Compared with those in scald+LPS+3 mg/kg LFM-A13 group, protein expressions of cleaved caspase-1 and caspase-11 in intestinal tissue of mice in scald+LPS+10 mg/kg LFM-A13 group and scald+LPS+30 mg/kg LFM-A13 group at PIH 12 and 24 were obviously decreased (P<0.05 or P<0.01).	lps	29-32	caspase 1	Mus musculus	87-96
34139835-19	2021	Compared with those in scald+LPS+3 mg/kg LFM-A13 group, protein expressions of cleaved caspase-1 and caspase-11 in intestinal tissue of mice in scald+LPS+10 mg/kg LFM-A13 group and scald+LPS+30 mg/kg LFM-A13 group at PIH 12 and 24 were obviously decreased (P<0.05 or P<0.01).	lps	150-153	caspase 1	Mus musculus	87-96
34139835-19	2021	Compared with those in scald+LPS+3 mg/kg LFM-A13 group, protein expressions of cleaved caspase-1 and caspase-11 in intestinal tissue of mice in scald+LPS+10 mg/kg LFM-A13 group and scald+LPS+30 mg/kg LFM-A13 group at PIH 12 and 24 were obviously decreased (P<0.05 or P<0.01).	lps	187-190	caspase 1	Mus musculus	87-96
34139835-20	2021	(4) At PIH 12, content of IL-1beta in intestinal tissue and serum of mice in scald+LPS group were obviously higher than those in sham injury group and scald alone group (P<0.01), and content of IL-1beta in intestinal tissue and serum of mice in scald+LPS+30 mg/kg LFM-A13 group were obviously lower than those in scald+LPS group (P<0.01).	lps	83-86	interleukin 1 alpha	Mus musculus	26-34
34139835-20	2021	(4) At PIH 12, content of IL-1beta in intestinal tissue and serum of mice in scald+LPS group were obviously higher than those in sham injury group and scald alone group (P<0.01), and content of IL-1beta in intestinal tissue and serum of mice in scald+LPS+30 mg/kg LFM-A13 group were obviously lower than those in scald+LPS group (P<0.01).	lps	251-254	interleukin 1 alpha	Mus musculus	26-34
34139835-20	2021	(4) At PIH 12, content of IL-1beta in intestinal tissue and serum of mice in scald+LPS group were obviously higher than those in sham injury group and scald alone group (P<0.01), and content of IL-1beta in intestinal tissue and serum of mice in scald+LPS+30 mg/kg LFM-A13 group were obviously lower than those in scald+LPS group (P<0.01).	lps	251-254	interleukin 1 alpha	Mus musculus	194-202
34139835-20	2021	(4) At PIH 12, content of IL-1beta in intestinal tissue and serum of mice in scald+LPS group were obviously higher than those in sham injury group and scald alone group (P<0.01), and content of IL-1beta in intestinal tissue and serum of mice in scald+LPS+30 mg/kg LFM-A13 group were obviously lower than those in scald+LPS group (P<0.01).	lps	319-322	interleukin 1 alpha	Mus musculus	26-34
34139835-21	2021	Conclusions: Phosphorylation of BTK is related to increases of cleaved caspase-1 and caspase-11 in intestinal tissue, and IL-1beta content in intestinal tissue and serum of scalded sepsis mice caused by LPS.	lps	203-206	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	32-35
34139835-21	2021	Conclusions: Phosphorylation of BTK is related to increases of cleaved caspase-1 and caspase-11 in intestinal tissue, and IL-1beta content in intestinal tissue and serum of scalded sepsis mice caused by LPS.	lps	203-206	interleukin 1 alpha	Mus musculus	122-130
34139835-22	2021	Phosphorylation of BTK mediated intestinal cell pyroptosis of scalded mice caused by LPS.	lps	85-88	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	19-22
35453419-16	2022	LPS significantly increased TNF-alpha, IL-6, TBARS, and H2O2 levels and decreased SOD, -SH groups, tGSH, the GSH/GSSG ratio, and GSH levels in rat ventricles and atria while alpha-LA administered after the injection of LPS significantly decreased TNF-alpha, IL-6, TBARS, and H2O2 levels.	lps	0-3	interleukin 6	Rattus norvegicus	39-43
35453419-16	2022	LPS significantly increased TNF-alpha, IL-6, TBARS, and H2O2 levels and decreased SOD, -SH groups, tGSH, the GSH/GSSG ratio, and GSH levels in rat ventricles and atria while alpha-LA administered after the injection of LPS significantly decreased TNF-alpha, IL-6, TBARS, and H2O2 levels.	lps	0-3	tumor necrosis factor	Rattus norvegicus	247-256
35453419-16	2022	LPS significantly increased TNF-alpha, IL-6, TBARS, and H2O2 levels and decreased SOD, -SH groups, tGSH, the GSH/GSSG ratio, and GSH levels in rat ventricles and atria while alpha-LA administered after the injection of LPS significantly decreased TNF-alpha, IL-6, TBARS, and H2O2 levels.	lps	0-3	interleukin 6	Rattus norvegicus	258-262
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 1 alpha	Rattus norvegicus	60-69
35325966-22	2022	After stimulation of 12 h, the protein expression of iNOS of RAW264.7 cells in LPS alone group was significantly higher than that in PBS group and LPS+ADSCs-Exos group, respectively (with t values of 11.20 and 5.06, respectively, P<0.05 or P<0.01), and the protein expression of Arg1 was significantly lower than that in LPS+ADSCs-Exos group (t=15.01, P<0.01).	lps	79-82	nitric oxide synthase 2, inducible	Mus musculus	53-57
35325966-22	2022	After stimulation of 12 h, the protein expression of iNOS of RAW264.7 cells in LPS alone group was significantly higher than that in PBS group and LPS+ADSCs-Exos group, respectively (with t values of 11.20 and 5.06, respectively, P<0.05 or P<0.01), and the protein expression of Arg1 was significantly lower than that in LPS+ADSCs-Exos group (t=15.01, P<0.01).	lps	79-82	arginase, liver	Mus musculus	279-283
35325966-22	2022	After stimulation of 12 h, the protein expression of iNOS of RAW264.7 cells in LPS alone group was significantly higher than that in PBS group and LPS+ADSCs-Exos group, respectively (with t values of 11.20 and 5.06, respectively, P<0.05 or P<0.01), and the protein expression of Arg1 was significantly lower than that in LPS+ADSCs-Exos group (t=15.01, P<0.01).	lps	147-150	nitric oxide synthase 2, inducible	Mus musculus	53-57
35325966-22	2022	After stimulation of 12 h, the protein expression of iNOS of RAW264.7 cells in LPS alone group was significantly higher than that in PBS group and LPS+ADSCs-Exos group, respectively (with t values of 11.20 and 5.06, respectively, P<0.05 or P<0.01), and the protein expression of Arg1 was significantly lower than that in LPS+ADSCs-Exos group (t=15.01, P<0.01).	lps	321-324	nitric oxide synthase 2, inducible	Mus musculus	53-57
2509610-11	1989	PBMC cultured with LPS and latex beads in the absence of serum released 30-40K Mr IL-1 alpha, as well as 17K Mr IL-1 alpha and 17K Mr IL-1 beta.	lps	19-22	interleukin 1 alpha	Homo sapiens	82-92
2509610-11	1989	PBMC cultured with LPS and latex beads in the absence of serum released 30-40K Mr IL-1 alpha, as well as 17K Mr IL-1 alpha and 17K Mr IL-1 beta.	lps	19-22	interleukin 1 beta	Homo sapiens	134-143
2477997-2	1989	Exposure to E. coli lipopolysacharide (LPS) resulted in a dose- and time-dependent increase of IL-1 activity in monocytes culture supernatants.	lps	39-42	interleukin 1 alpha	Homo sapiens	95-99
2477997-3	1989	Maximal levels of secreted IL-1 in response to 10 ng LPS/ml were obtained at 18 h. PGE1, PGE2, cholera toxin (CT) and the phosphodiesterase inhibitor, isobutylmethylxanthin (IBMX), when added with LPS, resulted in a dose-dependent increase in cellular cAMP and in secreted IL-1.	lps	53-56	interleukin 1 alpha	Homo sapiens	27-31
2477997-3	1989	Maximal levels of secreted IL-1 in response to 10 ng LPS/ml were obtained at 18 h. PGE1, PGE2, cholera toxin (CT) and the phosphodiesterase inhibitor, isobutylmethylxanthin (IBMX), when added with LPS, resulted in a dose-dependent increase in cellular cAMP and in secreted IL-1.	lps	197-200	interleukin 1 alpha	Homo sapiens	27-31
2477997-4	1989	Maximal levels of secreted IL-1 were 2.5-5.0-fold over LPS alone.	lps	55-58	interleukin 1 alpha	Homo sapiens	27-31
7451974-4	1981	The T cell mitogen Con A and the B cell mitogen LPS, on the other hand, induced Qa5+ NK cells only in the presence of lymphocytes.	lps	48-51	histocompatibility 2, Q region locus 5	Mus musculus	80-83
7451974-5	1981	Con A-stimulated T cells and LPS-stimulated B cells release factors into the culture medium that activate Qa5+ NK cells.	lps	29-32	histocompatibility 2, Q region locus 5	Mus musculus	106-109
35453364-7	2022	Overall, the findings show that BGE inhibits lung inflammation and mucus secretion by decreasing the activation of TAK1 both in human epithelial cells and in CS/LPS-exposed animals, and could be a potential adjuvant in the treatment and prevention of airway inflammatory diseases caused by airway irritants such as CS.	lps	161-164	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	115-119
2680597-5	1989	It is suggested that in vivo low concentrations of LPS in bloodstream (in the absence of conspicuous pathology) might induce hyperlipidemia directly influencing on hepatic cells, while, under the higher concentrations of LPS, hyperlipidemia caused by cachectin (or tumor necrosis factor) is probably observed.	lps	51-54	tumor necrosis factor	Oryctolagus cuniculus	251-260
2674853-2	1989	While hck transcripts were increased only in response to bacterial lipopolysaccaride (LPS), expression of c-fgr was transiently induced both by the monocyte/macrophage proliferative stimulus CSF-1 as well as by signals which activate monocytic cells to functional states (granulocyte-macrophage colony stimulating factor (GM-CSF), LPS, and gamma interferon).	lps	331-334	fibroblast growth factor receptor 1	Mus musculus	106-111
33868396-4	2021	Strictly controlled by NIR light, GE11 peptide modified and CUR/ICG-loaded LPs (GE11-CUR/ICG-LPs) could introduce hyperthermia in EGFR overexpressed A549 cancer cells for photothermal therapy, which could also trigger the increased release of CUR for enhanced cancer cell inhibition.	lps	75-78	epidermal growth factor receptor	Homo sapiens	130-134
33868396-4	2021	Strictly controlled by NIR light, GE11 peptide modified and CUR/ICG-loaded LPs (GE11-CUR/ICG-LPs) could introduce hyperthermia in EGFR overexpressed A549 cancer cells for photothermal therapy, which could also trigger the increased release of CUR for enhanced cancer cell inhibition.	lps	93-96	epidermal growth factor receptor	Homo sapiens	130-134
33868396-5	2021	GE11-CUR/ICG-LPs synergized photochemotherapy could induce reactive oxygen species (ROS) generation and cytoskeleton disruption to activate stronger apoptotic signaling events than the photothermal therapy or chemotherapy alone by regulating Bax/Bcl-2 and PI3K/AKT pathways.	lps	13-16	BCL2 associated X, apoptosis regulator	Homo sapiens	242-245
33868396-5	2021	GE11-CUR/ICG-LPs synergized photochemotherapy could induce reactive oxygen species (ROS) generation and cytoskeleton disruption to activate stronger apoptotic signaling events than the photothermal therapy or chemotherapy alone by regulating Bax/Bcl-2 and PI3K/AKT pathways.	lps	13-16	BCL2 apoptosis regulator	Homo sapiens	246-251
33868396-5	2021	GE11-CUR/ICG-LPs synergized photochemotherapy could induce reactive oxygen species (ROS) generation and cytoskeleton disruption to activate stronger apoptotic signaling events than the photothermal therapy or chemotherapy alone by regulating Bax/Bcl-2 and PI3K/AKT pathways.	lps	13-16	AKT serine/threonine kinase 1	Homo sapiens	261-264
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 17A	Rattus norvegicus	105-110
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interferon gamma	Rattus norvegicus	112-121
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	tumor necrosis factor	Rattus norvegicus	127-136
33551748-6	2020	Conversely, anti-inflammatory cytokines (like IL-10, IL-13, CNTF, and IL-1Ra) were upregulated in the LPS-PC cells but not in the LPS-induced cells.	lps	102-105	interleukin 10	Rattus norvegicus	46-51
33551748-6	2020	Conversely, anti-inflammatory cytokines (like IL-10, IL-13, CNTF, and IL-1Ra) were upregulated in the LPS-PC cells but not in the LPS-induced cells.	lps	102-105	interleukin 13	Rattus norvegicus	53-58
33551748-6	2020	Conversely, anti-inflammatory cytokines (like IL-10, IL-13, CNTF, and IL-1Ra) were upregulated in the LPS-PC cells but not in the LPS-induced cells.	lps	102-105	ciliary neurotrophic factor	Rattus norvegicus	60-64
33551748-6	2020	Conversely, anti-inflammatory cytokines (like IL-10, IL-13, CNTF, and IL-1Ra) were upregulated in the LPS-PC cells but not in the LPS-induced cells.	lps	102-105	interleukin 1 receptor antagonist	Rattus norvegicus	70-76
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 1 alpha	Rattus norvegicus	71-79
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 2	Rattus norvegicus	81-85
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 3	Rattus norvegicus	87-91
33551748-7	2020	Meanwhile, the LPS initiated caspase-8 which in turn activates effector caspase 3/7.	lps	15-18	caspase 8	Rattus norvegicus	29-38
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 4	Rattus norvegicus	93-97
33551748-7	2020	Meanwhile, the LPS initiated caspase-8 which in turn activates effector caspase 3/7.	lps	15-18	caspase 3	Rattus norvegicus	72-83
33551748-4	2020	LPS-treated cells secreted more inflammatory cytokines like IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-17, IFN-gamma, and TNF-alpha than LPS-PC cells.	lps	0-3	interleukin 6	Rattus norvegicus	99-103
33551748-8	2020	When the activities of caspases in the LPS-induced cells were inhibited using z-VADfmk and z-DEVDfmk, the expressions of c-MYC and Hsp70 were increased, but p53 was reduced.	lps	39-42	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	121-126
32340415-19	2020	It can alleviate the LPS-induced inflammatory responses by regulating the ratio of apoptotic regulators Bax to Bcl-2 and inhibiting apoptosis of human pulmonary epithelial cells.	lps	21-24	BCL2 associated X, apoptosis regulator	Homo sapiens	104-107
33551748-8	2020	When the activities of caspases in the LPS-induced cells were inhibited using z-VADfmk and z-DEVDfmk, the expressions of c-MYC and Hsp70 were increased, but p53 was reduced.	lps	39-42	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	131-136
33551748-8	2020	When the activities of caspases in the LPS-induced cells were inhibited using z-VADfmk and z-DEVDfmk, the expressions of c-MYC and Hsp70 were increased, but p53 was reduced.	lps	39-42	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	157-160
33551748-10	2020	In conclusion, this study provides a basis for future research to better understand the molecular mechanism underlying LPS pre-conditioning /TLR4 pre-activation and its functional role in offering cytoprotective response in neuronal environment.	lps	119-122	toll-like receptor 4	Rattus norvegicus	141-145
32556678-2	2020	We aimed to investigate the roles of lncRNA MIAT and miR-330-5p in modulating inflammatory responses and oxidative stress in lipopolysachariden (LPS)-induced septic cardiomyopathy.	lps	145-148	myocardial infarction associated transcript (non-protein coding)	Mus musculus	44-48
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	myocardial infarction associated transcript (non-protein coding)	Mus musculus	13-17
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	microRNA 330	Mus musculus	39-46
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	myocardial infarction associated transcript (non-protein coding)	Mus musculus	120-124
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	microRNA 330	Mus musculus	143-150
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	microRNA 330	Mus musculus	143-150
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	TNF receptor-associated factor 6	Mus musculus	219-224
32556678-8	2020	Knockdown of MIAT or overexpression of miR-330-5p restrained inflammation and oxidative stress induced by LPS in vitro; MIAT directly targeted miR-330-5p to regulate NF-kappaB signaling, and miR-330-5p targeted against TRAF6 to suppress the activation of NF-kappaB signaling.	lps	106-109	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	255-264
32556678-9	2020	We determined that lncRNA MIAT directly binds to miR-330-5p to activate TRAF6/NF-kappaB signaling axis and further promotes inflammation response as well as oxidative stress in LPS-induced septic cardiomyopathy.	lps	177-180	myocardial infarction associated transcript (non-protein coding)	Mus musculus	26-30
32556678-9	2020	We determined that lncRNA MIAT directly binds to miR-330-5p to activate TRAF6/NF-kappaB signaling axis and further promotes inflammation response as well as oxidative stress in LPS-induced septic cardiomyopathy.	lps	177-180	microRNA 330	Mus musculus	49-56
32556678-9	2020	We determined that lncRNA MIAT directly binds to miR-330-5p to activate TRAF6/NF-kappaB signaling axis and further promotes inflammation response as well as oxidative stress in LPS-induced septic cardiomyopathy.	lps	177-180	TNF receptor-associated factor 6	Mus musculus	72-77
32556678-9	2020	We determined that lncRNA MIAT directly binds to miR-330-5p to activate TRAF6/NF-kappaB signaling axis and further promotes inflammation response as well as oxidative stress in LPS-induced septic cardiomyopathy.	lps	177-180	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-87
32556678-10	2020	This finding suggests the potential therapeutic role of lncRNA MIAT and miR-330-5p in LPS-induced myocardial injury.	lps	86-89	myocardial infarction associated transcript (non-protein coding)	Mus musculus	63-67
32829604-23	2020	Compared with that in blank control group, the apoptosis rate of CD4(+) CD25(+) Tregs in simple LPS group was significantly declined (t=6.02, P<0.01).	lps	96-99	Cd4 molecule	Rattus norvegicus	65-68
32829604-24	2020	Compared with the rate in simple LPS group, the apoptosis rates of CD4(+) CD25(+) Tregs in LPS+ Xuebijing group and LPS+ paeoniflorin group were significantly increased (t=20.32, 8.60, P<0.01).	lps	33-36	Cd4 molecule	Rattus norvegicus	67-70
32829604-24	2020	Compared with the rate in simple LPS group, the apoptosis rates of CD4(+) CD25(+) Tregs in LPS+ Xuebijing group and LPS+ paeoniflorin group were significantly increased (t=20.32, 8.60, P<0.01).	lps	91-94	Cd4 molecule	Rattus norvegicus	67-70
32829604-24	2020	Compared with the rate in simple LPS group, the apoptosis rates of CD4(+) CD25(+) Tregs in LPS+ Xuebijing group and LPS+ paeoniflorin group were significantly increased (t=20.32, 8.60, P<0.01).	lps	91-94	Cd4 molecule	Rattus norvegicus	67-70
32829604-25	2020	(2) Compared with those in simple CD3/CD28" group, the proliferative rate of CD4(+) T cells was significantly decreased in simple LPS" group (t=22.47, P<0.01), while IL-4 level from culture supernatant was significantly elevated (t=3.51, P<0.01).	lps	130-133	Cd4 molecule	Rattus norvegicus	77-80
32829604-26	2020	Compared with those in simple LPS" group, the proliferative rates of CD4(+) T cells in LPS+ Xuebijing" group and LPS+ paeoniflorin" group were significantly increased (t=16.31, 11.48, P<0.01), while IL-4 level from culture supernatant showed no obvious change.	lps	30-33	Cd4 molecule	Rattus norvegicus	69-72
32829604-26	2020	Compared with those in simple LPS" group, the proliferative rates of CD4(+) T cells in LPS+ Xuebijing" group and LPS+ paeoniflorin" group were significantly increased (t=16.31, 11.48, P<0.01), while IL-4 level from culture supernatant showed no obvious change.	lps	87-90	Cd4 molecule	Rattus norvegicus	69-72
32829604-26	2020	Compared with those in simple LPS" group, the proliferative rates of CD4(+) T cells in LPS+ Xuebijing" group and LPS+ paeoniflorin" group were significantly increased (t=16.31, 11.48, P<0.01), while IL-4 level from culture supernatant showed no obvious change.	lps	87-90	interleukin 4	Rattus norvegicus	199-203
32829604-26	2020	Compared with those in simple LPS" group, the proliferative rates of CD4(+) T cells in LPS+ Xuebijing" group and LPS+ paeoniflorin" group were significantly increased (t=16.31, 11.48, P<0.01), while IL-4 level from culture supernatant showed no obvious change.	lps	87-90	Cd4 molecule	Rattus norvegicus	69-72
32829604-26	2020	Compared with those in simple LPS" group, the proliferative rates of CD4(+) T cells in LPS+ Xuebijing" group and LPS+ paeoniflorin" group were significantly increased (t=16.31, 11.48, P<0.01), while IL-4 level from culture supernatant showed no obvious change.	lps	87-90	interleukin 4	Rattus norvegicus	199-203
32556678-10	2020	This finding suggests the potential therapeutic role of lncRNA MIAT and miR-330-5p in LPS-induced myocardial injury.	lps	86-89	microRNA 330	Mus musculus	72-79
32832941-4	2020	Of the 16 metabolites tested, urolithins (Uro), and Uro A, in particular were the most potent, showing a modest increase in basal NF-kappaB activity and a reduction in lipopolysaccaride (LPS)-induced NF-kappaB activity, gene expression and secretion of pro-inflammatory cytokines.	lps	187-190	nuclear factor kappa B subunit 1	Homo sapiens	200-209
32832941-5	2020	Protocatechuic acid and its sulfate/glucuronide metabolites reduced LPS-induced NF-kappaB activity, but not IL-6 and TNF-alpha cytokine secretion.	lps	68-71	nuclear factor kappa B subunit 1	Homo sapiens	80-89
32832941-6	2020	Interestingly, both ellagic acid and its metabolite Uro A had immunomodulating effects, although they regulated the immune response differently, and both reduced LPS-induced NF-kappaB activity in U937 cells.	lps	162-165	nuclear factor kappa B subunit 1	Homo sapiens	174-183
32832941-9	2020	The dual role observed for Uro A, showing both a modest increase in basal NF-kappaB activity and a reduction in LPS-induced NF-kappaB activity, as well as a reduction in LPS-induced pro-inflammatory cytokine secretion, makes this metabolite particularly interesting for further studies in animals and humans.	lps	112-115	nuclear factor kappa B subunit 1	Homo sapiens	124-133
32829604-21	2020	Results: (1) Compared with those in blank control group, the expressions of CTLA-4 and Foxp3 of CD4(+) CD25(+) Tregs (t=27.19, 17.00, P<0.01) and IL-10 level from culture supernatant (t=40.76, P<0.01) were significantly increased in rats in simple LPS group.	lps	248-251	cytotoxic T-lymphocyte-associated protein 4	Rattus norvegicus	76-82
32829604-21	2020	Results: (1) Compared with those in blank control group, the expressions of CTLA-4 and Foxp3 of CD4(+) CD25(+) Tregs (t=27.19, 17.00, P<0.01) and IL-10 level from culture supernatant (t=40.76, P<0.01) were significantly increased in rats in simple LPS group.	lps	248-251	forkhead box P3	Rattus norvegicus	87-92
32829604-21	2020	Results: (1) Compared with those in blank control group, the expressions of CTLA-4 and Foxp3 of CD4(+) CD25(+) Tregs (t=27.19, 17.00, P<0.01) and IL-10 level from culture supernatant (t=40.76, P<0.01) were significantly increased in rats in simple LPS group.	lps	248-251	Cd4 molecule	Rattus norvegicus	96-99
32508636-6	2020	Additionally, knockdown of heme oxygenase-1 (HO-1), one of the most important DHQ induced antioxidant genes, cancelled the inhibition of DHQ treatment on LPS induced TNF-alpha, IFN-gamma production.	lps	154-157	heme oxygenase 1	Mus musculus	27-43
32508636-6	2020	Additionally, knockdown of heme oxygenase-1 (HO-1), one of the most important DHQ induced antioxidant genes, cancelled the inhibition of DHQ treatment on LPS induced TNF-alpha, IFN-gamma production.	lps	154-157	heme oxygenase 1	Mus musculus	45-49
32508636-6	2020	Additionally, knockdown of heme oxygenase-1 (HO-1), one of the most important DHQ induced antioxidant genes, cancelled the inhibition of DHQ treatment on LPS induced TNF-alpha, IFN-gamma production.	lps	154-157	tumor necrosis factor	Mus musculus	166-175
32508636-6	2020	Additionally, knockdown of heme oxygenase-1 (HO-1), one of the most important DHQ induced antioxidant genes, cancelled the inhibition of DHQ treatment on LPS induced TNF-alpha, IFN-gamma production.	lps	154-157	interferon gamma	Mus musculus	177-186
32340415-19	2020	It can alleviate the LPS-induced inflammatory responses by regulating the ratio of apoptotic regulators Bax to Bcl-2 and inhibiting apoptosis of human pulmonary epithelial cells.	lps	21-24	BCL2 apoptosis regulator	Homo sapiens	111-116
31707461-0	2019	Mesenchymal stem cells inhibited the inflammation and oxidative stress in LPS-activated microglial cells through AMPK pathway.	lps	74-77	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	113-117
31707461-7	2019	Our data demonstrated that hBM-MSCs significantly increased the phosphorylated AMPK in LPS-activated microglial cells.	lps	87-90	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	79-83
31515511-8	2020	Notably, treating L-G9a-/- mice with recombinant mouse GSTP1 reversed the LPS- or APAP overdose-induced liver damage.	lps	74-77	glutathione S-transferase, pi 1	Mus musculus	55-60
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	CD3 antigen, epsilon polypeptide	Mus musculus	45-48
31707461-8	2019	In addition, our study indicated the inhibitory effect of hBM-MSCs on the pro-inflammatory mediators and oxidative stress by the AMPK pathway in LPS-activated microglial cells.	lps	145-148	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	129-133
31077362-7	2019	Inflammatory mediators, like tumor necrosis factor-alpha and prostaglandin E2 , increased by LPS-induced EP, were diminished in gingival tissue of rats treated with Capz.	lps	93-96	tumor necrosis factor	Rattus norvegicus	29-56
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	tumor necrosis factor	Mus musculus	162-171
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	interleukin 2	Mus musculus	176-180
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	CD4 antigen	Mus musculus	62-65
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	interleukin 6	Mus musculus	229-233
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	interferon gamma	Mus musculus	151-160
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	interleukin 10	Mus musculus	238-243
31410136-5	2019	The expression levels of pyrin in the SM + LPS group were significantly increased in comparison with the SM + SAL group (P&lt;0.01).	lps	43-46	MEFV innate immuity regulator, pyrin	Rattus norvegicus	25-30
30806746-8	2019	WT and lcn2-/- mice both recovered voluntary activity on the fourth day following LPS.	lps	82-85	lipocalin 2	Mus musculus	7-11
30806746-9	2019	LPS induced equivalent reductions in sucrose preference and TST immobility in the WT and lcn2-/- mice.	lps	0-3	thiosulfate sulfurtransferase, mitochondrial	Mus musculus	60-63
30806746-9	2019	LPS induced equivalent reductions in sucrose preference and TST immobility in the WT and lcn2-/- mice.	lps	0-3	lipocalin 2	Mus musculus	89-93
31410136-6	2019	Additionally, the expression levels of pyrin were significantly increased in the HS + LPS group compared with the HS + SAL group (P&lt;0.01).	lps	86-89	MEFV innate immuity regulator, pyrin	Rattus norvegicus	39-44
31410136-7	2019	The expression levels of caspase-1 were significantly increased in the HS + LPS group compared with those in the other three groups (P&lt;0.01).	lps	76-79	caspase 1	Rattus norvegicus	25-34
31410136-8	2019	The expression levels of pyrin in the HS + LPS + IL-10 group were significantly increased compared with the HS + LPS group (P&lt;0.01).	lps	43-46	MEFV innate immuity regulator, pyrin	Rattus norvegicus	25-30
31410136-8	2019	The expression levels of pyrin in the HS + LPS + IL-10 group were significantly increased compared with the HS + LPS group (P&lt;0.01).	lps	113-116	MEFV innate immuity regulator, pyrin	Rattus norvegicus	25-30
31410136-9	2019	The expression levels of caspase-1 were significantly decreased following IL-10 treatment compared with those in the HS + LPS group (P&lt;0.01).	lps	122-125	caspase 1	Rattus norvegicus	25-34
31410136-10	2019	Therefore, HS attenuated LPS-induced pyrin expression in pulmonary vascular ECs and may also inhibit the expression of IL-10, resulting in the activation of caspase-1 subsequent to a second LPS insult.	lps	25-28	MEFV innate immuity regulator, pyrin	Rattus norvegicus	37-42
29984902-5	2018	Rifaximin (10, 50 and 100 mumol L-1 ) dose dependently inhibited the LPS-induced increase in IL-6 and IL-8 in stromal cells, whereas in epithelial cells it was not possible to detect any accumulation of these interleukins.	lps	69-72	interferon beta-2	Bos taurus	93-97
30952097-0	2019	Protective effect of Ketone musk on LPS/ATP-induced pyroptosis in J774A.1 cells through suppressing NLRP3/GSDMD pathway.	lps	36-39	NLR family, pyrin domain containing 3	Mus musculus	100-105
30952097-0	2019	Protective effect of Ketone musk on LPS/ATP-induced pyroptosis in J774A.1 cells through suppressing NLRP3/GSDMD pathway.	lps	36-39	gasdermin D	Mus musculus	106-111
30952097-5	2019	Our present study demonstrated that KM inhibited LPS/ATP-induced pyroptosis and the release of IL-1beta/18 in J774A.1 cells by inhibiting the activation of GSDMD and caspase-1 and the assembly of NLRP3 inflammasome.	lps	49-52	gasdermin D	Mus musculus	156-161
30952097-5	2019	Our present study demonstrated that KM inhibited LPS/ATP-induced pyroptosis and the release of IL-1beta/18 in J774A.1 cells by inhibiting the activation of GSDMD and caspase-1 and the assembly of NLRP3 inflammasome.	lps	49-52	caspase 1	Mus musculus	166-175
30952097-5	2019	Our present study demonstrated that KM inhibited LPS/ATP-induced pyroptosis and the release of IL-1beta/18 in J774A.1 cells by inhibiting the activation of GSDMD and caspase-1 and the assembly of NLRP3 inflammasome.	lps	49-52	NLR family, pyrin domain containing 3	Mus musculus	196-201
30890228-4	2019	Here, we employed a lipid-based delivery system (LPs) to codeliver Mcl-1 siRNA and Gem for pancreatic cancer treatment, named LP-Gem-siMcl-1.	lps	49-52	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	67-72
30890228-7	2019	Meanwhile, histological analysis demonstrated that LPs could efficiently co-deliver Gem and Mcl-1 siRNA to cancerous cells and overcome the resistance of Gem.	lps	51-54	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	92-97
31106533-10	2019	CONCLUSION: hADMSCs can blockade the LPS-induced pro-inflammatory microglia M1 phenotype, whereas induces protective microglial M2 phenotype, which may be related to inhibition of the TLR4-TRIF signaling pathway.	lps	37-40	toll like receptor 4	Homo sapiens	184-188
31106533-10	2019	CONCLUSION: hADMSCs can blockade the LPS-induced pro-inflammatory microglia M1 phenotype, whereas induces protective microglial M2 phenotype, which may be related to inhibition of the TLR4-TRIF signaling pathway.	lps	37-40	TIR domain containing adaptor molecule 1	Homo sapiens	189-193
30541898-4	2019	The number of Th2 and Th17 cells was elevated in the HDM and HDM+LPS groups compared with the control group; these responses were exacerbated when exposed to HDM+LPS.	lps	65-68	heart and neural crest derivatives expressed 2	Mus musculus	14-17
30541898-4	2019	The number of Th2 and Th17 cells was elevated in the HDM and HDM+LPS groups compared with the control group; these responses were exacerbated when exposed to HDM+LPS.	lps	162-165	heart and neural crest derivatives expressed 2	Mus musculus	14-17
30541898-5	2019	The number of HDM- and HDM+LPS-specific Th2/Th17 cells in young mice was higher than old mice; however, the Th2:Th17 cell ratio was greater in young mice, whereas the Th17:Th2 cell ratio was greater in old mice.	lps	27-30	heart and neural crest derivatives expressed 2	Mus musculus	40-43
30541898-6	2019	The expression of GATA-3 and RORc was increased in the HDM+LPS and HDM groups compared with the PBS group and exhibited most in HDM+LPS group.	lps	59-62	GATA binding protein 3	Mus musculus	18-24
30541898-6	2019	The expression of GATA-3 and RORc was increased in the HDM+LPS and HDM groups compared with the PBS group and exhibited most in HDM+LPS group.	lps	132-135	GATA binding protein 3	Mus musculus	18-24
30541898-7	2019	The expression of HDM+LPS-specific GATA-3 in young mice was higher, while the expression of HDM+LPS-specific RORc in old mice was higher.	lps	22-25	GATA binding protein 3	Mus musculus	35-41
30326372-6	2018	The compounds 9h and 9k also decreased liposaccharide (LPS)-induced IL-6, IL-1beta and vascular cell adhesion molecule-1 (VCAM-1) mRNA expression, both in vitro and in an in vivo model of ALI.	lps	55-58	interleukin 6	Mus musculus	68-72
30326372-6	2018	The compounds 9h and 9k also decreased liposaccharide (LPS)-induced IL-6, IL-1beta and vascular cell adhesion molecule-1 (VCAM-1) mRNA expression, both in vitro and in an in vivo model of ALI.	lps	55-58	interleukin 1 beta	Mus musculus	74-82
30326372-6	2018	The compounds 9h and 9k also decreased liposaccharide (LPS)-induced IL-6, IL-1beta and vascular cell adhesion molecule-1 (VCAM-1) mRNA expression, both in vitro and in an in vivo model of ALI.	lps	55-58	vascular cell adhesion molecule 1	Mus musculus	87-120
30326372-6	2018	The compounds 9h and 9k also decreased liposaccharide (LPS)-induced IL-6, IL-1beta and vascular cell adhesion molecule-1 (VCAM-1) mRNA expression, both in vitro and in an in vivo model of ALI.	lps	55-58	vascular cell adhesion molecule 1	Mus musculus	122-128
30481923-1	2018	Objective: To explore the effects of endotoxin/lipopolysaccharide (LPS) on early apoptosis of human neutrophil through PIM3.	lps	67-70	Pim-3 proto-oncogene, serine/threonine kinase	Homo sapiens	119-123
30481923-17	2018	(4) The expression level of PIM3 in cells of LPS group (1.297+-0.015) was significantly higher than that in control group (0.789+-0.021, P&lt;0.05).	lps	45-48	Pim-3 proto-oncogene, serine/threonine kinase	Homo sapiens	28-32
30481923-18	2018	The expression level of PIM3 in cells of LPS+ PIM447 group (0.731+-0.011) was significantly lower than that in LPS group (P&lt;0.05).	lps	41-44	Pim-3 proto-oncogene, serine/threonine kinase	Homo sapiens	24-28
30481923-18	2018	The expression level of PIM3 in cells of LPS+ PIM447 group (0.731+-0.011) was significantly lower than that in LPS group (P&lt;0.05).	lps	111-114	Pim-3 proto-oncogene, serine/threonine kinase	Homo sapiens	24-28
30481923-21	2018	The mechanism may be related to LPS promoting the expression of PIM3.	lps	32-35	Pim-3 proto-oncogene, serine/threonine kinase	Homo sapiens	64-68
30610044-3	2018	This study was conducted to investigate whether BMSCs could alleviate the inflammation reaction in lipopolysaccaride (LPS)-induced acute kidney injury (septic-AKI) of rats via inhibition of toll-like receptors (TLR4)-nuclear factor-kappa B (NF-kappaB) signaling pathway.	lps	118-121	toll-like receptor 4	Rattus norvegicus	211-239
30610044-6	2018	Results showed that LPS treatment caused the increases of the concentration of blood urea nitrogen (BUN) and serum creatinine (SCr), accompanied by tissue injury and the up-regulation of TLR4 and NF-kappaB, that was its key downstream signaling molecule, in both mRNA and protein level.	lps	20-23	toll-like receptor 4	Rattus norvegicus	187-191
29984902-5	2018	Rifaximin (10, 50 and 100 mumol L-1 ) dose dependently inhibited the LPS-induced increase in IL-6 and IL-8 in stromal cells, whereas in epithelial cells it was not possible to detect any accumulation of these interleukins.	lps	69-72	C-X-C motif chemokine ligand 8	Bos taurus	102-106
29969314-5	2018	Formoterol treatment decreased LPS-induced increase in serum corticosterone, TNFalpha upregulation, and NF-kappaB(p65) and Forkhead box protein O1 activation in the gastrocnemius.	lps	31-34	tumor necrosis factor	Rattus norvegicus	77-85
30402044-2	2018	Neostigmine suppressed (p &lt; 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal).	lps	37-40	interleukin 6	Homo sapiens	109-113
30402044-2	2018	Neostigmine suppressed (p &lt; 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal).	lps	37-40	tumor necrosis factor	Homo sapiens	119-152
30402044-2	2018	Neostigmine suppressed (p &lt; 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal).	lps	37-40	acetylcholinesterase (Cartwright blood group)	Homo sapiens	240-244
29969314-5	2018	Formoterol treatment decreased LPS-induced increase in serum corticosterone, TNFalpha upregulation, and NF-kappaB(p65) and Forkhead box protein O1 activation in the gastrocnemius.	lps	31-34	synaptotagmin 1	Rattus norvegicus	114-117
29969314-6	2018	Atrogin-1, muscle RING-finger protein-1, microtubule-associated protein-1 light chain 3b (LC3b), and the lipidation of LC3b-I to LC3b-II were increased by LPS, and formoterol blocked these effects.	lps	155-158	F-box protein 32	Rattus norvegicus	0-39
29969314-6	2018	Atrogin-1, muscle RING-finger protein-1, microtubule-associated protein-1 light chain 3b (LC3b), and the lipidation of LC3b-I to LC3b-II were increased by LPS, and formoterol blocked these effects.	lps	155-158	microtubule-associated protein 1 light chain 3 beta	Rattus norvegicus	41-88
29969314-7	2018	Serum IGF-I and its mRNA levels in the gastrocnemius were decreased, whereas mecano growth factor and IGF binding protein 3 mRNA levels were increased in the rats injected with LPS but not in the rats that received LPS and formoterol.	lps	177-180	insulin-like growth factor 1	Rattus norvegicus	6-11
29969314-7	2018	Serum IGF-I and its mRNA levels in the gastrocnemius were decreased, whereas mecano growth factor and IGF binding protein 3 mRNA levels were increased in the rats injected with LPS but not in the rats that received LPS and formoterol.	lps	177-180	insulin-like growth factor binding protein 3	Rattus norvegicus	102-123
29950389-3	2018	Here, we show that inhibitor of DNA-binding 2 (ID2) drives side branch formation through the differentiation of K6+ bipotent progenitor cells (BPs) into CD61+ luminal progenitor cells (LPs).	lps	185-188	inhibitor of DNA binding 2	Mus musculus	19-45
29969314-8	2018	Similarly, LPS decreased Akt and mammalian target of rapamycin phosphorylation, and formoterol blocked these decreases.	lps	11-14	AKT serine/threonine kinase 1	Homo sapiens	25-28
29969314-8	2018	Similarly, LPS decreased Akt and mammalian target of rapamycin phosphorylation, and formoterol blocked these decreases.	lps	11-14	mechanistic target of rapamycin kinase	Homo sapiens	33-62
29969314-13	2018	Those responses can be a direct effect of beta2 adrenergic receptor stimulation or/and of blocking the effects of LPS on corticosterone and IGF-I.	lps	114-117	insulin-like growth factor 1	Rattus norvegicus	140-145
29960167-10	2018	These findings provided novel evidence for the anti-apoptotic and anti-inflammatory effects of DEX in LPS-induced AKI mice through an alpha7 nAChR-dependent signaling pathway.	lps	102-105	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	134-146
30524892-5	2018	Further, active immunization of HLA(-A2/DR1)-humanized mice with mixes of the same mutated LPs yielded simultaneous, polyvalent CD8+/CD4+ T cell responses against the majority of peptides.	lps	91-94	down-regulator of transcription 1	Mus musculus	40-43
30227623-5	2018	Besides, catalpol co-administrated with LPS increased BMECs survival, decreased their endothelin-1, TNF-Alpha and IL-6 secretion, improved transmembrane electrical resistance in a time-dependent manner, and in addition increased the fluorescein sodium permeability coefficient of BMECs.	lps	40-43	endothelin 1	Mus musculus	86-98
30227623-5	2018	Besides, catalpol co-administrated with LPS increased BMECs survival, decreased their endothelin-1, TNF-Alpha and IL-6 secretion, improved transmembrane electrical resistance in a time-dependent manner, and in addition increased the fluorescein sodium permeability coefficient of BMECs.	lps	40-43	tumor necrosis factor	Mus musculus	100-109
30227623-5	2018	Besides, catalpol co-administrated with LPS increased BMECs survival, decreased their endothelin-1, TNF-Alpha and IL-6 secretion, improved transmembrane electrical resistance in a time-dependent manner, and in addition increased the fluorescein sodium permeability coefficient of BMECs.	lps	40-43	interleukin 6	Mus musculus	114-118
30227623-9	2018	This study thus indicated that catalpol, via inhibition of the RhoA/ROCK2 signaling pathway, reverses the disaggregation of cytoskeleton actin in BMECs and prevents down-regulation of junctional proteins, such as claudin-5, occludin, and ZO-1, and decreases endothelin-1 and inflammatory cytokine secretion, eventually alleviating the increase in LPS-induced BBB permeability.	lps	347-350	ras homolog family member A	Mus musculus	63-67
29950389-3	2018	Here, we show that inhibitor of DNA-binding 2 (ID2) drives side branch formation through the differentiation of K6+ bipotent progenitor cells (BPs) into CD61+ luminal progenitor cells (LPs).	lps	185-188	inhibitor of DNA binding 2	Mus musculus	47-50
29950389-3	2018	Here, we show that inhibitor of DNA-binding 2 (ID2) drives side branch formation through the differentiation of K6+ bipotent progenitor cells (BPs) into CD61+ luminal progenitor cells (LPs).	lps	185-188	integrin beta 3	Mus musculus	153-157
29950389-4	2018	Id2-null mice had side-branching defects, along with developmental blockage of the differentiation of K6+ BPs into CD61+ LPs.	lps	121-124	inhibitor of DNA binding 2	Mus musculus	0-3
29950389-5	2018	Notably, CD61+ LPs were found in budding and side branches, but not in terminal end buds.	lps	15-18	integrin beta 3	Mus musculus	9-13
29950389-7	2018	Our results suggest that CD61 is a marker of side branches and that ID2 regulates side branch formation by inducing luminal lineage commitment from K6+ BPs to CD61+ LPs.	lps	165-168	inhibitor of DNA binding 2	Mus musculus	68-71
29624777-11	2018	The LPS treatment increased sepiapterin reductase (SPR) expression, suggesting compensation by the salvage pathway.	lps	4-7	sepiapterin reductase	Mus musculus	28-49
29587166-7	2018	The fold changes of LPS-induced secretion of IL-6 and TNF-alpha from monocytes cultured for 6 and 18 h were all lower in the patient groups, and that was true for IL-1beta as monocytes cultured for 18 h. LIMITATIONS: Given the gap between the results of in vitro experiments and the actual response that happens in vivo when the immune system encounters pathogens from the external world, future research should include in vivo methods to test the results of the current study.	lps	20-23	interleukin 6	Homo sapiens	45-49
29587166-7	2018	The fold changes of LPS-induced secretion of IL-6 and TNF-alpha from monocytes cultured for 6 and 18 h were all lower in the patient groups, and that was true for IL-1beta as monocytes cultured for 18 h. LIMITATIONS: Given the gap between the results of in vitro experiments and the actual response that happens in vivo when the immune system encounters pathogens from the external world, future research should include in vivo methods to test the results of the current study.	lps	20-23	tumor necrosis factor	Homo sapiens	54-63
29587166-7	2018	The fold changes of LPS-induced secretion of IL-6 and TNF-alpha from monocytes cultured for 6 and 18 h were all lower in the patient groups, and that was true for IL-1beta as monocytes cultured for 18 h. LIMITATIONS: Given the gap between the results of in vitro experiments and the actual response that happens in vivo when the immune system encounters pathogens from the external world, future research should include in vivo methods to test the results of the current study.	lps	20-23	interleukin 1 beta	Homo sapiens	163-171
29624777-11	2018	The LPS treatment increased sepiapterin reductase (SPR) expression, suggesting compensation by the salvage pathway.	lps	4-7	sepiapterin reductase	Mus musculus	51-54
29442719-11	2018	Antioxidant and preventive effects of RSV-loaded LPs against diabetes-associated oxidative stress were determined with superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) enzyme assay.	lps	49-52	superoxide dismutase 1	Homo sapiens	119-139
29335159-6	2018	Domperidone treatment increased LPS-induced tumor necrosis factor (TNF) and interleukin (IL)-6 production in the bronchoalveolar lavage fluid, without altering tissue damage and the number of immune cells in the lungs and circulation.	lps	32-35	tumor necrosis factor	Mus musculus	44-65
29881282-8	2018	IL-6 was higher in the LPS group on day 2 (p=0.03) and day 3 (p=0.04).	lps	23-26	interleukin 6	Homo sapiens	0-4
29690739-14	2018	Protein expressions of occludin and claudin-1 of cells in SCFA+ LPS group were significantly higher than those in LPS group at PCH 24 (P&lt;0.05).	lps	64-67	occludin	Homo sapiens	23-31
29690739-14	2018	Protein expressions of occludin and claudin-1 of cells in SCFA+ LPS group were significantly higher than those in LPS group at PCH 24 (P&lt;0.05).	lps	64-67	claudin 1	Homo sapiens	36-45
29690739-15	2018	Protein expression of ZO-1 of cells in SCFA+ LPS group was higher than that in LPS group at PCH 24 with no significant difference (P&gt;0.05).	lps	45-48	tight junction protein 1	Homo sapiens	22-26
29690739-15	2018	Protein expression of ZO-1 of cells in SCFA+ LPS group was higher than that in LPS group at PCH 24 with no significant difference (P&gt;0.05).	lps	79-82	tight junction protein 1	Homo sapiens	22-26
29690739-17	2018	In LPS group, cells were sparse in arrangement with change in appearance, and ZO-1 was distributed uncontinuously along the cell membrane with curls and breaks.	lps	3-6	tight junction protein 1	Homo sapiens	78-82
29690739-18	2018	In SCFA+ LPS group, the appearance of cells and distribution of ZO-1 were remarkably ameliorated compared with those in LPS group.	lps	9-12	tight junction protein 1	Homo sapiens	64-68
29690739-19	2018	Conclusions: SCFA can alleviate the barrier disruption of human intestinal epithelial cell induced by LPS through interdicting the abnormal distribution of ZO-1 and decrease of TER and tight junction proteins" expressions.	lps	102-105	tight junction protein 1	Homo sapiens	156-160
29335159-6	2018	Domperidone treatment increased LPS-induced tumor necrosis factor (TNF) and interleukin (IL)-6 production in the bronchoalveolar lavage fluid, without altering tissue damage and the number of immune cells in the lungs and circulation.	lps	32-35	interleukin 6	Mus musculus	76-94
29335159-6	2018	Domperidone treatment increased LPS-induced tumor necrosis factor (TNF) and interleukin (IL)-6 production in the bronchoalveolar lavage fluid, without altering tissue damage and the number of immune cells in the lungs and circulation.	lps	32-35	tumor necrosis factor	Mus musculus	67-70
28946914-7	2017	Comparing with control group, the IL-6 levels were significantly higher in the culture medium of the cultured differentiated 3T3-L1 cells in LPS group and 17beta-E2 + LPS group (all P &lt; 0.05).	lps	141-144	interleukin 6	Mus musculus	34-38
29632734-3	2018	Here, we aimed to identify long peptides (LPs) derived from DEPDC1 and MPHOSPH1 that induced both T-helper (Th) cells and tumor-reactive cytotoxic T lymphocytes (CTLs).	lps	42-45	DEP domain containing 1	Homo sapiens	60-66
29632734-3	2018	Here, we aimed to identify long peptides (LPs) derived from DEPDC1 and MPHOSPH1 that induced both T-helper (Th) cells and tumor-reactive cytotoxic T lymphocytes (CTLs).	lps	42-45	kinesin family member 20B	Homo sapiens	71-79
29632734-5	2018	Three of six LPs encompassed HLA-A2- or -A24-restricted CTL epitopes or both, and all six LPs stimulated DEPDC1- or MPHOSPH1-specific Th cells restricted by promiscuous and frequently observed HLA class II molecules in the Japanese population.	lps	90-93	DEP domain containing 1	Homo sapiens	105-111
29632734-5	2018	Three of six LPs encompassed HLA-A2- or -A24-restricted CTL epitopes or both, and all six LPs stimulated DEPDC1- or MPHOSPH1-specific Th cells restricted by promiscuous and frequently observed HLA class II molecules in the Japanese population.	lps	90-93	kinesin family member 20B	Homo sapiens	116-124
29632734-9	2018	These DEPDC1- or MPHOSPH1-derived LPs may have applications in immunotherapy in patients with bladder cancer, and the TCR genes identified may be useful for monitoring of Th cells specific to LPs in vivo.	lps	34-37	kinesin family member 20B	Homo sapiens	17-25
29153599-0	2017	LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning.	lps	0-3	neurogranin	Homo sapiens	40-51
29153599-3	2017	Our results also indicate that dual-LPS increases Nrgn phosphorylation and concomitantly reduces phosphorylation of calmodulin kinase-II (CaMKII).	lps	36-39	neurogranin	Homo sapiens	50-54
29153599-3	2017	Our results also indicate that dual-LPS increases Nrgn phosphorylation and concomitantly reduces phosphorylation of calmodulin kinase-II (CaMKII).	lps	36-39	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	116-136
29153599-3	2017	Our results also indicate that dual-LPS increases Nrgn phosphorylation and concomitantly reduces phosphorylation of calmodulin kinase-II (CaMKII).	lps	36-39	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	138-144
28843610-5	2017	Here, we analysed the activation by lipopolysaccaride (LPS) of primary splenocytes obtained from two different Ogg1-/- mouse strains.	lps	55-58	8-oxoguanine DNA-glycosylase 1	Mus musculus	111-115
28843610-8	2017	In contrast, inhibitors of the MAP kinases p38 and JNK as well as the antioxidant N-acetylcysteine attenuated the LPS-stimulated TNF-alpha expression both in the absence and presence of OGG1.	lps	114-117	mitogen-activated protein kinase 14	Mus musculus	43-46
28843610-8	2017	In contrast, inhibitors of the MAP kinases p38 and JNK as well as the antioxidant N-acetylcysteine attenuated the LPS-stimulated TNF-alpha expression both in the absence and presence of OGG1.	lps	114-117	mitogen-activated protein kinase 8	Mus musculus	51-54
28843610-8	2017	In contrast, inhibitors of the MAP kinases p38 and JNK as well as the antioxidant N-acetylcysteine attenuated the LPS-stimulated TNF-alpha expression both in the absence and presence of OGG1.	lps	114-117	tumor necrosis factor	Mus musculus	129-138
28843610-8	2017	In contrast, inhibitors of the MAP kinases p38 and JNK as well as the antioxidant N-acetylcysteine attenuated the LPS-stimulated TNF-alpha expression both in the absence and presence of OGG1.	lps	114-117	8-oxoguanine DNA-glycosylase 1	Mus musculus	186-190
28843610-10	2017	The data demonstrate that OGG1 plays a role in an LSD1-dependent pathway of LPS-induced macrophage activation in mice.	lps	76-79	8-oxoguanine DNA-glycosylase 1	Mus musculus	26-30
28843610-10	2017	The data demonstrate that OGG1 plays a role in an LSD1-dependent pathway of LPS-induced macrophage activation in mice.	lps	76-79	lysine (K)-specific demethylase 1A	Mus musculus	50-54
28946914-7	2017	Comparing with control group, the IL-6 levels were significantly higher in the culture medium of the cultured differentiated 3T3-L1 cells in LPS group and 17beta-E2 + LPS group (all P &lt; 0.05).	lps	167-170	interleukin 6	Mus musculus	34-38
28946914-10	2017	ATGL expression in 17beta-E2 group was significantly higher than control group (P &lt; 0.05), which was abolished by ERalpha antagonist MPP or LPS.	lps	143-146	patatin-like phospholipase domain containing 2	Mus musculus	0-4
28493442-3	2017	Recently, we demonstrated that urokinase type plasminogen activator (uPA) suppressed lipopolysaccaride (LPS)-inflammatory osteoclastogenesis through the adenosine monophosphate-activated protein kinase (AMPK) pathway, whereas its receptor (uPAR) promoted that through the Akt pathway.	lps	104-107	plasminogen activator, urokinase	Mus musculus	31-67
28493442-3	2017	Recently, we demonstrated that urokinase type plasminogen activator (uPA) suppressed lipopolysaccaride (LPS)-inflammatory osteoclastogenesis through the adenosine monophosphate-activated protein kinase (AMPK) pathway, whereas its receptor (uPAR) promoted that through the Akt pathway.	lps	104-107	plasminogen activator, urokinase	Mus musculus	69-72
28493442-4	2017	METHODS: We investigated the effects of uPA-derived peptide (A6) in the LPS-induced inflammatory osteoclastogenesis and bone destruction.	lps	72-75	plasminogen activator, urokinase	Mus musculus	40-43
28493442-8	2017	CONCLUSION: A6 is involved in the suppression of LPS-promoted inflammatory osteoclastgensis and bone destruction by regulating the AMPK and Akt pathways.	lps	49-52	thymoma viral proto-oncogene 1	Mus musculus	140-143
28829493-0	2017	Effects of IL-10 on iron metabolism in LPS-induced inflammatory mice via modulating hepcidin expression.	lps	39-42	interleukin 10	Mus musculus	11-16
28829493-0	2017	Effects of IL-10 on iron metabolism in LPS-induced inflammatory mice via modulating hepcidin expression.	lps	39-42	hepcidin antimicrobial peptide	Mus musculus	84-92
28829493-10	2017	RESULTS: LPS model group had lower RBC, Hb, HCT, MCV and iron content in Hb, plus elevated hepcidin, IL-6, TNF-alpha, TfR2 and STAT3 expression (p &lt; 0.05 compared to the control group).	lps	9-12	hepcidin antimicrobial peptide	Mus musculus	91-99
28829493-10	2017	RESULTS: LPS model group had lower RBC, Hb, HCT, MCV and iron content in Hb, plus elevated hepcidin, IL-6, TNF-alpha, TfR2 and STAT3 expression (p &lt; 0.05 compared to the control group).	lps	9-12	interleukin 6	Mus musculus	101-105
28829493-10	2017	RESULTS: LPS model group had lower RBC, Hb, HCT, MCV and iron content in Hb, plus elevated hepcidin, IL-6, TNF-alpha, TfR2 and STAT3 expression (p &lt; 0.05 compared to the control group).	lps	9-12	tumor necrosis factor	Mus musculus	107-116
28829493-10	2017	RESULTS: LPS model group had lower RBC, Hb, HCT, MCV and iron content in Hb, plus elevated hepcidin, IL-6, TNF-alpha, TfR2 and STAT3 expression (p &lt; 0.05 compared to the control group).	lps	9-12	transferrin receptor 2	Mus musculus	118-122
28829493-10	2017	RESULTS: LPS model group had lower RBC, Hb, HCT, MCV and iron content in Hb, plus elevated hepcidin, IL-6, TNF-alpha, TfR2 and STAT3 expression (p &lt; 0.05 compared to the control group).	lps	9-12	signal transducer and activator of transcription 3	Mus musculus	127-132
28829493-11	2017	IL-10 treatment group significantly facilitated RBC, Hb, HCT, MCV and Hb iron contents in LPS-induced inflammatory model mice, which also had lower hepcidin, IL-6, TNF-alpha, TfR2 or STAT3 expression (p &lt; 0.05 compared to LPS group).	lps	90-93	interleukin 10	Mus musculus	0-5
28829493-11	2017	IL-10 treatment group significantly facilitated RBC, Hb, HCT, MCV and Hb iron contents in LPS-induced inflammatory model mice, which also had lower hepcidin, IL-6, TNF-alpha, TfR2 or STAT3 expression (p &lt; 0.05 compared to LPS group).	lps	90-93	signal transducer and activator of transcription 3	Mus musculus	183-188
28829493-11	2017	IL-10 treatment group significantly facilitated RBC, Hb, HCT, MCV and Hb iron contents in LPS-induced inflammatory model mice, which also had lower hepcidin, IL-6, TNF-alpha, TfR2 or STAT3 expression (p &lt; 0.05 compared to LPS group).	lps	225-228	interleukin 10	Mus musculus	0-5
28427134-11	2017	Compared with that in LPS control group, the mRNA expression of TNF-alpha of cells was decreased in each BMX-IN-1 pretreatment group, but only the mRNA expression of TNF-alpha of cells in 75 000 nmol/L BMX-IN-1 pretreatment group was significantly decreased (P&lt;0.05).	lps	22-25	tumor necrosis factor	Mus musculus	64-73
28747971-8	2017	PYC markedly reduced the collagen deposition caused by CS+LPS exposure, which was closely involved in TGF-beta1/Smad 2/3 signaling, which is associated with pulmonary fibrotic change.	lps	58-61	transforming growth factor, beta 1	Mus musculus	102-111
28747971-8	2017	PYC markedly reduced the collagen deposition caused by CS+LPS exposure, which was closely involved in TGF-beta1/Smad 2/3 signaling, which is associated with pulmonary fibrotic change.	lps	58-61	SMAD family member 2	Mus musculus	112-120
28232171-13	2017	However, both D1 and D2 agonists inhibited the AT1/NADPH-oxidase axis in lipopolysaccharide-treated (LPS; i.e. activated) microglia.	lps	101-104	leiomodin 1	Homo sapiens	14-23
28232171-13	2017	However, both D1 and D2 agonists inhibited the AT1/NADPH-oxidase axis in lipopolysaccharide-treated (LPS; i.e. activated) microglia.	lps	101-104	angiotensin II receptor type 1	Homo sapiens	47-50
28427134-1	2017	Objective: To investigate the role of bone marrow tyrosine kinase on chromosome X (BMX) in the production of tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1beta) from mouse mononuclear-macrophages induced by endotoxin/lipopolysaccharide (LPS) and its related mechanism.	lps	258-261	BMX non-receptor tyrosine kinase	Mus musculus	83-86
28427134-13	2017	(2) Compared with that in LPS control group, the mRNA expression of TNF-alpha of cells was not significantly changed in 2 and 4 h BMX-IN-1 pretreatment groups (with P values above 0.05) but significantly decreased in 8, 12, and 18 h BMX-IN-1 pretreatment groups (P&lt;0.05 or P&lt;0.01).	lps	26-29	tumor necrosis factor	Mus musculus	68-77
28427134-16	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in LPS control group were 2.97+-0.17 and 3.07+-0.60, respectively, while those in BMX-IN-1+ LPS group were 2.31+-0.94 and 2.55+-0.73, respectively, with the 4 values significantly higher than those in blank control group (with P values below 0.01).	lps	59-62	tumor necrosis factor	Mus musculus	24-33
28427134-16	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in LPS control group were 2.97+-0.17 and 3.07+-0.60, respectively, while those in BMX-IN-1+ LPS group were 2.31+-0.94 and 2.55+-0.73, respectively, with the 4 values significantly higher than those in blank control group (with P values below 0.01).	lps	59-62	interleukin 1 beta	Mus musculus	38-46
28427134-16	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in LPS control group were 2.97+-0.17 and 3.07+-0.60, respectively, while those in BMX-IN-1+ LPS group were 2.31+-0.94 and 2.55+-0.73, respectively, with the 4 values significantly higher than those in blank control group (with P values below 0.01).	lps	148-151	tumor necrosis factor	Mus musculus	24-33
28427134-16	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in LPS control group were 2.97+-0.17 and 3.07+-0.60, respectively, while those in BMX-IN-1+ LPS group were 2.31+-0.94 and 2.55+-0.73, respectively, with the 4 values significantly higher than those in blank control group (with P values below 0.01).	lps	148-151	interleukin 1 beta	Mus musculus	38-46
28427134-16	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in LPS control group were 2.97+-0.17 and 3.07+-0.60, respectively, while those in BMX-IN-1+ LPS group were 2.31+-0.94 and 2.55+-0.73, respectively, with the 4 values significantly higher than those in blank control group (with P values below 0.01).	lps	148-151	BMX non-receptor tyrosine kinase	Mus musculus	138-141
28427134-17	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in BMX-IN-1+ LPS group were significantly lower than those in LPS control group (with P values below 0.05).	lps	69-72	tumor necrosis factor	Mus musculus	24-33
28427134-17	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in BMX-IN-1+ LPS group were significantly lower than those in LPS control group (with P values below 0.05).	lps	69-72	interleukin 1 beta	Mus musculus	38-46
28427134-17	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in BMX-IN-1+ LPS group were significantly lower than those in LPS control group (with P values below 0.05).	lps	69-72	BMX non-receptor tyrosine kinase	Mus musculus	59-62
28427134-17	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in BMX-IN-1+ LPS group were significantly lower than those in LPS control group (with P values below 0.05).	lps	118-121	interleukin 1 beta	Mus musculus	38-46
28427134-17	2017	The mRNA expressions of TNF-alpha and IL-1beta of cells in BMX-IN-1+ LPS group were significantly lower than those in LPS control group (with P values below 0.05).	lps	118-121	BMX non-receptor tyrosine kinase	Mus musculus	59-62
28427134-19	2017	The activity values of BMX and p38MAPK of cells in LPS control group were 1.98+-0.33 and 2.05+-0.34, respectively, which were significantly higher than those of blank control group (with P values below 0.01).	lps	51-54	BMX non-receptor tyrosine kinase	Mus musculus	23-26
28427134-19	2017	The activity values of BMX and p38MAPK of cells in LPS control group were 1.98+-0.33 and 2.05+-0.34, respectively, which were significantly higher than those of blank control group (with P values below 0.01).	lps	51-54	mitogen-activated protein kinase 14	Mus musculus	31-38
28427134-20	2017	The activity values of BMX and p38MAPK of cells in BMX-IN-1+ LPS group were 1.00+-0.17 and 1.67+-0.27, respectively, which were obviously lower than those of LPS control group (P&lt;0.05 or P&lt;0.01).	lps	61-64	BMX non-receptor tyrosine kinase	Mus musculus	23-26
28427134-20	2017	The activity values of BMX and p38MAPK of cells in BMX-IN-1+ LPS group were 1.00+-0.17 and 1.67+-0.27, respectively, which were obviously lower than those of LPS control group (P&lt;0.05 or P&lt;0.01).	lps	61-64	mitogen-activated protein kinase 14	Mus musculus	31-38
28427134-20	2017	The activity values of BMX and p38MAPK of cells in BMX-IN-1+ LPS group were 1.00+-0.17 and 1.67+-0.27, respectively, which were obviously lower than those of LPS control group (P&lt;0.05 or P&lt;0.01).	lps	61-64	BMX non-receptor tyrosine kinase	Mus musculus	51-54
28427134-20	2017	The activity values of BMX and p38MAPK of cells in BMX-IN-1+ LPS group were 1.00+-0.17 and 1.67+-0.27, respectively, which were obviously lower than those of LPS control group (P&lt;0.05 or P&lt;0.01).	lps	158-161	BMX non-receptor tyrosine kinase	Mus musculus	51-54
28427134-21	2017	Conclusions: BMX can increase the production of pro-inflammatory cytokines TNF-alpha and IL-1beta from mouse mononuclear-macrophages induced by LPS, which may be associated with the activation of the p38MAPK pathway by BMX.	lps	144-147	BMX non-receptor tyrosine kinase	Mus musculus	13-16
28427134-21	2017	Conclusions: BMX can increase the production of pro-inflammatory cytokines TNF-alpha and IL-1beta from mouse mononuclear-macrophages induced by LPS, which may be associated with the activation of the p38MAPK pathway by BMX.	lps	144-147	tumor necrosis factor	Mus musculus	75-84
28427134-21	2017	Conclusions: BMX can increase the production of pro-inflammatory cytokines TNF-alpha and IL-1beta from mouse mononuclear-macrophages induced by LPS, which may be associated with the activation of the p38MAPK pathway by BMX.	lps	144-147	interleukin 1 beta	Mus musculus	89-97
28427134-21	2017	Conclusions: BMX can increase the production of pro-inflammatory cytokines TNF-alpha and IL-1beta from mouse mononuclear-macrophages induced by LPS, which may be associated with the activation of the p38MAPK pathway by BMX.	lps	144-147	mitogen-activated protein kinase 14	Mus musculus	200-207
28427134-21	2017	Conclusions: BMX can increase the production of pro-inflammatory cytokines TNF-alpha and IL-1beta from mouse mononuclear-macrophages induced by LPS, which may be associated with the activation of the p38MAPK pathway by BMX.	lps	144-147	BMX non-receptor tyrosine kinase	Mus musculus	219-222
27903758-8	2017	For postoperative pain, a significant interaction was found between OPRM1 and the low pain sensitivity (LPS; GCGG) haplotype of COMT ( p = .017).	lps	104-107	opioid receptor mu 1	Homo sapiens	68-73
27903758-8	2017	For postoperative pain, a significant interaction was found between OPRM1 and the low pain sensitivity (LPS; GCGG) haplotype of COMT ( p = .017).	lps	104-107	catechol-O-methyltransferase	Homo sapiens	128-132
27903758-9	2017	For patients with no copies of the LPS haplotype, AA of OPRM1 A118G was significantly associated with higher pain scores compared to the variant AG/GG.	lps	35-38	opioid receptor mu 1	Homo sapiens	56-61
28166724-10	2017	Concentration of IL-17 correlated with the disease activity score (DAS)-28, IL-6 and anti-LPS IgA levels.	lps	90-93	interleukin 17A	Homo sapiens	17-22
28104349-6	2017	Besides, IA could dramatically inhibit levels of inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) in peritoneal cavity in LPS-induced mice peritonitis model.	lps	127-130	tumor necrosis factor	Mus musculus	92-101
28104349-7	2017	In vitro study, the results showed that IA inhibited production of IL-1beta, IL-6 and TNF-alpha at transcriptional and translational levels in RAW 264.7 cells induced by LPS.	lps	170-173	interleukin 1 beta	Mus musculus	67-75
28104349-7	2017	In vitro study, the results showed that IA inhibited production of IL-1beta, IL-6 and TNF-alpha at transcriptional and translational levels in RAW 264.7 cells induced by LPS.	lps	170-173	interleukin 6	Mus musculus	77-81
28104349-7	2017	In vitro study, the results showed that IA inhibited production of IL-1beta, IL-6 and TNF-alpha at transcriptional and translational levels in RAW 264.7 cells induced by LPS.	lps	170-173	tumor necrosis factor	Mus musculus	86-95
28104349-8	2017	Furthermore, IA could suppress the LPS-induced activation of Akt and downstream degradation and phosphorylation of kappa B-alpha (IkappaB-alpha).	lps	35-38	thymoma viral proto-oncogene 1	Mus musculus	61-64
28104349-8	2017	Furthermore, IA could suppress the LPS-induced activation of Akt and downstream degradation and phosphorylation of kappa B-alpha (IkappaB-alpha).	lps	35-38	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	130-143
28104349-9	2017	Moreover, IA could significantly inhibit ERK 1/2 phosphorylation in RAW 264.7 cells induced by LPS.	lps	95-98	mitogen-activated protein kinase 3	Mus musculus	41-48
28166724-10	2017	Concentration of IL-17 correlated with the disease activity score (DAS)-28, IL-6 and anti-LPS IgA levels.	lps	90-93	CD79a molecule	Homo sapiens	94-97
28166724-12	2017	Conditioned media with SF containing IL-17 induced anti-LPS IgA production by SFMCs which was independent of IL-6 activity.	lps	56-59	interleukin 17A	Homo sapiens	37-42
28166724-12	2017	Conditioned media with SF containing IL-17 induced anti-LPS IgA production by SFMCs which was independent of IL-6 activity.	lps	56-59	CD79a molecule	Homo sapiens	60-63
28166724-13	2017	Concentrations of synovial TGF-beta1 and BAFF correlated with anti-LPS and total IgA levels, respectively.	lps	67-70	transforming growth factor beta 1	Homo sapiens	27-36
28039479-3	2017	TNF was produced primarily by LSCs and leukemic progenitors (LPs), whereas IL1beta was mainly produced by partially differentiated leukemic blasts (LBs).	lps	61-64	tumor necrosis factor	Homo sapiens	0-3
27977747-6	2016	RESULTS: Low-dose LPS application after PH results in a significant delay of liver regeneration between 48h and 72h, which is associated with a reduced number of CD3+ cells within the regenerating liver.	lps	18-21	CD3 antigen, epsilon polypeptide	Mus musculus	162-165
27977747-8	2016	Analysis of different leukocyte subpopulations showed less CD3+NK1.1+ NKT cells in the liver parenchyma of LFA-1-/- mice after PH and LPS application compared to WT controls, while CD3-NK1.1+ NK cells markedly increased.	lps	134-137	integrin subunit alpha L	Homo sapiens	107-112
27646125-11	2016	Choline treatment attenuated actin alpha cardiac muscle-1 overexpression after LPS.	lps	79-82	actin alpha cardiac muscle 1	Bos taurus	29-57
27646125-9	2016	In the LPS group, there were significant increases in serum levels of ragulator complex protein (189-fold) and galectin-3-binding protein (10-fold), but transcription factor MafF and corticosteroid binding globulin were down regulated (&gt;= 5 fold).	lps	7-10	galectin 3 binding protein	Bos taurus	111-137
27646125-9	2016	In the LPS group, there were significant increases in serum levels of ragulator complex protein (189-fold) and galectin-3-binding protein (10-fold), but transcription factor MafF and corticosteroid binding globulin were down regulated (&gt;= 5 fold).	lps	7-10	MAF bZIP transcription factor F	Bos taurus	174-178
26559921-3	2016	The patients were classified as non-late presenters or late presenters (LPs), defined as those with a CD4 count &lt; 350 cells/muL or AIDS.	lps	72-75	CD4 molecule	Homo sapiens	102-105
27627109-8	2016	Phosphatase and tensin homolog (PTEN) also tended to increase (p = 0.08) while phosphorylation of Akt at Thr308 tended to decrease (p = 0.09) during LPS compared with Placebo.	lps	149-152	AKT serine/threonine kinase 1	Homo sapiens	98-101
27627109-10	2016	CONCLUSION: LPS stimulated lipolysis in adipose tissue and is associated with increased pHSL and signs of increased PLIN1 phosphorylation combined with a trend toward decreased insulin signaling.	lps	12-15	perilipin 1	Homo sapiens	116-121
26944449-7	2016	PIF acts on macrophages down-stream of LPS (lipopolysaccharide-bacterial antigen) CD14/TLR4/MD2 complex, targeting myosin-9, thymosin-alpha1 and 14-3-3eta.	lps	39-42	PIF1 5'-to-3' DNA helicase	Homo sapiens	0-3
26944449-7	2016	PIF acts on macrophages down-stream of LPS (lipopolysaccharide-bacterial antigen) CD14/TLR4/MD2 complex, targeting myosin-9, thymosin-alpha1 and 14-3-3eta.	lps	39-42	toll like receptor 4	Homo sapiens	87-91
26944449-7	2016	PIF acts on macrophages down-stream of LPS (lipopolysaccharide-bacterial antigen) CD14/TLR4/MD2 complex, targeting myosin-9, thymosin-alpha1 and 14-3-3eta.	lps	39-42	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta	Homo sapiens	125-154
27403264-1	2016	OBJECTIVES: We aimed to investigate the influence of transient receptor potential channel 3 (TRPC3) on lipopolysaccharide-induced (LPS) preterm delivery mice.	lps	131-134	transient receptor potential cation channel, subfamily C, member 3	Mus musculus	53-91
26678889-3	2016	However, the activation status of Hes1 and its regulation in LSCs and leukemic progenitors (LPs) as well as normal hematopoietic stem cells (HSCs) in Hes1-low AML patients have not been elucidated.	lps	92-95	hes family bHLH transcription factor 1	Homo sapiens	34-38
26678889-5	2016	Our results showed that the level of either Hes1 or p21 was lower in LSCs or LPs than in HSCs whereas the level of miR-9 was highest in LPs and lowest in HSCs.	lps	77-80	hes family bHLH transcription factor 1	Homo sapiens	44-48
26678889-5	2016	Our results showed that the level of either Hes1 or p21 was lower in LSCs or LPs than in HSCs whereas the level of miR-9 was highest in LPs and lowest in HSCs.	lps	77-80	H3 histone pseudogene 16	Homo sapiens	52-55
27403264-1	2016	OBJECTIVES: We aimed to investigate the influence of transient receptor potential channel 3 (TRPC3) on lipopolysaccharide-induced (LPS) preterm delivery mice.	lps	131-134	transient receptor potential cation channel, subfamily C, member 3	Mus musculus	93-98
27403264-4	2016	A specific inhibitor of TRPC3 (SKF96365) was injected into the LPS-induced preterm delivery group to determine whether the delivery interval was prolonged.	lps	63-66	transient receptor potential cation channel, subfamily C, member 3	Mus musculus	24-29
27403264-6	2016	In addition, the LPS-induced preterm delivery group had an obviously higher expression level of TRPC3 mRNA and protein compared with the unpregnant and E15 groups, which were close to term delivery.	lps	17-20	transient receptor potential cation channel, subfamily C, member 3	Mus musculus	96-101
27403264-8	2016	CONCLUSION: Enhanced expression of TRPC3 may be associated with LPS-induced preterm delivery in mice.	lps	64-67	transient receptor potential cation channel, subfamily C, member 3	Mus musculus	35-40
26644077-0	2016	STAT4 knockout protects LPS-induced lung injury by increasing of MDSC and promoting of macrophage differentiation.	lps	24-27	signal transducer and activator of transcription 4	Mus musculus	0-5
26990318-11	2016	The nVNS group showed a significant percent increase in LPS-stimulated IL-10 levels at the 24-hour time point in comparison to SST.	lps	56-59	interleukin 10	Homo sapiens	71-76
26708229-7	2016	Our results revealed that PCr protects against LPS-induced HUVECs apoptosis, which probably related to stabilization of intracellular energy metabolism, especially for FADH2 pathway in mitochondrial respiratory chain, ATP synthase and CKmt.	lps	47-50	creatine kinase, mitochondrial 1B	Homo sapiens	235-239
26644077-3	2016	Here we report that STAT4 deficiency decreased the lethality and protein leakage in STAT4(-/-) mice and protected lipopolysaccharid (LPS)-induced lung injury with ameliorated edema, inflammatory infiltration and hemorrhage.	lps	133-136	signal transducer and activator of transcription 4	Mus musculus	20-25
26222266-1	2016	OBJECTIVES: In 2011, a consensus was reached defining "late presenters" (LPs) as individuals presenting for care with a CD4 count &lt; 350 cells/muL or with an AIDS-defining event, regardless of CD4 count.	lps	73-76	CD4 molecule	Homo sapiens	120-123
26644077-4	2016	The expression of CD11b(+)Gr-1(+) myeloid derived suppressor cells (MDSCs) markedly increased in the circulation of STAT4(-/-) mice after LPS stimuli, accompanying with increased macrophages infiltration in inflamed lung tissue.	lps	138-141	integrin alpha M	Mus musculus	18-23
26410851-5	2016	Our results demonstrated that piperine attenuated LPS-induced MPO activity, lung edema, and inflammatory cytokines TNF-alpha, IL-6, and IL-1beta production.	lps	50-53	myeloperoxidase	Homo sapiens	62-65
26644077-4	2016	The expression of CD11b(+)Gr-1(+) myeloid derived suppressor cells (MDSCs) markedly increased in the circulation of STAT4(-/-) mice after LPS stimuli, accompanying with increased macrophages infiltration in inflamed lung tissue.	lps	138-141	signal transducer and activator of transcription 4	Mus musculus	116-121
26410851-4	2016	LPS-induced lung injury was assessed by histological study, myeloperoxidase (MPO) activity, and inflammatory cytokine production.	lps	0-3	myeloperoxidase	Homo sapiens	60-75
26410851-4	2016	LPS-induced lung injury was assessed by histological study, myeloperoxidase (MPO) activity, and inflammatory cytokine production.	lps	0-3	myeloperoxidase	Homo sapiens	77-80
26410851-5	2016	Our results demonstrated that piperine attenuated LPS-induced MPO activity, lung edema, and inflammatory cytokines TNF-alpha, IL-6, and IL-1beta production.	lps	50-53	tumor necrosis factor	Homo sapiens	115-124
26410851-5	2016	Our results demonstrated that piperine attenuated LPS-induced MPO activity, lung edema, and inflammatory cytokines TNF-alpha, IL-6, and IL-1beta production.	lps	50-53	interleukin 6	Homo sapiens	126-130
26410851-5	2016	Our results demonstrated that piperine attenuated LPS-induced MPO activity, lung edema, and inflammatory cytokines TNF-alpha, IL-6, and IL-1beta production.	lps	50-53	interleukin 1 beta	Homo sapiens	136-144
26714634-9	2015	LPS interaction with TLR4 activates downstream mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways and subsequently causes inflammatory mediator production.	lps	0-3	toll-like receptor 4	Rattus norvegicus	21-25
26902274-18	2016	(4) The expression levels of p-ERK1/2 in cells of LPS and LPS+ iCORM-2 groups (respectively 0.0311+-0.001 and 0.0309+-0.0018) were close to the level in NC group (0.0304+-0.0046, with P values above 0.05).	lps	50-53	mitogen-activated protein kinase 3	Homo sapiens	31-37
26902274-18	2016	(4) The expression levels of p-ERK1/2 in cells of LPS and LPS+ iCORM-2 groups (respectively 0.0311+-0.001 and 0.0309+-0.0018) were close to the level in NC group (0.0304+-0.0046, with P values above 0.05).	lps	58-61	mitogen-activated protein kinase 3	Homo sapiens	31-37
26902274-19	2016	The expression level of p-ERK1/2 was significantly higher in cells of LPS+ 10 mumol/L CORM-2 and LPS+ 50 mumol/L CORM-2 groups (respectively 0.7891+-0.0201 and 1.2970+-0.0056) than in NC group (with P values below 0.05).	lps	70-73	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-19	2016	The expression level of p-ERK1/2 was significantly higher in cells of LPS+ 10 mumol/L CORM-2 and LPS+ 50 mumol/L CORM-2 groups (respectively 0.7891+-0.0201 and 1.2970+-0.0056) than in NC group (with P values below 0.05).	lps	97-100	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-20	2016	The expression level of p-ERK1/2 was significantly higher in cells of LPS+ 10 mumol/L CORM-2 and LPS+ 50 mumol/L CORM-2 groups than in LPS group (with P values below 0.05).	lps	70-73	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-20	2016	The expression level of p-ERK1/2 was significantly higher in cells of LPS+ 10 mumol/L CORM-2 and LPS+ 50 mumol/L CORM-2 groups than in LPS group (with P values below 0.05).	lps	97-100	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-20	2016	The expression level of p-ERK1/2 was significantly higher in cells of LPS+ 10 mumol/L CORM-2 and LPS+ 50 mumol/L CORM-2 groups than in LPS group (with P values below 0.05).	lps	97-100	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-21	2016	The expression level of p-ERK1/2 in cells of LPS+ iCORM-2 group was close to that of LPS group (P&gt;0.05).	lps	45-48	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-21	2016	The expression level of p-ERK1/2 in cells of LPS+ iCORM-2 group was close to that of LPS group (P&gt;0.05).	lps	85-88	mitogen-activated protein kinase 3	Homo sapiens	26-32
26902274-22	2016	CONCLUSIONS: CORM-2 can obviously increase the production of NETs in LPS-induced neutrophils, and it might be attributable to the promotion of inhibition of ROS generation and phosphorylation of ERK1/2.	lps	69-72	mitogen-activated protein kinase 3	Homo sapiens	195-201
26714634-8	2015	LPS, zymosan and poly(I:C) all down-regulated TLR4 messenger RNA (mRNA) and up-regulated TLR2 mRNA at 6 and 24 h. In spite of their inability to elaborate pro-inflammatory mediator output, the nominally microglia-free astrocytes (&gt;99 % purity) also showed similar behaviours to those of microglia, as well as changes in TLR3 gene expression.	lps	0-3	toll-like receptor 4	Rattus norvegicus	46-50
26714634-8	2015	LPS, zymosan and poly(I:C) all down-regulated TLR4 messenger RNA (mRNA) and up-regulated TLR2 mRNA at 6 and 24 h. In spite of their inability to elaborate pro-inflammatory mediator output, the nominally microglia-free astrocytes (&gt;99 % purity) also showed similar behaviours to those of microglia, as well as changes in TLR3 gene expression.	lps	0-3	toll-like receptor 2	Rattus norvegicus	89-93
26714634-8	2015	LPS, zymosan and poly(I:C) all down-regulated TLR4 messenger RNA (mRNA) and up-regulated TLR2 mRNA at 6 and 24 h. In spite of their inability to elaborate pro-inflammatory mediator output, the nominally microglia-free astrocytes (&gt;99 % purity) also showed similar behaviours to those of microglia, as well as changes in TLR3 gene expression.	lps	0-3	toll-like receptor 3	Rattus norvegicus	323-327
26714634-10	2015	The effects of LPS on TLR2 mRNA in both cell populations were antagonized by a nuclear factor-kappaB inhibitor.	lps	15-18	toll-like receptor 2	Rattus norvegicus	22-26
26714634-12	2015	The finding that both homologous (zymosan) and heterologous (LPS, poly(I:C)) TLR ligands are capable of regulating TLR2 gene expression, in particular, may have important implications in understanding the relative contributions of different TLRs in neurological disorders associated with neuroinflammation.	lps	61-64	toll-like receptor 2	Rattus norvegicus	115-119
25358442-7	2015	RESULTS: Dexamethasone reduced LPS-induced TNFalpha, IL-6 and CXCL-8 in all groups, but maximum inhibition was significantly reduced for GINA3/4 compared with GINA2 and GINA1 (P &lt; 0.01).	lps	31-34	tumor necrosis factor	Homo sapiens	43-51
26689559-4	2015	Purified B.pseudomallei-LPS activated only TLR2-transfected-HEK-cells during short stimulation but both HEK-TLR2 and HEK-TLR4-cells after 24 h. In human blood, an additive effect of TLR2 on TLR4-mediated signalling induced by B.pseudomallei-LPS was observed.	lps	24-27	toll like receptor 2	Homo sapiens	43-47
26689559-4	2015	Purified B.pseudomallei-LPS activated only TLR2-transfected-HEK-cells during short stimulation but both HEK-TLR2 and HEK-TLR4-cells after 24 h. In human blood, an additive effect of TLR2 on TLR4-mediated signalling induced by B.pseudomallei-LPS was observed.	lps	24-27	toll like receptor 4	Homo sapiens	190-194
26689559-5	2015	In contrast, murine peritoneal macrophages recognized B.pseudomallei-LPS solely through TLR4.	lps	69-72	toll-like receptor 4	Mus musculus	88-92
26689559-6	2015	Intranasal inoculation of B.pseudomallei-LPS showed that both TLR4-knockout(-/-) and TLR2x4-/-, but not TLR2-/- mice, displayed diminished cytokine responses and neutrophil influx compared to wild-type controls.	lps	41-44	toll-like receptor 4	Mus musculus	62-66
26689559-6	2015	Intranasal inoculation of B.pseudomallei-LPS showed that both TLR4-knockout(-/-) and TLR2x4-/-, but not TLR2-/- mice, displayed diminished cytokine responses and neutrophil influx compared to wild-type controls.	lps	41-44	toll like receptor 2	Homo sapiens	85-89
26689559-7	2015	These data suggest that B.pseudomallei-LPS signalling occurs solely through murine TLR4, while in human models TLR2 plays an additional role, highlighting important differences between specificity of human and murine models that may have important consequences for B.pseudomallei-LPS sensing by TLRs and subsequent susceptibility to melioidosis.	lps	39-42	toll-like receptor 4	Mus musculus	83-87
25358442-7	2015	RESULTS: Dexamethasone reduced LPS-induced TNFalpha, IL-6 and CXCL-8 in all groups, but maximum inhibition was significantly reduced for GINA3/4 compared with GINA2 and GINA1 (P &lt; 0.01).	lps	31-34	interleukin 6	Homo sapiens	53-57
25358442-7	2015	RESULTS: Dexamethasone reduced LPS-induced TNFalpha, IL-6 and CXCL-8 in all groups, but maximum inhibition was significantly reduced for GINA3/4 compared with GINA2 and GINA1 (P &lt; 0.01).	lps	31-34	C-X-C motif chemokine ligand 8	Homo sapiens	62-68
26535039-9	2015	Furthermore, LCD at a dose of 50, 100 and 400 mg/Kg was found to reduce significantly LPS induced tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta production in female Sprague Dawley (SD) rats.	lps	86-89	tumor necrosis factor	Rattus norvegicus	98-131
25894678-7	2015	The expression of mGluR1 protein was increased in the hippocampus and prefrontal cortex of rats from the LPS group, as well as in the prefrontal cortex of rats from the MPS group.	lps	105-108	glutamate metabotropic receptor 1	Rattus norvegicus	18-24
25894678-8	2015	Meanwhile, the expression of mGluR5 protein was facilitated in the hippocampus and prefrontal cortex of rats in the LPS group.	lps	116-119	glutamate receptor, ionotropic, kainate 1	Mus musculus	29-35
25894678-9	2015	The expression of mGluR5 protein was increased in the striatum of the female rats in both MPS and LPS groups, and only in the male rats from the LPS group.	lps	98-101	glutamate receptor, ionotropic, kainate 1	Mus musculus	18-24
25894678-9	2015	The expression of mGluR5 protein was increased in the striatum of the female rats in both MPS and LPS groups, and only in the male rats from the LPS group.	lps	145-148	glutamate receptor, ionotropic, kainate 1	Mus musculus	18-24
25894678-10	2015	In addition, the reduced BDNF mRNA level was detected in the hippocampus and prefrontal cortex in the LPS rats, and in the striatum of the female rats in LPS group.	lps	102-105	brain-derived neurotrophic factor	Rattus norvegicus	25-29
25894678-10	2015	In addition, the reduced BDNF mRNA level was detected in the hippocampus and prefrontal cortex in the LPS rats, and in the striatum of the female rats in LPS group.	lps	154-157	brain-derived neurotrophic factor	Rattus norvegicus	25-29
26535039-9	2015	Furthermore, LCD at a dose of 50, 100 and 400 mg/Kg was found to reduce significantly LPS induced tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta production in female Sprague Dawley (SD) rats.	lps	86-89	interleukin 1 beta	Rattus norvegicus	136-158
25576930-3	2015	The aim of this study was to detect the level of autoantibodies and lympho-proliferative response against myelin basic protein (MBP) in leprosy patients (LPs) and their correlation with clinical phenotypes of LPs.	lps	154-157	myelin basic protein	Homo sapiens	106-126
25576930-3	2015	The aim of this study was to detect the level of autoantibodies and lympho-proliferative response against myelin basic protein (MBP) in leprosy patients (LPs) and their correlation with clinical phenotypes of LPs.	lps	154-157	myelin basic protein	Homo sapiens	128-131
25576930-3	2015	The aim of this study was to detect the level of autoantibodies and lympho-proliferative response against myelin basic protein (MBP) in leprosy patients (LPs) and their correlation with clinical phenotypes of LPs.	lps	209-212	myelin basic protein	Homo sapiens	106-126
25576930-3	2015	The aim of this study was to detect the level of autoantibodies and lympho-proliferative response against myelin basic protein (MBP) in leprosy patients (LPs) and their correlation with clinical phenotypes of LPs.	lps	209-212	myelin basic protein	Homo sapiens	128-131
25576930-5	2015	We observed significantly high level of anti-MBP antibodies in LPs across the spectrum and a positive significant correlation between the level of anti-MBP antibodies and the number of nerves involved in LPs.	lps	63-66	myelin basic protein	Homo sapiens	45-48
25576930-5	2015	We observed significantly high level of anti-MBP antibodies in LPs across the spectrum and a positive significant correlation between the level of anti-MBP antibodies and the number of nerves involved in LPs.	lps	204-207	myelin basic protein	Homo sapiens	152-155
25493017-10	2014	After D-GalN/LPS treatment CYLD(-/-) mice exhibited significantly lower levels of alanine aminotransferase (ALT) (295 U/L vs 859 U/L, P &lt; 0.05) and aspartate aminotransferase (AST) (560 U/L vs 1025 U/L, P &lt; 0.01).	lps	13-16	CYLD lysine 63 deubiquitinase	Mus musculus	27-31
25540922-7	2015	Tumor necrosis factor-alpha (TNF-alpha) production was measured in cell cultures after stimulation with lipopolysaccharide endotoxin (LPS) and Pam3CysSK3, and in BAL.	lps	134-137	tumor necrosis factor	Homo sapiens	0-27
25540922-7	2015	Tumor necrosis factor-alpha (TNF-alpha) production was measured in cell cultures after stimulation with lipopolysaccharide endotoxin (LPS) and Pam3CysSK3, and in BAL.	lps	134-137	tumor necrosis factor	Homo sapiens	29-38
25540922-12	2015	PBMC"s mainly from IPF patients exhibited low TNF-alpha production after LPS stimulation but not after Pam3CysSK3 stimulation, while TLR4 expression on PBMC"s was found normal in all study groups.	lps	73-76	tumor necrosis factor	Homo sapiens	46-55
25598708-8	2014	RESULTS AND DISCUSSION: The LPS resulted in induction of systemic inflammation as evidenced by increased levels of IL-1beta in plasma of LPS-treated rats compared to their non-treated control counterparts.	lps	28-31	interleukin 1 beta	Rattus norvegicus	115-123
25598708-8	2014	RESULTS AND DISCUSSION: The LPS resulted in induction of systemic inflammation as evidenced by increased levels of IL-1beta in plasma of LPS-treated rats compared to their non-treated control counterparts.	lps	137-140	interleukin 1 beta	Rattus norvegicus	115-123
25598708-10	2014	However, the elevation of IL-1beta levels in plasma of LPS-induced rats consuming either RPO or rooibos alone were paralleled with increased levels of the anti-inflammatory cytokine, IL-10.	lps	55-58	interleukin 1 beta	Rattus norvegicus	26-34
24861250-6	2014	In the liver of mice receiving injections of D-GalN/LPS, hepatocytes apoptosis and the infiltration of monocytes/macrophages were blocked by SKLB010.	lps	52-55	galanin and GMAP prepropeptide	Mus musculus	47-51
24972244-5	2014	Mangiferin inhibited interaction of fluorescent p-IRAK1 antibody to LPS-stimulated peritoneal macrophages, but increased binding of fluorescent IRAK1 antibody.	lps	68-71	interleukin-1 receptor-associated kinase 1	Mus musculus	50-55
24972244-8	2014	Mangiferin (10 muM) inhibited LPS-stimulated expression of TNF-alpha, IL-1beta and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group.	lps	30-33	tumor necrosis factor	Mus musculus	59-68
24972244-8	2014	Mangiferin (10 muM) inhibited LPS-stimulated expression of TNF-alpha, IL-1beta and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group.	lps	30-33	interleukin 1 beta	Mus musculus	70-78
24972244-8	2014	Mangiferin (10 muM) inhibited LPS-stimulated expression of TNF-alpha, IL-1beta and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group.	lps	30-33	interleukin 6	Mus musculus	83-87
25263355-4	2014	RESULTS: Exposure to LPS caused significantly increased IL-10 and TNF-alpha concentrations in the supernatant of cultured macrophages but not in BMSC culture.	lps	21-24	interleukin 10	Rattus norvegicus	56-61
25263355-4	2014	RESULTS: Exposure to LPS caused significantly increased IL-10 and TNF-alpha concentrations in the supernatant of cultured macrophages but not in BMSC culture.	lps	21-24	tumor necrosis factor	Rattus norvegicus	66-75
25263355-5	2014	Macrophages co-cultured with BMSCs showed significantly lowered IL-10 and TNF-alpha secretions in response to LPS exposure as compared with the macrophages cultured alone.	lps	110-113	interleukin 10	Rattus norvegicus	64-69
25263355-5	2014	Macrophages co-cultured with BMSCs showed significantly lowered IL-10 and TNF-alpha secretions in response to LPS exposure as compared with the macrophages cultured alone.	lps	110-113	tumor necrosis factor	Rattus norvegicus	74-83
25205638-11	2014	The intensity of nuclear staining of TLR4 was significantly lower in LPs transforming into LSCC than in LPs without malignant transformation.	lps	69-72	toll like receptor 4	Homo sapiens	37-41
25205638-11	2014	The intensity of nuclear staining of TLR4 was significantly lower in LPs transforming into LSCC than in LPs without malignant transformation.	lps	104-107	toll like receptor 4	Homo sapiens	37-41
25205638-13	2014	Cytoplasmic TLR9 expression was significantly lower in LPs than in LSCC.	lps	55-58	toll like receptor 9	Homo sapiens	12-16
25205638-14	2014	CONCLUSION: The expression of TLR4 may serve as a predictive marker of malignant transformation in LPs.	lps	99-102	toll like receptor 4	Homo sapiens	30-34
24861250-9	2014	In vitro, the production of tumor necrosis factor (TNF)-alpha and nitrite/nitrate in LPS-stimulated RAW264.7 macrophages was decreased by SKLB010 in a dose-dependent manner.	lps	85-88	tumor necrosis factor	Mus musculus	28-61
24128422-2	2014	We investigated the effect of lipopolysacharide (LPS) and progesterone (P4) upon expression of TLR-4/MyD88, TNFalpha, IL-6, IL-8, IL-10, and HBD2 on the human amniotic epithelium.	lps	49-52	toll like receptor 4	Homo sapiens	95-100
24128422-5	2014	RESULTS: P4 significantly reduced the expression of LPS-induced TLR-4/MyD88.	lps	52-55	toll like receptor 4	Homo sapiens	64-69
24941800-0	2014	[Diammonium glycyrrhizinate promotes aquaporin-5 in LPS-induced acute lung injury via inactivation of NF-kappaB].	lps	52-55	aquaporin 5	Mus musculus	37-48
24941800-1	2014	OBJECTIVE: To determine the therapeutic value and associated mechanism of diammonium glycyrrhizinate (DG) on the expression of AQP-5 in lipapolysacchairides (LPS)-induced acute lung injury in mice.	lps	158-161	aquaporin 5	Mus musculus	127-132
24941800-7	2014	RESULTS: After 3 days of LPS intratracheal injection, severe pathological changes, increased W/D, down-regulated AQP-5 expression and increased p-NF-kappaB p65/total NF-kappaB p65 were observed.	lps	25-28	aquaporin 5	Mus musculus	113-118
24941800-7	2014	RESULTS: After 3 days of LPS intratracheal injection, severe pathological changes, increased W/D, down-regulated AQP-5 expression and increased p-NF-kappaB p65/total NF-kappaB p65 were observed.	lps	25-28	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	156-159
24941800-7	2014	RESULTS: After 3 days of LPS intratracheal injection, severe pathological changes, increased W/D, down-regulated AQP-5 expression and increased p-NF-kappaB p65/total NF-kappaB p65 were observed.	lps	25-28	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	176-179
24941800-8	2014	Compared with mice in the LPS group, mice in the LPS+DG group had more significantly ameliorated pathological changes and increased W/ D, up-regulated AQP-5 expression, and reduced p-NF-kappaB p65/total NF-kappaB p65.	lps	49-52	aquaporin 5	Mus musculus	151-156
24941800-8	2014	Compared with mice in the LPS group, mice in the LPS+DG group had more significantly ameliorated pathological changes and increased W/ D, up-regulated AQP-5 expression, and reduced p-NF-kappaB p65/total NF-kappaB p65.	lps	49-52	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	193-196
24941800-8	2014	Compared with mice in the LPS group, mice in the LPS+DG group had more significantly ameliorated pathological changes and increased W/ D, up-regulated AQP-5 expression, and reduced p-NF-kappaB p65/total NF-kappaB p65.	lps	49-52	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	213-216
24734272-2	2014	In this study, we attempted to identify CDCA1-derived long peptides (LPs) that induce both CD4+ helper T (Th) cells and CTLs.	lps	69-72	NUF2 component of NDC80 kinetochore complex	Homo sapiens	40-45
24734272-2	2014	In this study, we attempted to identify CDCA1-derived long peptides (LPs) that induce both CD4+ helper T (Th) cells and CTLs.	lps	69-72	CD4 molecule	Homo sapiens	91-94
24416369-0	2014	Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.	lps	89-92	mitogen-activated protein kinase 3	Homo sapiens	114-120
24416369-11	2014	However the combination of LPS 0.1 microg/ml with CSE 2% or 4% induced an important production of these chemokines, that appears to be dependent of ERK1/2 and JAK/STAT pathways but did not require JNK and p38 pathways.	lps	27-30	mitogen-activated protein kinase 3	Homo sapiens	148-154
24416369-12	2014	Moreover, RNO associated with PGE2 reduced CSE+LPS-induced cytokine release, which can happen by occur through of ERK1/2 and JAK/STAT pathways.	lps	47-50	mitogen-activated protein kinase 3	Homo sapiens	114-120
24128422-5	2014	RESULTS: P4 significantly reduced the expression of LPS-induced TLR-4/MyD88.	lps	52-55	MYD88 innate immune signal transduction adaptor	Homo sapiens	70-75
24128422-6	2014	LPS increased the concentrations of TNFalpha, IL-6, IL-8, IL-10, and HBD2 by factors of 30-, eight, three, three, and fivefold, respectively.	lps	0-3	tumor necrosis factor	Homo sapiens	36-44
24128422-6	2014	LPS increased the concentrations of TNFalpha, IL-6, IL-8, IL-10, and HBD2 by factors of 30-, eight, three, three, and fivefold, respectively.	lps	0-3	interleukin 6	Homo sapiens	46-50
24128422-6	2014	LPS increased the concentrations of TNFalpha, IL-6, IL-8, IL-10, and HBD2 by factors of 30-, eight, three, three, and fivefold, respectively.	lps	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
24128422-6	2014	LPS increased the concentrations of TNFalpha, IL-6, IL-8, IL-10, and HBD2 by factors of 30-, eight, three, three, and fivefold, respectively.	lps	0-3	interleukin 10	Homo sapiens	58-63
24128422-2	2014	We investigated the effect of lipopolysacharide (LPS) and progesterone (P4) upon expression of TLR-4/MyD88, TNFalpha, IL-6, IL-8, IL-10, and HBD2 on the human amniotic epithelium.	lps	49-52	MYD88 innate immune signal transduction adaptor	Homo sapiens	101-106
24128422-2	2014	We investigated the effect of lipopolysacharide (LPS) and progesterone (P4) upon expression of TLR-4/MyD88, TNFalpha, IL-6, IL-8, IL-10, and HBD2 on the human amniotic epithelium.	lps	49-52	tumor necrosis factor	Homo sapiens	108-116
24128422-2	2014	We investigated the effect of lipopolysacharide (LPS) and progesterone (P4) upon expression of TLR-4/MyD88, TNFalpha, IL-6, IL-8, IL-10, and HBD2 on the human amniotic epithelium.	lps	49-52	interleukin 6	Homo sapiens	118-122
24128422-6	2014	LPS increased the concentrations of TNFalpha, IL-6, IL-8, IL-10, and HBD2 by factors of 30-, eight, three, three, and fivefold, respectively.	lps	0-3	defensin beta 4A	Homo sapiens	69-73
24128422-9	2014	CONCLUSION: P4 inhibited LPS-induced TLR-4/MyD88 and pro-inflammatory factors in the human amniotic epithelium.	lps	25-28	toll like receptor 4	Homo sapiens	37-42
24190079-7	2014	The results showed that emodin significantly reduced the expression and release of amylase, attenuated calcium overload and decreased the mRNA expression of Bip, PERK, ATF6 and IRE1 which was significantly elevated in AR42J cells treated with cerulein and LPS.	lps	256-259	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	157-160
24128422-9	2014	CONCLUSION: P4 inhibited LPS-induced TLR-4/MyD88 and pro-inflammatory factors in the human amniotic epithelium.	lps	25-28	MYD88 innate immune signal transduction adaptor	Homo sapiens	43-48
23933765-5	2014	CD45RA-depleted LPs contained effector and central memory CD4(+) and CD8(+) T cells that showed sustained IFN-gamma secretion to CMV, EBV, Aspergillus and Candida Ags.	lps	16-19	CD4 molecule	Homo sapiens	0-3
23933765-5	2014	CD45RA-depleted LPs contained effector and central memory CD4(+) and CD8(+) T cells that showed sustained IFN-gamma secretion to CMV, EBV, Aspergillus and Candida Ags.	lps	16-19	CD8a molecule	Homo sapiens	69-72
23933765-5	2014	CD45RA-depleted LPs contained effector and central memory CD4(+) and CD8(+) T cells that showed sustained IFN-gamma secretion to CMV, EBV, Aspergillus and Candida Ags.	lps	16-19	interferon gamma	Homo sapiens	106-115
23933765-8	2014	In conclusion, clinical grade depletion of CD45RA(+) naive T cells from donor LPs is feasible and highly efficient.	lps	78-81	protein tyrosine phosphatase receptor type C	Homo sapiens	43-47
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	62-65	DNA-damage inducible transcript 3	Rattus norvegicus	0-24
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	62-65	DNA-damage inducible transcript 3	Rattus norvegicus	26-33
23969982-2	2013	Endotoxin/lipopolysaccharide (LPS) has been reported to decrease the expression of resistin mRNA and protein in both lean and db/db obese mice, although the underlying mechanism remains unclear.	lps	30-33	resistin	Mus musculus	83-91
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	62-65	DNA-damage inducible transcript 3	Rattus norvegicus	35-40
23969982-3	2013	Several models such as ex vivo culture of adipose tissues, primary rat adipocytes and 3T3-L1 adipocytes were used to further characterize the effect of LPS on the expression of resistin.	lps	152-155	resistin	Rattus norvegicus	177-185
23969982-4	2013	LPS attenuated both the resistin mRNA and protein in a time- and dose-dependent manner.	lps	0-3	resistin	Rattus norvegicus	24-32
23969982-6	2013	The lipid A fraction is crucial for the inhibition of resistin expression induced by LPS.	lps	85-88	resistin	Rattus norvegicus	54-62
23969982-7	2013	Pharmacological intervention of c-Jun N-terminal kinase (JNK) reversed the inhibitory effect of LPS.	lps	96-99	mitogen-activated protein kinase 8	Rattus norvegicus	32-55
23969982-7	2013	Pharmacological intervention of c-Jun N-terminal kinase (JNK) reversed the inhibitory effect of LPS.	lps	96-99	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	CCAAT/enhancer binding protein alpha	Rattus norvegicus	19-55
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	CCAAT/enhancer binding protein alpha	Rattus norvegicus	57-68
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	62-65	resistin	Rattus norvegicus	135-143
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	CCAAT/enhancer binding protein alpha	Rattus norvegicus	70-75
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	81-129
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	163-166	DNA-damage inducible transcript 3	Rattus norvegicus	26-33
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	131-141
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	163-166	DNA-damage inducible transcript 3	Rattus norvegicus	75-82
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	143-148
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	CCAAT/enhancer binding protein alpha	Rattus norvegicus	171-182
23969982-9	2013	C/EBP homologous protein (CHOP-10; DDIT3) was up-regulated by LPS, while a CHOP-10 antisense oligonucleotide reversed the decrement of resistin protein induced by LPS.	lps	163-166	resistin	Rattus norvegicus	135-143
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	186-196
23969982-10	2013	Taken together, these results suggest that LPS inhibits resistin expression through a unique signaling pathway involving toll-like receptor 4, JNK, CHOP-10 and C/EBP-alpha/PPAR-gamma.	lps	43-46	resistin	Rattus norvegicus	56-64
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	186-196
23969982-8	2013	LPS down-regulated CCAAT/enhancer-binding protein alpha (C/EBP-alpha; CEBPA) and peroxisome proliferator-activated receptor gamma (PPAR-gamma; PPARG), while activation of C/EBP-alpha or PPAR-gamma by either over-expressing these transcriptional factors or by rosiglitazone, an agonist of PPAR-gamma, blocked the inhibitory effect of LPS on resistin.	lps	0-3	resistin	Rattus norvegicus	340-348
23969982-10	2013	Taken together, these results suggest that LPS inhibits resistin expression through a unique signaling pathway involving toll-like receptor 4, JNK, CHOP-10 and C/EBP-alpha/PPAR-gamma.	lps	43-46	mitogen-activated protein kinase 8	Rattus norvegicus	143-146
23969982-10	2013	Taken together, these results suggest that LPS inhibits resistin expression through a unique signaling pathway involving toll-like receptor 4, JNK, CHOP-10 and C/EBP-alpha/PPAR-gamma.	lps	43-46	DNA-damage inducible transcript 3	Rattus norvegicus	148-155
23969982-10	2013	Taken together, these results suggest that LPS inhibits resistin expression through a unique signaling pathway involving toll-like receptor 4, JNK, CHOP-10 and C/EBP-alpha/PPAR-gamma.	lps	43-46	CCAAT/enhancer binding protein alpha	Rattus norvegicus	160-171
23969982-10	2013	Taken together, these results suggest that LPS inhibits resistin expression through a unique signaling pathway involving toll-like receptor 4, JNK, CHOP-10 and C/EBP-alpha/PPAR-gamma.	lps	43-46	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	172-182
23959899-8	2013	Although reduced adrenal inflammation and HPA-axis activation mediated by LPS were found in Mx1(Cre+)-MyD88(fl/fl) mice, adrenocortical-specific MyD88 deletion did not alter the adrenal inflammation or HPA-axis activity under systemic inflammatory response syndrome conditions.	lps	74-77	MX dynamin-like GTPase 1	Mus musculus	92-95
23595503-3	2013	LPS or LAM-induced TNF-alpha production was 5 to 18 times higher in AB than in CB monocytes, whereas interleukin-1alpha (IL-1alpha) stimulated similar levels of TNF-alpha in both groups, suggesting that decreased responses to LPS or LAM in CB are unlikely to be due to differences in the MyD88-dependent signaling pathway.	lps	0-3	tumor necrosis factor	Homo sapiens	19-28
24327937-2	2013	We have recently identified ideal tumor-associated antigen (TAA)-derived long peptides (LPs) that elicit not only TAA-specific TH1 response, but also CTLs, through cross-presentation.	lps	88-91	negative elongation factor complex member C/D	Homo sapiens	127-130
26155222-4	2013	Lipopolysaccarides (LPS) induced the expression of TNF-alpha, IL-1beta, and IL-6.	lps	20-23	interleukin 6	Mus musculus	76-80
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferator activated receptor alpha	Mus musculus	52-100
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferator activated receptor alpha	Mus musculus	102-111
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferator activator receptor delta	Mus musculus	114-122
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferator activated receptor gamma	Mus musculus	130-139
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	158-188
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	190-200
26155222-5	2013	LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARbeta/delta, PPARgamma, and coactivators PPARgamma co-activator 1 alpha (PGC-1alpha), PGC-1beta messenger RNA (mRNA) in the liver of Balb/c mouse.	lps	0-3	peroxisome proliferative activated receptor, gamma, coactivator 1 beta	Mus musculus	203-212
26155222-6	2013	In addition, LPS-induced inflammation diminishes the protein level of PPARalpha, PPARbeta/delta, and PPARgamma.	lps	13-16	peroxisome proliferator activated receptor alpha	Mus musculus	70-79
26155222-6	2013	In addition, LPS-induced inflammation diminishes the protein level of PPARalpha, PPARbeta/delta, and PPARgamma.	lps	13-16	peroxisome proliferator activator receptor delta	Mus musculus	81-89
26155222-6	2013	In addition, LPS-induced inflammation diminishes the protein level of PPARalpha, PPARbeta/delta, and PPARgamma.	lps	13-16	peroxisome proliferator activated receptor gamma	Mus musculus	101-110
26155222-11	2013	Fenofibrate inhibited LPS-induced TNF-alpha, IL-1beta, and IL-6 production in the serum and liver.	lps	22-25	tumor necrosis factor	Mus musculus	34-43
26155222-11	2013	Fenofibrate inhibited LPS-induced TNF-alpha, IL-1beta, and IL-6 production in the serum and liver.	lps	22-25	interleukin 1 beta	Mus musculus	45-53
26155222-11	2013	Fenofibrate inhibited LPS-induced TNF-alpha, IL-1beta, and IL-6 production in the serum and liver.	lps	22-25	interleukin 6	Mus musculus	59-63
26155222-4	2013	Lipopolysaccarides (LPS) induced the expression of TNF-alpha, IL-1beta, and IL-6.	lps	20-23	tumor necrosis factor	Mus musculus	51-60
26155222-4	2013	Lipopolysaccarides (LPS) induced the expression of TNF-alpha, IL-1beta, and IL-6.	lps	20-23	interleukin 1 beta	Mus musculus	62-70
23595503-6	2013	CB from Kenyan newborns sensitized to parasite antigens in utero had more CD14(+) CD16(+) monocytes (P = 0.02) and produced higher levels of TNF-alpha in response to LPS (P = 0.004) than CB from unsensitized Kenyan or North American newborns.	lps	166-169	tumor necrosis factor	Homo sapiens	141-150
23595503-7	2013	Thus, a reduced CD14(+) CD16(+) activated/differentiated monocyte subset and a correspondingly lower level of functional TLR4 on monocytes contributes to the relatively low TNF-alpha response to LPS observed in immunologically naive newborns compared to the response in adults.	lps	195-198	CD14 molecule	Homo sapiens	16-20
23595503-7	2013	Thus, a reduced CD14(+) CD16(+) activated/differentiated monocyte subset and a correspondingly lower level of functional TLR4 on monocytes contributes to the relatively low TNF-alpha response to LPS observed in immunologically naive newborns compared to the response in adults.	lps	195-198	Fc gamma receptor IIIa	Homo sapiens	24-28
23595503-3	2013	LPS or LAM-induced TNF-alpha production was 5 to 18 times higher in AB than in CB monocytes, whereas interleukin-1alpha (IL-1alpha) stimulated similar levels of TNF-alpha in both groups, suggesting that decreased responses to LPS or LAM in CB are unlikely to be due to differences in the MyD88-dependent signaling pathway.	lps	0-3	MYD88 innate immune signal transduction adaptor	Homo sapiens	288-293
23595503-7	2013	Thus, a reduced CD14(+) CD16(+) activated/differentiated monocyte subset and a correspondingly lower level of functional TLR4 on monocytes contributes to the relatively low TNF-alpha response to LPS observed in immunologically naive newborns compared to the response in adults.	lps	195-198	toll like receptor 4	Homo sapiens	121-125
23595503-7	2013	Thus, a reduced CD14(+) CD16(+) activated/differentiated monocyte subset and a correspondingly lower level of functional TLR4 on monocytes contributes to the relatively low TNF-alpha response to LPS observed in immunologically naive newborns compared to the response in adults.	lps	195-198	tumor necrosis factor	Homo sapiens	173-182
23595503-4	2013	This impaired signaling was attributable, in part, to lower functional TLR4 expression, especially on CD14(+) CD16(+) monocytes, which are the primary cell subset for LPS-induced TNF-alpha production.	lps	167-170	toll like receptor 4	Homo sapiens	71-75
23595503-4	2013	This impaired signaling was attributable, in part, to lower functional TLR4 expression, especially on CD14(+) CD16(+) monocytes, which are the primary cell subset for LPS-induced TNF-alpha production.	lps	167-170	CD14 molecule	Homo sapiens	102-106
23595503-4	2013	This impaired signaling was attributable, in part, to lower functional TLR4 expression, especially on CD14(+) CD16(+) monocytes, which are the primary cell subset for LPS-induced TNF-alpha production.	lps	167-170	Fc gamma receptor IIIa	Homo sapiens	110-114
23595503-4	2013	This impaired signaling was attributable, in part, to lower functional TLR4 expression, especially on CD14(+) CD16(+) monocytes, which are the primary cell subset for LPS-induced TNF-alpha production.	lps	167-170	tumor necrosis factor	Homo sapiens	179-188
24021789-6	2013	RESULTS: High-concentration (200 mumol/L) treatments of both cordyceps acid and cordycepin significantly inhibited the LPS-induced up-regulation of MCP-1 transcription and secretion (mRNA: 2.07 +/- 0.29 vs. 3.35 +/- 0.26, t = 15.90 and 1.15 +/- 0.23 vs. 4.17 +/- 0.61, t = 8.93; protein: 1.88 +/- 0.06 vs. 2.33 +/- 0.06, t = 10.39 and 1.47 +/- 0.25 vs. 1.97 +/- 0.04, t = 4.60; all P less than 0.05).	lps	119-122	chemokine (C-C motif) ligand 2	Mus musculus	148-153
23335284-13	2013	The latter was due to NOS2 induction in Mps from in vivo LPS-treated mice.	lps	57-60	nitric oxide synthase 2, inducible	Mus musculus	22-26
23335284-7	2013	In vivo LPS treatment (0.1 mg/mouse) increased NO production more than fourfold and induced de novo NOS2 expression in Mps.	lps	8-11	nitric oxide synthase 2, inducible	Mus musculus	100-104
23335284-8	2013	Immunoblotting assays also showed an induction in VEGF-A and MMP-9 expression in lysates obtained from LPS-treated Mps, and MMP-9 activity was detected by zymography in cell supernatants.	lps	103-106	vascular endothelial growth factor A	Mus musculus	50-56
23335284-8	2013	Immunoblotting assays also showed an induction in VEGF-A and MMP-9 expression in lysates obtained from LPS-treated Mps, and MMP-9 activity was detected by zymography in cell supernatants.	lps	103-106	matrix metallopeptidase 9	Mus musculus	61-66
23335284-9	2013	LPS-activated Mps co-cultured with normal heart induced the expression of CD31 and VEGF-A in heart homogenates and increased MMP-9 activity in the supernatants.	lps	0-3	platelet/endothelial cell adhesion molecule 1	Mus musculus	74-78
23335284-9	2013	LPS-activated Mps co-cultured with normal heart induced the expression of CD31 and VEGF-A in heart homogenates and increased MMP-9 activity in the supernatants.	lps	0-3	vascular endothelial growth factor A	Mus musculus	83-89
23335284-9	2013	LPS-activated Mps co-cultured with normal heart induced the expression of CD31 and VEGF-A in heart homogenates and increased MMP-9 activity in the supernatants.	lps	0-3	matrix metallopeptidase 9	Mus musculus	125-130
23335284-11	2013	When LPS-stimulated Mps were co-cultured with isolated cardiomyocytes in a transwell assay, the expression of NOS2, VEGF-A and MMP-9 was induced in cardiac cells.	lps	5-8	nitric oxide synthase 2, inducible	Mus musculus	110-114
23335284-11	2013	When LPS-stimulated Mps were co-cultured with isolated cardiomyocytes in a transwell assay, the expression of NOS2, VEGF-A and MMP-9 was induced in cardiac cells.	lps	5-8	vascular endothelial growth factor A	Mus musculus	116-122
23335284-11	2013	When LPS-stimulated Mps were co-cultured with isolated cardiomyocytes in a transwell assay, the expression of NOS2, VEGF-A and MMP-9 was induced in cardiac cells.	lps	5-8	matrix metallopeptidase 9	Mus musculus	127-132
23591808-4	2013	We developed a cationic lipoplexes (LPs)-based carrier that efficiently delivered miR-29b both in vitro and in vivo.	lps	36-39	microRNA 29b-1	Homo sapiens	82-89
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	microRNA 29b-1	Homo sapiens	15-22
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	microRNA 29b-1	Homo sapiens	27-34
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	microRNA 29b-1	Homo sapiens	27-34
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	cyclin dependent kinase 6	Homo sapiens	125-129
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	DNA methyltransferase 3 beta	Homo sapiens	131-137
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	143-175
23591808-5	2013	LPs containing miR-29b (LP-miR-29b) efficiently delivered miR-29b to NSCLC A549 cells, reduced the expression of key targets CDK6, DNMT3B, and myeloid cell leukemia sequence 1 (MCL1), as well as cell growth and clonogenicity of A549 cells.	lps	0-3	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	177-181
23610519-5	2013	These markers were highly stimulated by LPS and were inhibited both by nano-GA and unprocessed GA in a dose-dependent manner, especially PGE2 and TNF-alpha.	lps	40-43	tumor necrosis factor	Mus musculus	146-155
23395614-3	2013	In this study we investigated the modulation of the lipopolisaccharide (LPS)-induced inflammatory response of microglial BV-2 cells by Grp75.	lps	72-75	heat shock protein 9	Mus musculus	135-140
23395614-5	2013	Overexpression of Grp75 attenuates the LPS-induced oxidative and metabolic responses, and suppresses proinflammatory activation, which depends on both NF-kappaB activation and lactate.	lps	39-42	heat shock protein 9	Mus musculus	18-23
24152964-4	2013	In this study, the therapeutic effects of compound A and roflumilast were evaluated on lipopolysaccaride (LPS) injection-induced plasma TNF-alpha elevation and on LPS inhalation-induced pulmonary neutrophilia in mice.	lps	106-109	tumor necrosis factor	Mus musculus	136-145
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	0-3	toll like receptor 4	Homo sapiens	43-63
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	0-3	toll like receptor 4	Homo sapiens	65-70
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	0-3	interleukin 1 receptor associated kinase 1	Homo sapiens	93-126
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	0-3	interleukin 1 receptor associated kinase 1	Homo sapiens	128-134
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	0-3	TNF receptor associated factor 6	Homo sapiens	140-190
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	0-3	TNF receptor associated factor 6	Homo sapiens	192-198
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	313-316	toll like receptor 4	Homo sapiens	43-63
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	313-316	toll like receptor 4	Homo sapiens	65-70
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	313-316	interleukin 1 receptor associated kinase 1	Homo sapiens	93-126
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	313-316	interleukin 1 receptor associated kinase 1	Homo sapiens	128-134
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	313-316	TNF receptor associated factor 6	Homo sapiens	140-190
22972459-5	2012	LPS-challenge increased gene-expression of toll-like receptor-4 (TLR-4) and downstream genes IL-1 receptor-associated kinase 1 (IRAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6) up to 2.58-, 2.39-, and 3.73-fold, respectively, relative to DMSO-treated controls that were not challenged with LPS.	lps	313-316	TNF receptor associated factor 6	Homo sapiens	192-198
22972459-6	2012	LPS up-regulated TLR-4, IRAK-1, and TRAF-6 in SCE pretreated cells (5 mg L(-1)), only up to 0.69-, 1.28-, and 1.15-fold, respectively.	lps	0-3	toll like receptor 4	Homo sapiens	17-22
22972459-6	2012	LPS up-regulated TLR-4, IRAK-1, and TRAF-6 in SCE pretreated cells (5 mg L(-1)), only up to 0.69-, 1.28-, and 1.15-fold, respectively.	lps	0-3	interleukin 1 receptor associated kinase 1	Homo sapiens	24-30
22972459-6	2012	LPS up-regulated TLR-4, IRAK-1, and TRAF-6 in SCE pretreated cells (5 mg L(-1)), only up to 0.69-, 1.28-, and 1.15-fold, respectively.	lps	0-3	TNF receptor associated factor 6	Homo sapiens	36-42
22972459-9	2012	LPS-challenge induced mRNA levels of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) up to 5.65- and 10.65-fold, respectively.	lps	0-3	vascular cell adhesion molecule 1	Homo sapiens	37-70
22972459-9	2012	LPS-challenge induced mRNA levels of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) up to 5.65- and 10.65-fold, respectively.	lps	0-3	vascular cell adhesion molecule 1	Homo sapiens	72-78
22972459-9	2012	LPS-challenge induced mRNA levels of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) up to 5.65- and 10.65-fold, respectively.	lps	0-3	intercellular adhesion molecule 1	Homo sapiens	84-122
22972459-9	2012	LPS-challenge induced mRNA levels of vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-1) up to 5.65- and 10.65-fold, respectively.	lps	0-3	intercellular adhesion molecule 1	Homo sapiens	124-130
26105386-11	2012	An increase in TLR4 MFIs was detected after monocytes from NT pregnant women were stimulated with LPS while TLR2 expression was increased after PG-stimulation.	lps	98-101	toll like receptor 4	Homo sapiens	15-19
22410671-0	2012	Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells.	lps	18-21	C-C motif chemokine ligand 2	Rattus norvegicus	30-34
22410671-0	2012	Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells.	lps	18-21	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
22410671-3	2012	This study investigated the inhibitory effect of curcumin on lipopolysacharide (LPS)-induced chemokine CCL2 (or monocyte chemoattractant protein-1, MCP-1) production and whether the effect is mediated by mitogen-activated protein kinases (MAPKs) in the rat astrocytoma cell C6.	lps	80-83	C-C motif chemokine ligand 2	Rattus norvegicus	103-107
22410671-4	2012	We observed that LPS (1 mug/ml) induced the upregulation of CCL2 mRNA and protein in C6.	lps	17-20	C-C motif chemokine ligand 2	Rattus norvegicus	60-64
22410671-5	2012	Treatment with curcumin (2.5, 10, and 25 muM) decreased the expression of CCL2 mRNA and protein in a dose-dependent manner under treatment with LPS.	lps	144-147	C-C motif chemokine ligand 2	Rattus norvegicus	74-78
22410671-6	2012	Additionally, the c-jun N-terminal kinase (JNK) inhibitor (SP600125) dose-dependently inhibited LPS-induced CCL2 upregulation, whereas the MAPK kinase (MEK) inhibitor (PD98059) only had a mild effect and the p38 MAPK inhibitor (SB203580) had no effect.	lps	96-99	mitogen-activated protein kinase 8	Rattus norvegicus	43-46
22410671-6	2012	Additionally, the c-jun N-terminal kinase (JNK) inhibitor (SP600125) dose-dependently inhibited LPS-induced CCL2 upregulation, whereas the MAPK kinase (MEK) inhibitor (PD98059) only had a mild effect and the p38 MAPK inhibitor (SB203580) had no effect.	lps	96-99	C-C motif chemokine ligand 2	Rattus norvegicus	108-112
22410671-7	2012	Finally, western blot showed that LPS induced rapid JNK activation and curcumin reduced LPS-induced phosphoJNK (pJNK) expression at 30 min after LPS stimulation.	lps	34-37	mitogen-activated protein kinase 8	Rattus norvegicus	52-55
22580404-3	2012	In the present study, we showed that treatment with SB216763, a highly specific GSK-3beta inhibitor, resulted in a dose-dependent decrease in the mRNA and protein expression of CD40, as well as production of pro-inflammatory cytokines IL-6, TNF-alpha and IL-1beta, in the Porphyromonas gingivalis-lipopolysaccharide (LPS)-stimulated murine osteoblastic-like MC3T3-E1 cells.	lps	317-320	glycogen synthase kinase 3 beta	Mus musculus	80-89
22580404-4	2012	Furthermore, inhibition of GSK-3beta remarkably represses the LPS-induced activation of the nuclear factor kappa B (NF-kappaB) signaling pathway by suppressing IkappaBalpha phosphorylation, NF-kappaBp65 nuclear translocation, and NF-kappaBp65 DNA binding activity.	lps	62-65	glycogen synthase kinase 3 beta	Mus musculus	27-36
22580404-4	2012	Furthermore, inhibition of GSK-3beta remarkably represses the LPS-induced activation of the nuclear factor kappa B (NF-kappaB) signaling pathway by suppressing IkappaBalpha phosphorylation, NF-kappaBp65 nuclear translocation, and NF-kappaBp65 DNA binding activity.	lps	62-65	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-114
22580404-4	2012	Furthermore, inhibition of GSK-3beta remarkably represses the LPS-induced activation of the nuclear factor kappa B (NF-kappaB) signaling pathway by suppressing IkappaBalpha phosphorylation, NF-kappaBp65 nuclear translocation, and NF-kappaBp65 DNA binding activity.	lps	62-65	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
22580404-4	2012	Furthermore, inhibition of GSK-3beta remarkably represses the LPS-induced activation of the nuclear factor kappa B (NF-kappaB) signaling pathway by suppressing IkappaBalpha phosphorylation, NF-kappaBp65 nuclear translocation, and NF-kappaBp65 DNA binding activity.	lps	62-65	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	160-172
22580404-6	2012	The negative regulation effect of GSK-3beta inhibitor on CD40 expression is mediated through beta-catenin, for siRNA of beta-catenin attenuated the GSK-3beta inhibitor-induced repression of NF-kappaB activation and, consequently, the expression of CD40 and production of pro-inflammatory cytokines in LPS-stimulated MC3T3-E1 cells.	lps	301-304	glycogen synthase kinase 3 beta	Mus musculus	34-43
22580404-6	2012	The negative regulation effect of GSK-3beta inhibitor on CD40 expression is mediated through beta-catenin, for siRNA of beta-catenin attenuated the GSK-3beta inhibitor-induced repression of NF-kappaB activation and, consequently, the expression of CD40 and production of pro-inflammatory cytokines in LPS-stimulated MC3T3-E1 cells.	lps	301-304	CD40 antigen	Mus musculus	57-61
22580404-6	2012	The negative regulation effect of GSK-3beta inhibitor on CD40 expression is mediated through beta-catenin, for siRNA of beta-catenin attenuated the GSK-3beta inhibitor-induced repression of NF-kappaB activation and, consequently, the expression of CD40 and production of pro-inflammatory cytokines in LPS-stimulated MC3T3-E1 cells.	lps	301-304	catenin (cadherin associated protein), beta 1	Mus musculus	93-105
22580404-6	2012	The negative regulation effect of GSK-3beta inhibitor on CD40 expression is mediated through beta-catenin, for siRNA of beta-catenin attenuated the GSK-3beta inhibitor-induced repression of NF-kappaB activation and, consequently, the expression of CD40 and production of pro-inflammatory cytokines in LPS-stimulated MC3T3-E1 cells.	lps	301-304	catenin (cadherin associated protein), beta 1	Mus musculus	120-132
22580404-6	2012	The negative regulation effect of GSK-3beta inhibitor on CD40 expression is mediated through beta-catenin, for siRNA of beta-catenin attenuated the GSK-3beta inhibitor-induced repression of NF-kappaB activation and, consequently, the expression of CD40 and production of pro-inflammatory cytokines in LPS-stimulated MC3T3-E1 cells.	lps	301-304	glycogen synthase kinase 3 beta	Mus musculus	148-157
22580404-6	2012	The negative regulation effect of GSK-3beta inhibitor on CD40 expression is mediated through beta-catenin, for siRNA of beta-catenin attenuated the GSK-3beta inhibitor-induced repression of NF-kappaB activation and, consequently, the expression of CD40 and production of pro-inflammatory cytokines in LPS-stimulated MC3T3-E1 cells.	lps	301-304	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	190-199
22580404-7	2012	Thus our results elucidate the molecular mechanisms whereby GSK-3beta inhibitor prevents the LPS-induced CD40 expression on osteoblasts and provide supportive evidence of the potential role of GSK-3beta inhibitors in suppressing the immune function of osteoblasts in inflammatory bone diseases.	lps	93-96	glycogen synthase kinase 3 beta	Mus musculus	60-69
22580404-7	2012	Thus our results elucidate the molecular mechanisms whereby GSK-3beta inhibitor prevents the LPS-induced CD40 expression on osteoblasts and provide supportive evidence of the potential role of GSK-3beta inhibitors in suppressing the immune function of osteoblasts in inflammatory bone diseases.	lps	93-96	CD40 antigen	Mus musculus	105-109
22580404-7	2012	Thus our results elucidate the molecular mechanisms whereby GSK-3beta inhibitor prevents the LPS-induced CD40 expression on osteoblasts and provide supportive evidence of the potential role of GSK-3beta inhibitors in suppressing the immune function of osteoblasts in inflammatory bone diseases.	lps	93-96	glycogen synthase kinase 3 beta	Mus musculus	193-202
23388481-2	2012	We analyse whether cyclooxygenase-2 inhibition by meloxicam administration is able to modify the response of skeletal muscle to inflammation induced by lipopolysaccharide endotoxin (LPS).	lps	182-185	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	19-35
23388481-8	2012	Cyclooxygenase-2 was increased, whereas MyoD was decreased at 4, 24 and 72 h. Both types of meloxicam treatment blocked LPS-induced increase in atrogin-1.	lps	120-123	F-box protein 32	Rattus norvegicus	144-153
23388481-11	2012	These data suggest that cyclooxygenase-2 inhibition by meloxicam administration can prevent the increase in atrogin-1 and the decrease in MyoD induced by LPS administration.	lps	154-157	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	24-40
22640899-9	2012	GRP78 expression was down-regulated in cerulein group and upregulated in cerulein plus LPS group.	lps	87-90	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	0-5
26105386-14	2012	In contrast, when monocytes were stimulated with the TLRs ligands LPS and PG, the release of TNF-alpha was significantly reduced, while IL-12p70 levels were significantly higher in women with PE compared to NT group.	lps	66-69	tumor necrosis factor	Homo sapiens	93-102
22240362-4	2012	Concentration of TNF-alpha in supernatants of LPS-stimulated mononuclear cells was evaluated in vitro by flow cytometry as well.	lps	46-49	tumor necrosis factor	Mus musculus	17-26
22484827-8	2012	Sivelestat or edaravone treatment also attenuated the LPS-induced production of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-alpha) in rat lungs.	lps	54-57	interleukin 6	Rattus norvegicus	107-125
22484827-8	2012	Sivelestat or edaravone treatment also attenuated the LPS-induced production of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-alpha) in rat lungs.	lps	54-57	tumor necrosis factor	Rattus norvegicus	130-157
22484827-8	2012	Sivelestat or edaravone treatment also attenuated the LPS-induced production of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-alpha) in rat lungs.	lps	54-57	tumor necrosis factor	Rattus norvegicus	159-168
22521196-0	2012	Prokaryotic selectivity and LPS-neutralizing activity of short antimicrobial peptides designed from the human antimicrobial peptide LL-37.	lps	28-31	cathelicidin antimicrobial peptide	Homo sapiens	132-137
22563259-4	2012	Cilostazol significantly suppressed the level of LPS-stimulated TNFalpha mRNA and protein with a similar degree to that by pentoxifylline.	lps	49-52	tumor necrosis factor	Mus musculus	64-72
22119708-5	2012	All PFCs suppressed LPS-induced TNF-alpha production in hPBL and THP-1 cells, while IL-6 production was suppressed by PFOSA, PFOS, PFDA and fluorotelomer.	lps	20-23	tumor necrosis factor	Homo sapiens	32-41
22415090-6	2012	RESULTS: LPS increased COX-2 expression and stimulated production of prostaglandins, including prostaglandin E(2) (PGE(2)).	lps	9-12	cytochrome c oxidase II, mitochondrial	Mus musculus	23-28
22240362-6	2012	In addition, LPS stimulation apparently increased the expression of CD11b/CD18 on neutrophils, the concentration of plasma TNF-alpha, and the production of TNF-alpha from mononuclear cells.	lps	13-16	integrin alpha M	Mus musculus	68-73
22240362-6	2012	In addition, LPS stimulation apparently increased the expression of CD11b/CD18 on neutrophils, the concentration of plasma TNF-alpha, and the production of TNF-alpha from mononuclear cells.	lps	13-16	lymphotoxin B receptor	Mus musculus	74-78
22240362-6	2012	In addition, LPS stimulation apparently increased the expression of CD11b/CD18 on neutrophils, the concentration of plasma TNF-alpha, and the production of TNF-alpha from mononuclear cells.	lps	13-16	tumor necrosis factor	Mus musculus	123-132
22240362-6	2012	In addition, LPS stimulation apparently increased the expression of CD11b/CD18 on neutrophils, the concentration of plasma TNF-alpha, and the production of TNF-alpha from mononuclear cells.	lps	13-16	tumor necrosis factor	Mus musculus	156-165
22685683-11	2012	Preconditioning of newborn rats with LPS increased TLR4, Caspase-9 and -3 levels, but failed to affect basal expression of HSP60, Bax, and Bcl-2.	lps	37-40	toll-like receptor 4	Rattus norvegicus	51-55
22685683-11	2012	Preconditioning of newborn rats with LPS increased TLR4, Caspase-9 and -3 levels, but failed to affect basal expression of HSP60, Bax, and Bcl-2.	lps	37-40	caspase 9	Rattus norvegicus	57-73
21527272-6	2011	These data indicate that COX-2-mediated prostaglandin synthesis is necessary for LPS anorexia and much of the initial LPS-induced neural activation.	lps	81-84	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	25-30
22511970-3	2012	We therefore propose that lipopolysacharides (LPS) may stimulate CD14 production in liver cells and promote the removal of endotoxins.	lps	46-49	CD14 molecule	Rattus norvegicus	65-69
22511970-4	2012	The aims of this study are to test the hypothesis that CD14 is upregulated by LPS and investigate the pathophysiological role of CD14 production during cholestasis.	lps	78-81	CD14 molecule	Rattus norvegicus	55-59
22511970-5	2012	Using Western blotting, qRT-PCR, and promoter activity assay, we demonstrated that LPS was associated with a significant increase in CD14 and MD2 protein and mRNA expression and CD14 promoter activity in C9 rat hepatocytes but not in the HSC-T6 hepatic stellate cell line in vitro.	lps	83-86	CD14 molecule	Rattus norvegicus	133-137
22511970-5	2012	Using Western blotting, qRT-PCR, and promoter activity assay, we demonstrated that LPS was associated with a significant increase in CD14 and MD2 protein and mRNA expression and CD14 promoter activity in C9 rat hepatocytes but not in the HSC-T6 hepatic stellate cell line in vitro.	lps	83-86	lymphocyte antigen 96	Rattus norvegicus	142-145
22511970-5	2012	Using Western blotting, qRT-PCR, and promoter activity assay, we demonstrated that LPS was associated with a significant increase in CD14 and MD2 protein and mRNA expression and CD14 promoter activity in C9 rat hepatocytes but not in the HSC-T6 hepatic stellate cell line in vitro.	lps	83-86	CD14 molecule	Rattus norvegicus	178-182
22511970-7	2012	CD14 expression and endotoxin levels were found to significantly increase after LPS administration in BDL rats.	lps	80-83	CD14 molecule	Rattus norvegicus	0-4
22511970-10	2012	In conclusion, cholestasis and LPS stimulation were here found to upregulate hepatic CD14 expression, which may have led to increased endotoxin sensitivity and host proinflammatory reactions, causing organ failure and death in BDL rats.	lps	31-34	CD14 molecule	Rattus norvegicus	85-89
21958471-7	2011	KEY FINDINGS: Prior supplementation of LPS-challenged rats with L. plantarum (10(10)CFU per rat given orally for 10 days) demonstrated decreased levels of liver enzymes, NO and TNF-alpha.	lps	39-42	tumor necrosis factor	Rattus norvegicus	177-186
22745684-5	2012	miR-155 expression in these cultures was negligible, but was significantly expressed in PBMCs stimulated with Lipopolysaccahride (LPS) or most other Toll-like receptor (TLR) ligands, making it the prototypic "PAMPmiR".	lps	130-133	microRNA 155	Mus musculus	0-7
21567435-15	2011	In primary murine Kupffer cells, FK866 suppressed LPS-induced interleukin (IL)-6 production, whereas incubation with recombinant PBEF resulted in increased IL-6 release.	lps	50-53	interleukin 6	Mus musculus	62-80
21147093-6	2011	Present investigation demonstrated that, Biochanin-A inhibited lipopolysacharide (LPS)-induced nitric oxide(NO) production in macrophage and showed dose dependent inhibition of inducible nitric oxide synthase (iNOS) expression.	lps	82-85	nitric oxide synthase 2, inducible	Mus musculus	210-214
21592111-4	2011	DCs modified with siRNA targeting against IL-10R or IL-10 (DC/siIL-10R or DC/siIL-10) led to up-regulation of major histocompatibility complex (MHC) class II, CD40 co-stimulatory molecule, and IL-12 proinflammatory cytokine after lipopolysacharide (LPS) stimulation compared to DC/siGFP.	lps	249-252	interleukin 10 receptor subunit alpha	Homo sapiens	42-48
21592111-4	2011	DCs modified with siRNA targeting against IL-10R or IL-10 (DC/siIL-10R or DC/siIL-10) led to up-regulation of major histocompatibility complex (MHC) class II, CD40 co-stimulatory molecule, and IL-12 proinflammatory cytokine after lipopolysacharide (LPS) stimulation compared to DC/siGFP.	lps	249-252	interleukin 10	Homo sapiens	42-47
21592111-4	2011	DCs modified with siRNA targeting against IL-10R or IL-10 (DC/siIL-10R or DC/siIL-10) led to up-regulation of major histocompatibility complex (MHC) class II, CD40 co-stimulatory molecule, and IL-12 proinflammatory cytokine after lipopolysacharide (LPS) stimulation compared to DC/siGFP.	lps	249-252	CD40 molecule	Homo sapiens	159-163
21592111-5	2011	Notably, the LPS-induced functional profiles of DC/siIL-10R were strongly resistant to the addition of recombinant IL-10, which mimicked paracrine IL-10.	lps	13-16	interleukin 10	Homo sapiens	53-58
21592111-5	2011	Notably, the LPS-induced functional profiles of DC/siIL-10R were strongly resistant to the addition of recombinant IL-10, which mimicked paracrine IL-10.	lps	13-16	interleukin 10	Homo sapiens	115-120
21461920-0	2011	Guggulipid and nimesulide differentially regulated inflammatory genes mRNA expressions via inhibition of NF-kB and CHOP activation in LPS-stimulated rat astrocytoma cells, C6.	lps	134-137	DNA-damage inducible transcript 3	Rattus norvegicus	115-119
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	nitric oxide synthase 2	Rattus norvegicus	149-180
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	nitric oxide synthase 2	Rattus norvegicus	182-186
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	nuclear factor kappa B subunit 1	Rattus norvegicus	189-211
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	nuclear factor kappa B subunit 1	Rattus norvegicus	213-218
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	DNA-damage inducible transcript 3	Rattus norvegicus	221-248
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	DNA-damage inducible transcript 3	Rattus norvegicus	250-254
21461920-5	2011	We observed that LPS (10 mug/ml) treatment of rat astrocytoma cells, C6, for 24 h significantly increased intracellular Ca(2+) ion and expression of inducible nitric oxide synthase (iNOS), nuclear factor kappa-B (NF-kB), C/EBP homologous protein 10 (CHOP), c-fos, and c-jun proteins.	lps	17-20	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	257-262
21461920-6	2011	At transcriptional stage, LPS upregulated mRNA levels of cyclooxygenase-2 and IL-6 with downregulation in IL-1alpha, IL-1beta, and microsomal prostaglandin E synthase-1 (mPGES-1) through activating NF-kB translocation.	lps	26-29	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	57-73
21461920-6	2011	At transcriptional stage, LPS upregulated mRNA levels of cyclooxygenase-2 and IL-6 with downregulation in IL-1alpha, IL-1beta, and microsomal prostaglandin E synthase-1 (mPGES-1) through activating NF-kB translocation.	lps	26-29	interleukin 6	Rattus norvegicus	78-82
21461920-6	2011	At transcriptional stage, LPS upregulated mRNA levels of cyclooxygenase-2 and IL-6 with downregulation in IL-1alpha, IL-1beta, and microsomal prostaglandin E synthase-1 (mPGES-1) through activating NF-kB translocation.	lps	26-29	interleukin 1 alpha	Rattus norvegicus	106-115
21461920-6	2011	At transcriptional stage, LPS upregulated mRNA levels of cyclooxygenase-2 and IL-6 with downregulation in IL-1alpha, IL-1beta, and microsomal prostaglandin E synthase-1 (mPGES-1) through activating NF-kB translocation.	lps	26-29	interleukin 1 beta	Rattus norvegicus	117-125
21461920-6	2011	At transcriptional stage, LPS upregulated mRNA levels of cyclooxygenase-2 and IL-6 with downregulation in IL-1alpha, IL-1beta, and microsomal prostaglandin E synthase-1 (mPGES-1) through activating NF-kB translocation.	lps	26-29	prostaglandin E synthase	Mus musculus	170-177
21461920-6	2011	At transcriptional stage, LPS upregulated mRNA levels of cyclooxygenase-2 and IL-6 with downregulation in IL-1alpha, IL-1beta, and microsomal prostaglandin E synthase-1 (mPGES-1) through activating NF-kB translocation.	lps	26-29	nuclear factor kappa B subunit 1	Rattus norvegicus	198-203
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	lps	42-45	nitric oxide synthase 2	Rattus norvegicus	66-70
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	lps	42-45	nuclear factor kappa B subunit 1	Rattus norvegicus	72-77
21461920-8	2011	Treatment with nimesulide also attenuated LPS-induced Ca(2+) ion, iNOS, NF-kB, and c-fos expressions, but does not significantly influence CHOP, c-jun protein expressions, and mRNA levels of IL-6, IL-1alpha, IL-1beta, and mPGES-1 genes.	lps	42-45	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	83-88
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	tumor necrosis factor	Mus musculus	49-76
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	tumor necrosis factor	Mus musculus	78-87
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	interleukin 6	Mus musculus	89-102
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	interleukin 6	Mus musculus	104-108
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	interleukin 12b	Mus musculus	115-123
21575254-9	2011	OMC inhibited LPS-induced production of prostaglandin E2 (PGE2) and nitric oxide (NO) through the down-regulation of expression of COX-2 and iNOS, respectively.	lps	14-17	cytochrome c oxidase II, mitochondrial	Mus musculus	131-136
21575254-9	2011	OMC inhibited LPS-induced production of prostaglandin E2 (PGE2) and nitric oxide (NO) through the down-regulation of expression of COX-2 and iNOS, respectively.	lps	14-17	nitric oxide synthase 2, inducible	Mus musculus	141-145
21237302-7	2011	Moreover, treatment with TA decreased LPS-induced DNA binding of nuclear factor-kappa B (NF-kappaB) and nuclear translocation of p65 and p50 subunits of NF-kappaB.	lps	38-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
21237302-7	2011	Moreover, treatment with TA decreased LPS-induced DNA binding of nuclear factor-kappa B (NF-kappaB) and nuclear translocation of p65 and p50 subunits of NF-kappaB.	lps	38-41	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	129-132
21237302-7	2011	Moreover, treatment with TA decreased LPS-induced DNA binding of nuclear factor-kappa B (NF-kappaB) and nuclear translocation of p65 and p50 subunits of NF-kappaB.	lps	38-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	137-140
21237302-7	2011	Moreover, treatment with TA decreased LPS-induced DNA binding of nuclear factor-kappa B (NF-kappaB) and nuclear translocation of p65 and p50 subunits of NF-kappaB.	lps	38-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	153-162
21237302-8	2011	Consistent with these findings, TA also suppressed the LPS-stimulated degradation and phosphorylation of inhibitor of kappa B-alpha (IkappaB-alpha).	lps	55-58	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	133-146
21290574-9	2011	The effects of the sealers on LPS-activated THP1 were biphasic, with some increases and decreases cytokine secretion of &gt;20%, but few larger effects.	lps	30-33	GLI family zinc finger 2	Homo sapiens	44-48
21147093-9	2011	LPS-induced phosphorylation of IkappaBalpha and p38 MAPK was blocked by Biochanin-A and it inhibited IL-6, IL-1beta and TNF-alpha production in RAW264.7 cells indicating its anti-inflammatory activity in association with anti-proliferation.	lps	0-3	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	31-43
21147093-9	2011	LPS-induced phosphorylation of IkappaBalpha and p38 MAPK was blocked by Biochanin-A and it inhibited IL-6, IL-1beta and TNF-alpha production in RAW264.7 cells indicating its anti-inflammatory activity in association with anti-proliferation.	lps	0-3	mitogen-activated protein kinase 14	Mus musculus	48-56
21147093-9	2011	LPS-induced phosphorylation of IkappaBalpha and p38 MAPK was blocked by Biochanin-A and it inhibited IL-6, IL-1beta and TNF-alpha production in RAW264.7 cells indicating its anti-inflammatory activity in association with anti-proliferation.	lps	0-3	interleukin 6	Mus musculus	101-105
21147093-9	2011	LPS-induced phosphorylation of IkappaBalpha and p38 MAPK was blocked by Biochanin-A and it inhibited IL-6, IL-1beta and TNF-alpha production in RAW264.7 cells indicating its anti-inflammatory activity in association with anti-proliferation.	lps	0-3	interleukin 1 beta	Mus musculus	107-115
21147093-9	2011	LPS-induced phosphorylation of IkappaBalpha and p38 MAPK was blocked by Biochanin-A and it inhibited IL-6, IL-1beta and TNF-alpha production in RAW264.7 cells indicating its anti-inflammatory activity in association with anti-proliferation.	lps	0-3	tumor necrosis factor	Mus musculus	120-129
21567435-10	2011	Liver-targeted overexpression of PBEF rendered mice more susceptible to ConA- and D-galactosamine/LPS-induced hepatitis compared with control animals.	lps	98-101	nicotinamide phosphoribosyltransferase	Mus musculus	33-37
21567435-14	2011	In vitro, PBEF-silenced mouse hepatocytes showed decreased responses after stimulation with LPS, lipoteichoic acid, and tumor necrosis factor alpha.	lps	92-95	nicotinamide phosphoribosyltransferase	Mus musculus	10-14
21575254-11	2011	Oral administration of OMC markedly suppressed secretion of TNF-alpha and IL-6 in mice challenged with LPS in vivo.	lps	103-106	tumor necrosis factor	Mus musculus	60-69
21575254-11	2011	Oral administration of OMC markedly suppressed secretion of TNF-alpha and IL-6 in mice challenged with LPS in vivo.	lps	103-106	interleukin 6	Mus musculus	74-78
21237302-0	2011	Tormentic acid, a triterpenoid saponin, isolated from Rosa rugosa, inhibited LPS-induced iNOS, COX-2, and TNF-alpha expression through inactivation of the nuclear factor-kappab pathway in RAW 264.7 macrophages.	lps	77-80	nitric oxide synthase 2, inducible	Mus musculus	89-93
21237302-0	2011	Tormentic acid, a triterpenoid saponin, isolated from Rosa rugosa, inhibited LPS-induced iNOS, COX-2, and TNF-alpha expression through inactivation of the nuclear factor-kappab pathway in RAW 264.7 macrophages.	lps	77-80	prostaglandin-endoperoxide synthase 2	Mus musculus	95-100
21237302-0	2011	Tormentic acid, a triterpenoid saponin, isolated from Rosa rugosa, inhibited LPS-induced iNOS, COX-2, and TNF-alpha expression through inactivation of the nuclear factor-kappab pathway in RAW 264.7 macrophages.	lps	77-80	tumor necrosis factor	Mus musculus	106-115
21237302-5	2011	TA dose-dependently reduced the productions of NO, prostaglandin E(2) (PGE(2)), and tumor necrosis factor-alpha (TNF-alpha) induced by LPS.	lps	135-138	tumor necrosis factor	Mus musculus	84-111
21237302-5	2011	TA dose-dependently reduced the productions of NO, prostaglandin E(2) (PGE(2)), and tumor necrosis factor-alpha (TNF-alpha) induced by LPS.	lps	135-138	tumor necrosis factor	Mus musculus	113-122
21237302-6	2011	In addition, TA significantly suppressed the LPS-induced expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-alpha at the mRNA and protein levels.	lps	45-48	nitric oxide synthase 2, inducible	Mus musculus	72-103
21237302-6	2011	In addition, TA significantly suppressed the LPS-induced expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-alpha at the mRNA and protein levels.	lps	45-48	nitric oxide synthase 2, inducible	Mus musculus	105-109
21237302-6	2011	In addition, TA significantly suppressed the LPS-induced expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-alpha at the mRNA and protein levels.	lps	45-48	prostaglandin-endoperoxide synthase 2	Mus musculus	112-128
21237302-6	2011	In addition, TA significantly suppressed the LPS-induced expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-alpha at the mRNA and protein levels.	lps	45-48	prostaglandin-endoperoxide synthase 2	Mus musculus	130-135
21237302-6	2011	In addition, TA significantly suppressed the LPS-induced expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-alpha at the mRNA and protein levels.	lps	45-48	tumor necrosis factor	Mus musculus	142-151
21237302-7	2011	Moreover, treatment with TA decreased LPS-induced DNA binding of nuclear factor-kappa B (NF-kappaB) and nuclear translocation of p65 and p50 subunits of NF-kappaB.	lps	38-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	65-87
21147093-7	2011	The induction of NF-kappaB binding activity by LPS was inhibited markedly by co-incubation with different doses of Biochanin-A.	lps	47-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	17-26
21306618-11	2011	Pretreatment with IGF-I or antidepressants significantly decreased duration of immobility in the TST in both the absence and presence of LPS.	lps	137-140	insulin-like growth factor 1	Mus musculus	18-23
21306618-13	2011	LPS increased, whereas IGF-I decreased, expression of inflammatory markers interleukin-1ss (IL-1ss), tumor necrosis factor-(TNF)alpha, inducible nitric oxide synthase (iNOS) and glial fibrillary acidic protein (GFAP).	lps	0-3	nitric oxide synthase 2, inducible	Mus musculus	168-172
21306618-13	2011	LPS increased, whereas IGF-I decreased, expression of inflammatory markers interleukin-1ss (IL-1ss), tumor necrosis factor-(TNF)alpha, inducible nitric oxide synthase (iNOS) and glial fibrillary acidic protein (GFAP).	lps	0-3	glial fibrillary acidic protein	Mus musculus	178-209
21306618-13	2011	LPS increased, whereas IGF-I decreased, expression of inflammatory markers interleukin-1ss (IL-1ss), tumor necrosis factor-(TNF)alpha, inducible nitric oxide synthase (iNOS) and glial fibrillary acidic protein (GFAP).	lps	0-3	glial fibrillary acidic protein	Mus musculus	211-215
21378315-4	2011	These data were supported by the down-regulation of the LPS-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes in the RAW264.7 cells.	lps	56-59	nitric oxide synthase 2, inducible	Mus musculus	117-121
21378315-4	2011	These data were supported by the down-regulation of the LPS-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes in the RAW264.7 cells.	lps	56-59	prostaglandin-endoperoxide synthase 2	Mus musculus	127-143
21378315-4	2011	These data were supported by the down-regulation of the LPS-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes in the RAW264.7 cells.	lps	56-59	nitric oxide synthase 2, inducible	Mus musculus	84-115
21378315-4	2011	These data were supported by the down-regulation of the LPS-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes in the RAW264.7 cells.	lps	56-59	prostaglandin-endoperoxide synthase 2	Mus musculus	145-150
21378315-5	2011	The effects of E3330 were mediated by the inhibition of transcription factors nuclear factor-kappaB (NF-kappaB) and activator protein 1 (AP-1) in the LPS-stimulated macrophages, both known targets of APE1.	lps	150-153	jun proto-oncogene	Mus musculus	116-135
21378315-5	2011	The effects of E3330 were mediated by the inhibition of transcription factors nuclear factor-kappaB (NF-kappaB) and activator protein 1 (AP-1) in the LPS-stimulated macrophages, both known targets of APE1.	lps	150-153	jun proto-oncogene	Mus musculus	137-141
20148771-6	2010	RESULTS: Before surgery, the production of interleukin (IL)-12 p40 by LPS-stimulated monocytes was similar in the patients and the healthy volunteers.	lps	70-73	interleukin 9	Homo sapiens	63-66
21425912-5	2011	Here, we show that LPS-induced MMP-9 gene expression and protein secretion are potentiated by incubation with methamphetamine alone and gp120 alone.	lps	19-22	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	136-141
21425912-6	2011	Further, concomitant incubation with gp120 and methamphetamine potentiated LPS-induced MMP-9 expression and biological activity in MDM.	lps	75-78	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	37-42
21425912-6	2011	Further, concomitant incubation with gp120 and methamphetamine potentiated LPS-induced MMP-9 expression and biological activity in MDM.	lps	75-78	matrix metallopeptidase 9	Homo sapiens	87-92
22174822-7	2011	MMP-9 levels were significantly elevated in culture supernatants from both LPS- and PMA-activated astrocytes and microglia in comparison to controls.	lps	75-78	matrix metallopeptidase 9	Rattus norvegicus	0-5
20412465-9	2010	Furthermore, LPs decreased oleate-induced mature sterol regulatory element binding protein 2 (SREBP-2), a transcription factor that activates cholesterol biosynthesis.	lps	13-16	sterol regulatory element binding transcription factor 2	Homo sapiens	49-92
20412465-9	2010	Furthermore, LPs decreased oleate-induced mature sterol regulatory element binding protein 2 (SREBP-2), a transcription factor that activates cholesterol biosynthesis.	lps	13-16	sterol regulatory element binding transcription factor 2	Homo sapiens	94-101
20412465-10	2010	This is the first study to show that LPs can decrease oleate-induced apo-B secretion in HepG2 cells.	lps	37-40	apolipoprotein B	Homo sapiens	69-74
20412465-11	2010	The modulations of MTTP mRNA expression, cellular total cholesterol metabolism and mature SREBP-2 expression may be important factors in the regulation of apo-B secretion by LPs.	lps	174-177	microsomal triglyceride transfer protein	Homo sapiens	19-23
20412465-11	2010	The modulations of MTTP mRNA expression, cellular total cholesterol metabolism and mature SREBP-2 expression may be important factors in the regulation of apo-B secretion by LPs.	lps	174-177	sterol regulatory element binding transcription factor 2	Homo sapiens	90-97
20412465-11	2010	The modulations of MTTP mRNA expression, cellular total cholesterol metabolism and mature SREBP-2 expression may be important factors in the regulation of apo-B secretion by LPs.	lps	174-177	apolipoprotein B	Homo sapiens	155-160
23554645-8	2010	Lipopolysacchorides (LPS) dramatically increased NF-kappaB DNA binding activity of HMCs, which was inhibited by IL-13 in a dose-dependent manner.	lps	21-24	nuclear factor kappa B subunit 1	Homo sapiens	49-58
23554645-8	2010	Lipopolysacchorides (LPS) dramatically increased NF-kappaB DNA binding activity of HMCs, which was inhibited by IL-13 in a dose-dependent manner.	lps	21-24	interleukin 13	Homo sapiens	112-117
23554645-9	2010	LPS-activated NF-kappaB contained p50 and p65 dimers, but not c-Rel subunit.	lps	0-3	nuclear factor kappa B subunit 1	Homo sapiens	14-23
23554645-9	2010	LPS-activated NF-kappaB contained p50 and p65 dimers, but not c-Rel subunit.	lps	0-3	nuclear factor kappa B subunit 1	Homo sapiens	34-37
23554645-9	2010	LPS-activated NF-kappaB contained p50 and p65 dimers, but not c-Rel subunit.	lps	0-3	RELA proto-oncogene, NF-kB subunit	Homo sapiens	42-45
23554645-10	2010	IL-13 blocked LPS-induced NF-kappaB subunit p65.	lps	14-17	interleukin 13	Homo sapiens	0-5
23554645-10	2010	IL-13 blocked LPS-induced NF-kappaB subunit p65.	lps	14-17	nuclear factor kappa B subunit 1	Homo sapiens	26-35
23554645-10	2010	IL-13 blocked LPS-induced NF-kappaB subunit p65.	lps	14-17	RELA proto-oncogene, NF-kB subunit	Homo sapiens	44-47
23554645-11	2010	LPS stimulated JNK/AP-1 activation, which was inhibited by IL-13 in a dose-dependent manner.	lps	0-3	mitogen-activated protein kinase 8	Homo sapiens	15-18
23554645-11	2010	LPS stimulated JNK/AP-1 activation, which was inhibited by IL-13 in a dose-dependent manner.	lps	0-3	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	19-23
23554645-11	2010	LPS stimulated JNK/AP-1 activation, which was inhibited by IL-13 in a dose-dependent manner.	lps	0-3	interleukin 13	Homo sapiens	59-64
20219279-1	2010	OBJECTIVE: The purpose of this study is to assess the effect of luteal phase supplementation (LPS) on pregnancy rates in human chorionic gonadotropin (hCG)-induced natural frozen-thawed (FET) cycles.	lps	94-97	hypertrichosis 2 (generalised, congenital)	Homo sapiens	151-154
21075133-4	2011	PFOA and PFOS suppressed LPS-induced TNF-alpha production in primary human cultures and THP-1 cells, while IL-8 was suppressed only in THP-1 cells.	lps	25-28	tumor necrosis factor	Homo sapiens	37-46
21075133-8	2011	Mechanistic investigations carried out in THP-1 cells demonstrated that the effect on cytokine release was pre-transcriptional, as assessed by a reduction in LPS-induced TNF-alpha mRNA expression.	lps	158-161	tumor necrosis factor	Homo sapiens	170-179
21075133-10	2011	The dissimilar role of PPAR-alpha in PFOA and PFOS-induced immunotoxicity was consistent with the differing effects observed on LPS-induced MMP-9 release: PFOA, as the PPAR-alpha agonist fenofibrate, modulated the release, while PFOS had no effect.	lps	128-131	matrix metallopeptidase 9	Homo sapiens	140-145
21075133-10	2011	The dissimilar role of PPAR-alpha in PFOA and PFOS-induced immunotoxicity was consistent with the differing effects observed on LPS-induced MMP-9 release: PFOA, as the PPAR-alpha agonist fenofibrate, modulated the release, while PFOS had no effect.	lps	128-131	peroxisome proliferator activated receptor alpha	Homo sapiens	168-178
18955363-0	2011	Hypericum triquetrifolium-Derived Factors Downregulate the Production Levels of LPS-Induced Nitric Oxide and Tumor Necrosis Factor-alpha in THP-1 Cells.	lps	80-83	GLI family zinc finger 2	Homo sapiens	140-145
18955363-5	2011	Hypericum triquetrifolium extracts remarkably suppressed the LPS-induced NO release, significantly attenuated the LPS-induced transcription of iNOS and inhibited in a dose-dependent manner the expression and release of TNF-alpha.	lps	114-117	nitric oxide synthase 2	Homo sapiens	143-147
18955363-5	2011	Hypericum triquetrifolium extracts remarkably suppressed the LPS-induced NO release, significantly attenuated the LPS-induced transcription of iNOS and inhibited in a dose-dependent manner the expression and release of TNF-alpha.	lps	114-117	tumor necrosis factor	Homo sapiens	219-228
21425912-4	2011	We have investigated the role of methamphetamine and HIV-1 gp120 in the regulation of lipopolysaccaride (LPS) induced-MMP-9 production in monocyte-derived macrophages (MDM).	lps	105-108	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	59-64
21425912-4	2011	We have investigated the role of methamphetamine and HIV-1 gp120 in the regulation of lipopolysaccaride (LPS) induced-MMP-9 production in monocyte-derived macrophages (MDM).	lps	105-108	matrix metallopeptidase 9	Homo sapiens	118-123
21425912-5	2011	Here, we show that LPS-induced MMP-9 gene expression and protein secretion are potentiated by incubation with methamphetamine alone and gp120 alone.	lps	19-22	matrix metallopeptidase 9	Homo sapiens	31-36
21637332-4	2011	Tim-3 expression is significantly reduced and IL-12 expression increased upon stimulation with Toll-like receptor 4 (TLR4) ligand--lipopolysaccharide (LPS) and TLR7/8 ligand--R848.	lps	151-154	hepatitis A virus cellular receptor 2	Homo sapiens	0-5
21637332-4	2011	Tim-3 expression is significantly reduced and IL-12 expression increased upon stimulation with Toll-like receptor 4 (TLR4) ligand--lipopolysaccharide (LPS) and TLR7/8 ligand--R848.	lps	151-154	toll like receptor 4	Homo sapiens	95-115
21637332-4	2011	Tim-3 expression is significantly reduced and IL-12 expression increased upon stimulation with Toll-like receptor 4 (TLR4) ligand--lipopolysaccharide (LPS) and TLR7/8 ligand--R848.	lps	151-154	toll like receptor 4	Homo sapiens	117-121
20412465-7	2010	LPs decreased oleate-induced apo-B secretion in a dose-dependent manner.	lps	0-3	apolipoprotein B	Homo sapiens	29-34
20412465-8	2010	LPs also decreased oleate-induced microsomal triglyceride transfer protein (MTTP) mRNA expression and cellular total cholesterol, suggesting that lipid bioavailability and lipidation of lipoprotein are likely involved in the decreased secretion of apo-B.	lps	0-3	microsomal triglyceride transfer protein	Homo sapiens	76-80
20412465-8	2010	LPs also decreased oleate-induced microsomal triglyceride transfer protein (MTTP) mRNA expression and cellular total cholesterol, suggesting that lipid bioavailability and lipidation of lipoprotein are likely involved in the decreased secretion of apo-B.	lps	0-3	apolipoprotein B	Homo sapiens	248-253
20959047-12	2010	TNF-alpha and IL-6 levels in liver tissue homogenates in the endotoxemia groups were significantly higher than those in the normal control group 6 and 12 hrs after LPS injection (P&lt;0.05).	lps	164-167	tumor necrosis factor	Rattus norvegicus	0-9
20959047-12	2010	TNF-alpha and IL-6 levels in liver tissue homogenates in the endotoxemia groups were significantly higher than those in the normal control group 6 and 12 hrs after LPS injection (P&lt;0.05).	lps	164-167	interleukin 6	Rattus norvegicus	14-18
20231081-5	2010	GR function was measured by glucocorticoid inhibition of lypopolysaccharide (LPS)-stimulated interleukin-6 (IL-6) levels.	lps	77-80	nuclear receptor subfamily 3 group C member 1	Homo sapiens	0-2
20231081-5	2010	GR function was measured by glucocorticoid inhibition of lypopolysaccharide (LPS)-stimulated interleukin-6 (IL-6) levels.	lps	77-80	interleukin 6	Homo sapiens	93-106
20231081-5	2010	GR function was measured by glucocorticoid inhibition of lypopolysaccharide (LPS)-stimulated interleukin-6 (IL-6) levels.	lps	77-80	interleukin 6	Homo sapiens	108-112
20231081-6	2010	Compared to vehicle-treated cells, all antidepressants inhibited dexamethasone (DEX, 10-100nM) inhibition of LPS-stimulated IL-6 levels (p values ranging from 0.007 to 0.1).	lps	109-112	interleukin 6	Homo sapiens	124-128
20148771-9	2010	After surgery, the production of IL-12 p40 was dramatically reduced in the LPS-stimulated monocytes of the septic patients from day 1 to day 3, as compared with that of the non-septic patients.	lps	75-78	interleukin 9	Homo sapiens	39-42
20148771-13	2010	CONCLUSION: After surgery, the septic patients showed drastic failure to up-regulate monocyte LPS-stimulated production of IL-12 p40.	lps	94-97	interleukin 9	Homo sapiens	129-132
20119897-8	2010	RESULTS: Treatment of human islets with RvE1 (500 nM) for 24 h reduced LPS-induced increase in mRNA and protein levels of selected pro-inflammatory markers (IL-8, MCP-1, and TF).	lps	71-74	C-X-C motif chemokine ligand 8	Homo sapiens	157-161
20424131-5	2010	A combined extract of clove, oregano, thyme, walnuts, and coffee synergistically inhibited lipopolysaccaride (LPS)-induced NF-kappaB activation in a monocytic cell line, compared with the sum of effects from the single extracts.	lps	110-113	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	123-132
20424131-9	2010	Based on the area under the curve, the extract decreased whole body LPS-induced NF-kappaB activity the first 6 hours by 35% compared with control mice.	lps	68-71	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	80-89
20119897-8	2010	RESULTS: Treatment of human islets with RvE1 (500 nM) for 24 h reduced LPS-induced increase in mRNA and protein levels of selected pro-inflammatory markers (IL-8, MCP-1, and TF).	lps	71-74	C-C motif chemokine ligand 2	Homo sapiens	163-168
20119897-8	2010	RESULTS: Treatment of human islets with RvE1 (500 nM) for 24 h reduced LPS-induced increase in mRNA and protein levels of selected pro-inflammatory markers (IL-8, MCP-1, and TF).	lps	71-74	coagulation factor III, tissue factor	Homo sapiens	174-176
20060598-4	2010	In addition, TNFalpha secretion was assessed in lypopolysaccharide (LPS)-stimulated Abeta(1-42)- or IAPP-treated DCs.	lps	68-71	tumor necrosis factor	Mus musculus	13-21
19686718-1	2009	In a previous study, we reported a new gamma-hydroxybutenolide derivative, 4-benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one (BTH), as inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) expression in lypopolysaccharide (LPS) stimulated RAW 264.7 and TPH-1 cells, without affecting cyclooxygenase-2 (COX-2).	lps	237-240	transmembrane channel-like gene family 1	Mus musculus	133-136
19852511-3	2010	In this study, transferrin (Tf) conjugated pH-sensitive lipopolyplex nanoparticles (LPs) were prepared to deliver GTI-2040, an antisense ODN against the R2 subunit of ribonucleotide reductase that has been shown to contribute to chemoresistance in AML.	lps	84-87	transferrin	Homo sapiens	15-26
19852511-3	2010	In this study, transferrin (Tf) conjugated pH-sensitive lipopolyplex nanoparticles (LPs) were prepared to deliver GTI-2040, an antisense ODN against the R2 subunit of ribonucleotide reductase that has been shown to contribute to chemoresistance in AML.	lps	84-87	transferrin	Homo sapiens	28-30
19852511-9	2010	Moreover, Tf-LPs were more effective than nontargeted LPs, with 10 to 100% improvement at various concentrations in Kasumi-1 cells and an average of 45% improvement at 3 microM concentration in AML patient primary cells.	lps	13-16	transferrin	Homo sapiens	10-12
19892005-5	2010	However, in the brains of LPS-exposed mice, ultrafine TiO(2) significantly elevated proinflammatory cytokine interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) mRNAs, and IL-1beta protein levels.	lps	26-29	interleukin 1 beta	Mus musculus	109-126
19892005-5	2010	However, in the brains of LPS-exposed mice, ultrafine TiO(2) significantly elevated proinflammatory cytokine interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) mRNAs, and IL-1beta protein levels.	lps	26-29	interleukin 1 beta	Mus musculus	128-136
19892005-5	2010	However, in the brains of LPS-exposed mice, ultrafine TiO(2) significantly elevated proinflammatory cytokine interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) mRNAs, and IL-1beta protein levels.	lps	26-29	tumor necrosis factor	Mus musculus	142-169
19892005-5	2010	However, in the brains of LPS-exposed mice, ultrafine TiO(2) significantly elevated proinflammatory cytokine interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) mRNAs, and IL-1beta protein levels.	lps	26-29	tumor necrosis factor	Mus musculus	171-180
19892005-5	2010	However, in the brains of LPS-exposed mice, ultrafine TiO(2) significantly elevated proinflammatory cytokine interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) mRNAs, and IL-1beta protein levels.	lps	26-29	interleukin 1 beta	Mus musculus	193-201
19892005-7	2010	In BV2 microglial cells stimulated with LPS, ultrafine TiO(2) enhanced TNF-alpha production and augmented nuclear factor-kB binding activity.	lps	40-43	tumor necrosis factor	Mus musculus	71-80
20354348-6	2010	Nobiletin suppressed GalN/LPS-induced increases in plasma tumor necrosis factor (TNF)-alpha and nitric oxide (NO) concentrations and hepatic mRNA levels for inducible NO synthase and DNA fragmentation.	lps	26-29	tumor necrosis factor	Rattus norvegicus	58-91
20354348-6	2010	Nobiletin suppressed GalN/LPS-induced increases in plasma tumor necrosis factor (TNF)-alpha and nitric oxide (NO) concentrations and hepatic mRNA levels for inducible NO synthase and DNA fragmentation.	lps	26-29	nitric oxide synthase 2	Rattus norvegicus	157-178
20939428-4	2010	Even after mouse monocytic leukaemia RAW264.7 cells had been washed free of (-)-DHMEQ, lipopolysacharide (LPS)-induced activation of NF-kappaB in these cells was still inhibited.	lps	106-109	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	133-142
20939428-5	2010	Moreover, topical application for 15 min was found to induce dormancy of the cells against LPS for 2-8 h. When it was topically added to RAW264.7 cells in which NF-kappaB was activated by LPS, the inhibition lasted at least for 2 h. NF-kappaB derectly upregulates expression of iNOS that produces NO.	lps	188-191	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	161-170
20939428-5	2010	Moreover, topical application for 15 min was found to induce dormancy of the cells against LPS for 2-8 h. When it was topically added to RAW264.7 cells in which NF-kappaB was activated by LPS, the inhibition lasted at least for 2 h. NF-kappaB derectly upregulates expression of iNOS that produces NO.	lps	188-191	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	233-242
20939428-5	2010	Moreover, topical application for 15 min was found to induce dormancy of the cells against LPS for 2-8 h. When it was topically added to RAW264.7 cells in which NF-kappaB was activated by LPS, the inhibition lasted at least for 2 h. NF-kappaB derectly upregulates expression of iNOS that produces NO.	lps	188-191	nitric oxide synthase 2, inducible	Mus musculus	278-282
20939428-5	2010	Moreover, topical application for 15 min was found to induce dormancy of the cells against LPS for 2-8 h. When it was topically added to RAW264.7 cells in which NF-kappaB was activated by LPS, the inhibition lasted at least for 2 h. NF-kappaB derectly upregulates expression of iNOS that produces NO.	lps	91-94	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	161-170
19675145-0	2009	Simultaneous in vivo time course and dose response evaluation for TCDD-induced impairment of the LPS-stimulated primary IgM response.	lps	97-100	immunoglobulin heavy constant mu	Mus musculus	120-123
19675145-7	2009	TCDD treatment dose-dependently suppressed LPS-induced IgM antibody-forming cell number, which was correlated with decreased frequency of CD19+ CD138+ cells.	lps	43-46	immunoglobulin heavy constant mu	Mus musculus	55-58
19675145-7	2009	TCDD treatment dose-dependently suppressed LPS-induced IgM antibody-forming cell number, which was correlated with decreased frequency of CD19+ CD138+ cells.	lps	43-46	CD19 antigen	Mus musculus	138-142
19675145-9	2009	TCDD also dose-dependently suppressed LPS-stimulated increases in Blimp-1 protein expression in CD19+ B cells.	lps	38-41	PR domain containing 1, with ZNF domain	Mus musculus	66-73
19675145-9	2009	TCDD also dose-dependently suppressed LPS-stimulated increases in Blimp-1 protein expression in CD19+ B cells.	lps	38-41	CD19 antigen	Mus musculus	96-100
19686718-7	2009	The acetic acid-induced hyperalgesia model in LPS-sensitized mice showed a dose-dependent analgesic effect of BTH, exerting an ED(50) value of 6.2 mg/kg.	lps	46-49	transmembrane channel-like gene family 1	Mus musculus	110-113
19384897-13	2009	Filopodia were eliminated by the Nck PAK-binding domain and LPs by the PAK Nck-binding domain.	lps	60-63	NCK adaptor protein 1	Homo sapiens	75-78
18368033-4	2008	Glucocorticoid function was measured by glucocorticoid inhibition of lypopolysaccharide (LPS)-stimulated interleukin-6 (IL-6) levels.	lps	89-92	interleukin 6	Homo sapiens	105-118
19291371-1	2009	PURPOSE: Transferrin (Tf) conjugated lipopolyplexes (LPs) carrying G3139, an antisense oligonucleotide for Bcl-2, were synthesized and evaluated in Tf receptor positive K562 erythroleukemia cells and then in a murine K562 xenograft model.	lps	53-56	transferrin	Homo sapiens	9-20
19291371-1	2009	PURPOSE: Transferrin (Tf) conjugated lipopolyplexes (LPs) carrying G3139, an antisense oligonucleotide for Bcl-2, were synthesized and evaluated in Tf receptor positive K562 erythroleukemia cells and then in a murine K562 xenograft model.	lps	53-56	transferrin	Homo sapiens	22-24
19384897-2	2009	These large protrusions (LPs) were increased in cells expressing RhoA(N19) with Cdc42-associated kinase (ACK).	lps	25-28	ras homolog family member A	Homo sapiens	65-69
19384897-2	2009	These large protrusions (LPs) were increased in cells expressing RhoA(N19) with Cdc42-associated kinase (ACK).	lps	25-28	tyrosine kinase non receptor 2	Homo sapiens	80-103
19384897-2	2009	These large protrusions (LPs) were increased in cells expressing RhoA(N19) with Cdc42-associated kinase (ACK).	lps	25-28	tyrosine kinase non receptor 2	Homo sapiens	105-108
19384897-8	2009	KID or Nck expression increased LPs but not filopodia.	lps	32-35	NCK adaptor protein 1	Homo sapiens	7-10
19560500-12	2009	GLP-1 reduced the LPS increase in L(p) by 75% (AUC: LPS+GLP-1=34+/-1.5, p&lt;0.0001).	lps	18-21	glucagon	Rattus norvegicus	0-5
19560500-12	2009	GLP-1 reduced the LPS increase in L(p) by 75% (AUC: LPS+GLP-1=34+/-1.5, p&lt;0.0001).	lps	18-21	glucagon	Rattus norvegicus	56-61
19560500-12	2009	GLP-1 reduced the LPS increase in L(p) by 75% (AUC: LPS+GLP-1=34+/-1.5, p&lt;0.0001).	lps	52-55	glucagon	Rattus norvegicus	0-5
19560500-13	2009	GLP-1 antagonism reduced the effects of GLP-1 by 60% (AUC: LPS+GLP-1+antagonist=46+/-2.0, p&lt;0.001).	lps	59-62	glucagon	Rattus norvegicus	0-5
19560500-13	2009	GLP-1 antagonism reduced the effects of GLP-1 by 60% (AUC: LPS+GLP-1+antagonist=46+/-2.0, p&lt;0.001).	lps	59-62	glucagon	Rattus norvegicus	40-45
19560500-13	2009	GLP-1 antagonism reduced the effects of GLP-1 by 60% (AUC: LPS+GLP-1+antagonist=46+/-2.0, p&lt;0.001).	lps	59-62	glucagon	Rattus norvegicus	40-45
19560500-14	2009	The cAMP synthesis inhibitor reduced the effects of GLP-1 by 60% (AUC: LPS+GLP-1+cAMP inhibitor=46+/-1.5, p&lt;0.0001).	lps	71-74	glucagon	Rattus norvegicus	52-57
19560500-15	2009	The PKA inhibitor reduced the effects of GLP-1 by 100% (AUC: LPS+GLP-1+PKA inhibitor=56+/-1.5, p&lt;0.0001).	lps	61-64	glucagon	Rattus norvegicus	41-46
19560500-16	2009	GLP-1 attenuates the increase in microvascular permeability induced by LPS.	lps	71-74	glucagon	Rattus norvegicus	0-5
19520742-8	2009	Tumor necrosis factor (TNF)-alpha/lipopolysaccharide (LPS)-induced VCAM-1 expression in HIMEC was suppressed by Akt small-interfering RNA, curcumin, and inhibitors of NF-kappaB (SN-50), p38 MAPK (SB-203580) and PI 3-kinase/Akt (LY-294002).	lps	54-57	tumor necrosis factor	Homo sapiens	0-21
19520742-8	2009	Tumor necrosis factor (TNF)-alpha/lipopolysaccharide (LPS)-induced VCAM-1 expression in HIMEC was suppressed by Akt small-interfering RNA, curcumin, and inhibitors of NF-kappaB (SN-50), p38 MAPK (SB-203580) and PI 3-kinase/Akt (LY-294002).	lps	54-57	tumor necrosis factor	Homo sapiens	23-33
19520742-8	2009	Tumor necrosis factor (TNF)-alpha/lipopolysaccharide (LPS)-induced VCAM-1 expression in HIMEC was suppressed by Akt small-interfering RNA, curcumin, and inhibitors of NF-kappaB (SN-50), p38 MAPK (SB-203580) and PI 3-kinase/Akt (LY-294002).	lps	54-57	vascular cell adhesion molecule 1	Homo sapiens	67-73
19520742-8	2009	Tumor necrosis factor (TNF)-alpha/lipopolysaccharide (LPS)-induced VCAM-1 expression in HIMEC was suppressed by Akt small-interfering RNA, curcumin, and inhibitors of NF-kappaB (SN-50), p38 MAPK (SB-203580) and PI 3-kinase/Akt (LY-294002).	lps	54-57	AKT serine/threonine kinase 1	Homo sapiens	112-115
19520742-8	2009	Tumor necrosis factor (TNF)-alpha/lipopolysaccharide (LPS)-induced VCAM-1 expression in HIMEC was suppressed by Akt small-interfering RNA, curcumin, and inhibitors of NF-kappaB (SN-50), p38 MAPK (SB-203580) and PI 3-kinase/Akt (LY-294002).	lps	54-57	nuclear factor kappa B subunit 1	Homo sapiens	167-176
19520742-8	2009	Tumor necrosis factor (TNF)-alpha/lipopolysaccharide (LPS)-induced VCAM-1 expression in HIMEC was suppressed by Akt small-interfering RNA, curcumin, and inhibitors of NF-kappaB (SN-50), p38 MAPK (SB-203580) and PI 3-kinase/Akt (LY-294002).	lps	54-57	AKT serine/threonine kinase 1	Homo sapiens	223-226
19520742-10	2009	Curcumin inhibited Akt/MAPK/NF-kappaB activity and prevented nuclear translocation of the p65 NF-kappaB subunit following TNF-alpha/LPS.	lps	132-135	RELA proto-oncogene, NF-kB subunit	Homo sapiens	90-93
19520742-10	2009	Curcumin inhibited Akt/MAPK/NF-kappaB activity and prevented nuclear translocation of the p65 NF-kappaB subunit following TNF-alpha/LPS.	lps	132-135	nuclear factor kappa B subunit 1	Homo sapiens	94-103
19074588-3	2009	This study investigated the effects of prostaglandin on CRF and alpha-MSH neuronal activities in LPS-induced anorexia.	lps	97-100	proopiomelanocortin	Rattus norvegicus	64-73
19074588-8	2009	In comparison with saline treatment, LPS administration induced lower food intake and increased plasma ACTH and corticosterone levels, as well as an increase in Fos-CRF and Fos-alpha-MSH double-labelled neurons in vehicle-pretreated rats.	lps	37-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	161-164
19074588-8	2009	In comparison with saline treatment, LPS administration induced lower food intake and increased plasma ACTH and corticosterone levels, as well as an increase in Fos-CRF and Fos-alpha-MSH double-labelled neurons in vehicle-pretreated rats.	lps	37-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	173-176
19074588-8	2009	In comparison with saline treatment, LPS administration induced lower food intake and increased plasma ACTH and corticosterone levels, as well as an increase in Fos-CRF and Fos-alpha-MSH double-labelled neurons in vehicle-pretreated rats.	lps	37-40	proopiomelanocortin	Rattus norvegicus	177-186
19074588-9	2009	In contrast, indomethacin treatment partly reversed the hypophagic effect, blunted the hormonal increase and blocked the Fos-CRF and Fos-alpha-MSH hypothalamic double labelling increase in response to the LPS stimulus.	lps	205-208	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	121-124
19074588-9	2009	In contrast, indomethacin treatment partly reversed the hypophagic effect, blunted the hormonal increase and blocked the Fos-CRF and Fos-alpha-MSH hypothalamic double labelling increase in response to the LPS stimulus.	lps	205-208	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	133-136
19074588-9	2009	In contrast, indomethacin treatment partly reversed the hypophagic effect, blunted the hormonal increase and blocked the Fos-CRF and Fos-alpha-MSH hypothalamic double labelling increase in response to the LPS stimulus.	lps	205-208	proopiomelanocortin	Rattus norvegicus	137-146
19074588-10	2009	These data demonstrate that the activation of pro-opiomelanocortin and CRF hypothalamic neurons following LPS administration is at least partly mediated by the prostaglandin pathway and is likely to be involved in the modulation of feeding behaviour during endotoxaemia.	lps	106-109	proopiomelanocortin	Rattus norvegicus	46-66
18368033-4	2008	Glucocorticoid function was measured by glucocorticoid inhibition of lypopolysaccharide (LPS)-stimulated interleukin-6 (IL-6) levels.	lps	89-92	interleukin 6	Homo sapiens	120-124
18368033-5	2008	The results show that glucocorticoids (dexamethasone, prednisolone, cortisol and corticosterone) caused a concentration-dependent inhibition of LPS-stimulated IL-6 levels.	lps	144-147	interleukin 6	Homo sapiens	159-163
18368033-6	2008	In healthy controls, CMI decreased glucocorticoid inhibition of LPS-stimulated IL-6 levels, while this effect was not present in depressed patients.	lps	64-67	interleukin 6	Homo sapiens	79-83
18819401-2	2008	It was found that LPS preparations derived from virulent(S-LPS) or isogenic avirulent mutant (R-LPS) strains of F. tularensis had markedly lower affinity to LBP as compared with typical S-LPS of Salmonella abortus and R-LPS of Yersinia pestis.	lps	18-21	lipopolysaccharide binding protein	Homo sapiens	157-160
18823975-1	2008	Pretreatment using celecoxib, a cyclooxygenase (COX) 2 inhibitor, or indomethacin, a nonselective COX inhibitor, reduced lypopolyssaccharide (LPS)-induced leukocyte migration to the rat peritoneal cavity.	lps	142-145	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	32-54
18602073-0	2008	Anti-inflammatory effect of allylpyrocatechol in LPS-induced macrophages is mediated by suppression of iNOS and COX-2 via the NF-kappaB pathway.	lps	49-52	nitric oxide synthase 2, inducible	Mus musculus	103-107
18602073-0	2008	Anti-inflammatory effect of allylpyrocatechol in LPS-induced macrophages is mediated by suppression of iNOS and COX-2 via the NF-kappaB pathway.	lps	49-52	cytochrome c oxidase II, mitochondrial	Mus musculus	112-117
18483478-7	2008	Obese rats fed the t10c12 diet produced less TNF-alpha and IL-1beta (lippopolysaccharide (LPS), P &lt; 0.05).	lps	90-93	interleukin 1 beta	Rattus norvegicus	59-67
18549679-3	2008	Treatment with eutigoside C inhibited LPS-stimulated production of nitric oxide (NO), prostaglandin E(2) (PGE(2)) and interleukin-6 (IL-6).	lps	38-41	interleukin 6	Mus musculus	118-131
18549679-3	2008	Treatment with eutigoside C inhibited LPS-stimulated production of nitric oxide (NO), prostaglandin E(2) (PGE(2)) and interleukin-6 (IL-6).	lps	38-41	interleukin 6	Mus musculus	133-137
18767394-1	2008	The beta-endorphin 10(-7-)-10(-11) M in LPS (lypopolisaccharide) presence and in spontaneous cultures promoted the IL-1beta production in mixed leukocyte fraction.	lps	40-43	proopiomelanocortin	Homo sapiens	4-18
18767394-2	2008	LPS-induced IL-8 production in leukocyte fraction was inhibited by beta-endorphin 10(-7), 10(-11) M. The enchasing effect of beta-endorphin on IL-1beta production was not blocked by naloxone and naltrindole.	lps	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	12-16
18767394-2	2008	LPS-induced IL-8 production in leukocyte fraction was inhibited by beta-endorphin 10(-7), 10(-11) M. The enchasing effect of beta-endorphin on IL-1beta production was not blocked by naloxone and naltrindole.	lps	0-3	proopiomelanocortin	Homo sapiens	67-81
18767394-2	2008	LPS-induced IL-8 production in leukocyte fraction was inhibited by beta-endorphin 10(-7), 10(-11) M. The enchasing effect of beta-endorphin on IL-1beta production was not blocked by naloxone and naltrindole.	lps	0-3	proopiomelanocortin	Homo sapiens	125-139
18767394-2	2008	LPS-induced IL-8 production in leukocyte fraction was inhibited by beta-endorphin 10(-7), 10(-11) M. The enchasing effect of beta-endorphin on IL-1beta production was not blocked by naloxone and naltrindole.	lps	0-3	interleukin 1 beta	Homo sapiens	143-151
18767394-4	2008	In mononuclear and neutrophile fractions beta-endorphin and delta-agonist DADLE enchased IL-1beta production in spontaneous and LPS-stimulating cultures, when IL-8 production inhibited beta-endorphin and delta-agonist DADLE only in LPS presence.	lps	128-131	proopiomelanocortin	Homo sapiens	41-55
18767394-4	2008	In mononuclear and neutrophile fractions beta-endorphin and delta-agonist DADLE enchased IL-1beta production in spontaneous and LPS-stimulating cultures, when IL-8 production inhibited beta-endorphin and delta-agonist DADLE only in LPS presence.	lps	232-235	proopiomelanocortin	Homo sapiens	41-55
18819401-2	2008	It was found that LPS preparations derived from virulent(S-LPS) or isogenic avirulent mutant (R-LPS) strains of F. tularensis had markedly lower affinity to LBP as compared with typical S-LPS of Salmonella abortus and R-LPS of Yersinia pestis.	lps	59-62	lipopolysaccharide binding protein	Homo sapiens	157-160
18819401-8	2008	The observed more efficient binding of avirulent strain R-LPS to LBP is likely determines the more intensive host response directed to destruction and rapid elimination of the causative agent.	lps	58-61	lipopolysaccharide binding protein	Homo sapiens	65-68
18819401-9	2008	At the same time, weak affinity of the vaccine and virulent strains S-LPS to LBP probably allows the bacterium to avoid activation of host defense mechanisms thus contributing to its long-term persistence in microorganism and development of specific immunity against tularemia.	lps	70-73	lipopolysaccharide binding protein	Homo sapiens	77-80
18767394-4	2008	In mononuclear and neutrophile fractions beta-endorphin and delta-agonist DADLE enchased IL-1beta production in spontaneous and LPS-stimulating cultures, when IL-8 production inhibited beta-endorphin and delta-agonist DADLE only in LPS presence.	lps	232-235	C-X-C motif chemokine ligand 8	Homo sapiens	159-163
18767394-5	2008	No effect of mu-agonist DAGO were observed on IL-1beta production, whereas LPS-induced IL-8 secretion in neutrophile fraction inhibited by DAGO.	lps	75-78	C-X-C motif chemokine ligand 8	Homo sapiens	87-91